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Abstract 
As patients reach the palliative stage of a haematological malignancy such as 
leukaemia, lymphoma, myeloma or myelodysplasia, most will require regular 
blood transfusions. This thesis reports my professional doctorate study, the 
purpose of which was to gain a deep insight into the everyday life experiences 
of this patient population, who were receiving their blood transfusions in a day 
unit setting.  
 
A narrative inquiry approach, underpinned by a pragmatic philosophical 
foundation, was employed. Twenty-two longitudinal, unstructured interviews 
with a purposive sample of eight participants allowed exploration of rich 
narratives of everyday-life blood transfusion experiences. During data 
collection and narrative analysis of transcripts, experiences were explored 
through three dimensions: sociality, place and temporality. Analysis produced 
eight narrative accounts. Meaning, implicit within and across these accounts 
was revealed through resonant plotlines (themes or threads). Plotlines of 
special interest were those which illuminated feelings, hardships and 
concerns. These plotlines provided the foundation for the development of five 
overarching narrative storylines. Found poetry, developed from raw data, 
supports storyline findings.  
 
Discussion and implications for clinical practice are addressed through a 
review of the literature and a palliative lens focussed on the six Cs of nursing: 
compassion, care, communication, confidence, competence and courage. 
Essentially, to provide compassionate blood transfusion care healthcare 
professionals should: communicate realistic expectations when explaining 
benefits of blood transfusions; consider early involvement of the palliative care 
team to aid with difficulties around goal setting; the setting where blood is 
administered should be reconsidered; waiting in clinical areas should be 
significantly reduced and professional competence, courage and commitment 
should be developed to achieve individualised patient-centred care.  
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Prologue: Reflection on a scenario from my clinical area 
My personal motivation to explore patients’ experiences of blood transfusions 
arose from a disturbing encounter with a haematology patient who attended 
our Haematology Day Unit for a blood transfusion. As highlighted in the 
scenario below, reflection on this clinical situation made me question whether 
the care we were providing this patient was compassionate.  
 
John (pseudonym) was sixty-two, married and had been diagnosed with 
multiple myeloma five years previously. Chemotherapy had been stopped 
several months previously, and he was now coming to the Haematology Day 
Unit of the hospital for blood transfusions. He was desperately poorly, 
cachexic, barely able to walk and covered in bruises. It was his second visit to 
the hospital that week. During the first visit he had attended the Pathology 
Department for blood tests to check his haemoglobin, white cell, red cell and 
platelet count and to cross match his blood. Today, his second visit, he 
attended the unit to receive his three-unit blood transfusion. He would be on 
the unit for the whole day. Three nurses all expert in intravenous cannulation 
had tried, in total, nine times to gain intravenous access without success 
before calling on me as the haematology nurse practitioner to try. John was in 
bed and clearly in the terminal phase of his disease. The skin on his arms was 
fragile and broken, with no veins to be seen or felt. Intravenous access was 
established, but at what expense to this man who would need to repeat the 
whole episode again within the next two weeks. Sadly, John died the following 
week.  
 
The scenario was not new to me. I have witnessed many seriously ill, palliative 
phase haematology patients struggling with fragility, breathlessness and 
fatigue, come to the day unit of the hospital. Generally, these patients attend 
the hospital once or twice a week, every two to three weeks, to have their 
blood tests and receive blood transfusions (BT) to help alleviate the symptoms 
of anaemia. Although the scenario was not new to me, this incident with a 
patient I knew very well provoked a critical reflection concerning nursing care. 
It made me wonder “what is going on” in this situation from a moral 
perspective, and “what is the fitting action” (Niebuhr, 1963, p. 60ff), in terms of 
xii 
 
the right course of action in these circumstances. I wondered how John felt 
about having to attend the day unit so often when he was so unwell, and how 
was he expecting to feel after he had received his blood transfusion. I 
wondered whether this was the right place to administer BT to a patient who 
was obviously in the palliative stage of his disease and I questioned whether 
blood transfusions increased, rather than alleviated, his suffering. I asked 
myself whether the care he was receiving was truly compassionate; that is, 
attended to with a reflective kindness that could serve to ease his situation 
(Tierney, Seers, Tutton & Reeve, 2017). 
 
Personal rationale for undertaking study 
In my senior nursing role as haematology Nurse Practitioner I, as all nurses, 
am duty bound to adhere to our Professional Code of Conduct (Nursing 
Midwifery Council, 2015). Of importance in John’s circumstances this relates, 
to: Section 1.1 of the code, to treat people with kindness, respect and 
compassion; 3.2 to recognise and respond compassionately to the needs of 
those who are in the last few days and hours of life; and 3.4 to act as advocate 
for the vulnerable, challenging poor practice. 
 
My Haematology Nurse Practitioner role was established, within the Trust, to 
comply with the guidance manual “Improving Outcomes in Haematological 
Cancers” (NICE, 2003), which states that every haematology patient should 
have access to a haematology clinical nurse specialist. One of my 
responsibilities in this senior position (band 8a) is to reflect on nursing care 
locally and undertake research to ensure that the clinical care provided is up 
to date and evidenced-based. It is also to ensure that haematology patients 
receive appropriate information, and excellent individualised, physical and 
psychological care appropriate to their needs. Values recognised as inherent 
to excellence in nursing care are the 6Cs of nursing: compassion, 
communication, care, competence, courage and confidence (DH, 2012). As a 
nurse, committed to providing compassion and excellence in nursing care, and 
reducing patients’ suffering, I determined that this clinical practice was an area 
demanding further exploration.  
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My first step was to determine how many patients were transfused in our day 
unit setting while in the palliative phase of a haematological malignancy. A 
retrospective audit over an eight-month period demonstrated that ten patients 
in a palliative stage had received BT; nine in the acute Haematology Day Unit 
(HDU) and one in a hospice day unit. The fact that the case of John was not 
an isolated incident provided powerful evidence that this matter, which fell 
under the remit of nursing care, should be investigated. A discussion with 
members of the Haematology and Palliative Care Team and my academic 
supervisor followed. All believed that exploring the experiences of palliative 
patients receiving blood transfusions was an important area to explore. This 
was in the recognition that gaining the perspectives of patients, particularly the 
most vulnerable, is vitally important to improving clinical services and 
healthcare provision (National Quality Board, 2015).  
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Chapter 1  
1.1 Setting the scene 
All blood cells, that is red blood cells, white blood cells and platelets are 
produced in the bone marrow. Bone marrow disorders, which arise from 
genetic abnormalities, result in haematological malignancies, such as 
leukaemia, lymphoma (hodgkins or non-hodgkins), myeloma and 
myelodysplastic syndrome. As patients with these blood cancers are no longer 
able to produce their own healthy red blood cells, most will become anaemic 
at some point in their disease trajectory, especially when a palliative stage of 
disease is reached. To help alleviate the symptoms of anaemia, which include 
breathlessness and fatigue, patients require blood transfusions, generally 
every two to three weeks. These transfusions are most commonly 
administered in the day unit of secondary care hospitals. This narrative inquiry 
study explores the experiences of patients who receive regular blood 
transfusions in a day unit whilst in the palliative phase of a haematological 
malignancy. 
 
1.2 Haematological malignancies: incidence, disease groups, nature and 
treatment overview 
Haematological malignancies (HM) are the fifth most frequently occurring type 
of cancer in the United Kingdom (NICE, 2003), with over thirty-nine thousand 
new cases expected each year in the UK (Haematological Malignancy 
Research Network, 2018). The incidence of acquiring a HM generally 
escalates with advancing age (Sant, et al., 2010), with a suggested median 
age of 70.6 years (Smith, Howell, Patmore, Jack, & Roman, 2011, p. 1684). 
 
These malignancies are a diverse group of cancers that affect blood, bone 
marrow and lymph nodes. The World Health Organisation recognises twelve 
major haematological malignancy disease groups that are subdivided into at 
least a hundred and twenty-five differential diagnoses (Swerdlow, et al., 2008). 
In clinical practice, however, HM are generally subdivided into four main 
disease groups: leukaemia, myeloma, lymphoma and myelodysplastic 
syndrome (MDS).  
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The nature of HM and the treatment of these diseases varies enormously. For 
instance, acute leukaemia is an aggressive disease that is life threatening and 
requires immediate, intensive inpatient chemotherapy treatment. In 
comparison, MDS is not considered an aggressive disease. Individuals can 
live for many years with just the support of blood transfusions. (see Appendix 
1 for examples of HM, presenting clinical features, treatment administrative 
route, and settings in which chemotherapy treatments are administered). 
 
Despite the huge variation in haematological malignancies a commonality is 
that most patients will develop anaemia as their illness deteriorates to a 
palliative phase. For instance, every patient diagnosed with leukaemia will 
become anaemic throughout the course of their disease; over seventy percent 
of those with myeloma or lymphoma will be anaemic when first diagnosed; and 
up to eighty percent of those with MDS will suffer with anaemia at some point 
in their disease trajectory (Schrijvers, De Samblanx & Roila, 2010).  
 
1.3 Definition and symptoms of anaemia 
Anaemia is generally defined as a reduced haemoglobin (Hb) concentration. 
It may be classified as mild, moderate, severe or life threatening according to 
the Hb level. Generally, a Hb level that lies between 10 and 11.9g/dL is 
characterised as mild anaemia; between 8 and 9.9g/dL a moderate anaemia; 
below 8g/dL is considered severe anaemia (Schrijvers, De Samblanx & Roila, 
2010, p. 244), and a level of below 6.5g/dL is associated with an increased 
risk of death (Wilson, et al., 2007).  
 
Symptoms of anaemia in adults vary significantly. Some patients show no 
symptoms or signs, despite having a Hb level below 8g/dL, and others are 
severely incapacitated by mild anaemia. The signs and symptoms of anaemia 
are related to adaptive changes in the cardiovascular system and in decreased 
tissue oxygenation (Hughes-Jones, Wickramasinghe & Hatton, 2008). Elderly 
patients are more susceptible to the effects of anaemia, due to cardiac 
dysfunction and cerebral vascular disease (Hoffbrand & Pettit, 1993). 
Symptoms of anaemia frequently observed in clinical practice include 
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breathlessness, lethargy and fatigue, however, a multitude of symptoms 
associated with anaemia may occur (see Table 1).  
 
Table 1 Symptoms associated with anaemia (Watson & Royle, 1987, p. 
250) Adapted. 
Part of body 
affected 
Compensatory 
mechanism 
Dysfunction  
Brain  Fatigue/tiredness, 
headaches, dizziness, 
difficulty thinking or 
concentrating, 
depression 
Eyes  Retinal damage 
Heart Rapid pulse 
palpitations 
Angina 
 
Lungs Rapid breathing  Breathlessness  
Kidneys  Water retention 
Gut Loss of appetite Indigestion, irregular 
bowel movements 
Muscles/legs  Fatigue, reduced 
exercise capacity, 
oedema 
Skin Pallor, feeling cold Brittle/broken nails 
   
  
One of the most overwhelming symptoms of anaemia in patients at the end-
of-life is fatigue (Brown, Hurlow, Rahman, Closs & Bennett, 2010; Orme, Still, 
Day & Evans, 2013; Woodwark and Dean, 2017). In a recent study, which 
involved looking at electronic patient records retrospectively over a 54-month 
period, Woodwark and Dean (2017) found that fatigue was the most frequent 
reason for administering BT (84% of cases) in patients who were dying in a 
hospice. Fatigue, along with other recognised symptoms of anaemia have a 
significant impact on patients’ quality of life in terms of limiting mobility and the 
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ability to carry out usual activities of daily living (Campos, Hassan, Riechelman 
& Del Giglio, 2011; Jabbour, Kantarjian, Koller & Taher, 2008; Szende, et al., 
2009). Nineteen percent of patients with advanced disease are said to be so 
debilitated by fatigue that “they felt they wanted to die” (Curt, 2000, cited in 
Brown, Hurlow, Rahman, Closs, & Bennett, 2010, p.1327). 
 
1.4 Blood transfusions: healthcare use and associated risks 
The most common therapeutic choice to treat anaemia in patients with an 
advanced haematological malignancy is the administration of blood 
transfusions (BT), which may be required over many months or years (Killick, 
et al., 2013; Bishop, Faithful, & Allan, 2011). Erythropoietic agents are not 
generally employed in these patients to alleviate anaemia, as it is suggested 
that they are not comparable with BT in terms of “response rate, time to onset 
and duration of response” (Tanneberger, Melilli, Strocchi, Frenquelli, & 
Pannuti, 2004, p. 840). 
 
BT are widely used within the National Health Service (NHS) with 
approximately two million units of blood per annum provided to hospitals in 
England and Wales alone (NHS Blood and Transplant, 2011). Historically, BT 
were associated with transmission of infectious diseases such as HIV and 
Hepatitis B, however due to improved screening there is now negligible risk of 
acquiring blood transfusion associated infections (BMJ, 2000; Bolton-Maggs 
and Cohen, 2013) Other risks remain, including: the accumulation of iron 
which cannot be excreted and hence accumulates in organs, such as the heart 
and liver and which can lead to significant morbidity and mortality; 
administration of the wrong blood type; acute anaphylactic reactions; and 
transfusion associated circulatory overload (TACO). TACO, which can be a 
serious, life-threatening condition, has been noted by a host of researchers 
(Alam, Lin, Lima, Hansen, Callum, 2013; Agnihotri, & Agnihotri, 2014; Bolton-
Maggs & Cohen, 2013; Bosboom, et al., 2018; Hendrickson, et al., 2016; 
Henneman, et al., 2017; Popovsky, et al., 2006; Robinson, et al, 2017; 
Roubinian, et al., 2018). Indeed, it has recently been recognised as the most 
frequent cause of blood transfusion associated morbidity and mortality 
(Robinson et al. 2017). 
5 
 
1.5 Literature review 
Despite BT being the therapeutic option to treat anaemia in patients diagnosed 
with a palliative phase HM, there is much debate in the academic literature 
around their administration to patients in a palliative stage of cancer. Most of 
the discussion surrounding administration of BT to patients with an advanced 
cancer is concerned with efficacy in these circumstances, the place of 
administration and the ethical issues involved. 
 
1.5.1 Efficacy of blood transfusions administered to patients in a 
palliative stage of malignancy1 
There has been much debate regarding the effectiveness of BT for those with 
an advanced cancer in terms of longevity of effect. Some researchers suggest 
that BT are associated with beneficial effects, in terms of relieving fatigue, 
breathlessness and improving quality of life (QoL), proposing that these 
positive effects are maintained over a sustained period (Gleeson & Spencer, 
1995). Other studies suggest that, although patients may experience 
beneficial effects shortly after receiving blood transfusions these are short 
lived (Chin-Yee, et al., 2018; Mercadante, Ferrera, Villari, David & Riina, 2009: 
Preston, Hurlow, Brine, & Bennett, 2012)   
 
One of the first landmark studies to assess the effects of BT in a palliative 
population was undertaken by Gleeson and Spencer (1995). These 
researchers employed a Visual Analogue Scale2 to measure well-being, 
strength and breathlessness following BT in a population of 91 patients with a 
variety of advanced cancers. Their findings suggest that over seventy percent 
of patients showed improvement in these parameters after two days, most 
sustaining the beneficial effect at two weeks post transfusion. However, as 
almost a third of their participants died during the two-week assessment 
period, their findings must be taken with some caution.  
                                            
1 The term employed in this thesis to describe the phase of patients’ malignancy is, palliative 
‘stage’ or ‘phase’. However, where different terms have been used in the literature with 
evidence quoted, the term used by the authors (advanced cancer, terminal cancer, late, or 
end, or final (stage or phase) cancer) was kept. 
 
2 A self-report measure consisting of a 10-centimetre line with a statement at each end 
representing one extreme of the dimension being measured (Crichton, 2001). 
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In comparison, Mercadante, Ferrera, Villari, David and Riina, (2009) suggest 
that any beneficial effect experienced post BT was short lived. They measured 
fatigue and breathlessness in sixty-one participants who had a variety of 
tumour types using a symptom assessment scale. Some of the participants 
were terminally ill, while others were still receiving oncologic chemotherapy. 
They report that patients experienced relief of fatigue and breathlessness 
shortly after receiving BT, but this effect was not significant 15 days post 
transfusion. They also suggest that any beneficial effect reported by 
participants may have been due to a psychological or placebo effect because 
participants held such faith in BT to reduce their symptoms of anaemia, which 
is a suggestion shared by others (Brown, Hurlow, Rahman, Closs & Bennett, 
2010; Mercadante, Ferrera, Villari, David & Riina, 2009, p. 62; Monti, 
Castellani, Berlusconi & Cunietti, 1996). 
 
Other authors have also suggested that BT administered to those with an 
advanced cancer has little influence on quality of life, in terms of relieving 
symptoms of breathlessness or fatigue, when administered in the last four 
(Monti, Castellani, Berlusconi & Cunietti, 1996, p.21) to five (Brown and 
Bennett, 2007) weeks of life. Indeed, some authors found minimal association 
between anaemia and fatigue in patients with an advanced cancer, stressing 
instead that the fatigue experienced by these patients is multi-factorial (Brown, 
Hurlow, Rahman, Closs & Bennett, 2010; Dunn et al., 2003; Munch, Zhang, 
Willey, Palmer & Bruera, 2005; Wang, 2008). 
 
More recently, Goksu, et al., (2014) proposed that patients with a terminal 
cancer who received BT lived significantly longer than those who did not (15 
days versus 8 days: p. 4251). This finding they suggest warrants the 
administration of BT to patients in the final stage of their disease. Two literature 
reviews have explored the administration of BT in palliative patients (Chin-
Yee, et al., 2018; Preston, Hurlow, Brine & Bennett, 2012). According to both 
reviews there is still limited evidence to support or guide the administration of 
BT in patients who are in a palliative stage of their disease. The authors 
suggest that BT may confer some relief of anaemia-related symptoms such as 
breathlessness and fatigue, although this effect is small and of limited duration. 
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However, as stressed by: Chin-Yee, et al., (2018), and Preston, Hurlow, Brine 
and Bennett (2012), due to the clinical diversity of the palliative population 
involved in their reviews, and the fact that no large-scale studies or random 
controlled trials have been undertaken, it was not possible to compile the 
findings of studies together.  
 
One Cochrane Review (Preston, Hurlow, Brine & Bennett, 2012) corelates the 
administration of BT to patients with advanced cancer with an increased risk 
of mortality. These researchers report that between twenty-three percent to 
thirty-five percent of participants died within 14 days of receiving a blood 
transfusion. They suggest that the increased mortality rate, post BT, may be 
due to either “fluid overload or higher plasma viscosity” (p. 9). Woodwark and 
Dean (2017) also noted that fifty percent of patients died within four weeks of 
receiving a blood transfusion. The finding associated with increased risk of 
adverse events and lack of efficacy was, perhaps, what prompted Preston et 
al., (2012) to suggest that physicians should try other options prior to 
prescribing a blood transfusion:  
 
 Clinicians that treat patients with advanced cancer who present with 
anaemia, fatigue and breathlessness (not related to cancer treatment 
or haemorrhage), need to consider whether alternative management 
strategies should be tried before prescribing blood transfusion (Preston, 
Hurlow, Brine & Bennett, 2012, p.9). 
 
This suggestion is perhaps countered in the NICE (2003) guidance, ‘Improving 
Outcomes in Haemato-Oncology Cancer’, in which BT are recognised as 
essential supportive therapy for prolonging life in those in the later stages of 
leukaemia and myeloma (NICE, 2003, p. 101). 
 
1.5.2 Authorisation of blood transfusion administration 
Traditionally, BT were prescribed only by medical physicians. In recent times, 
however, it has been noted that BT cannot be prescribed as they are not 
legally defined as a medicine (Joint United Kingdom (UK) Blood Transfusion 
and Tissue Transplantation Services Professional Advisory Committee, 2013), 
rather, BT are authorised. Authorisation of BT can be undertaken by 
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appropriately trained and competent nurses, midwives or other healthcare 
professionals if this lies within their scope of practice. In this study, BT were 
only authorised by physicians.  
 
The decision to administer a BT to terminally ill cancer patients is significantly 
influenced by the medical team (Leibovitz, et al., 2004) and by blood 
transfusion guidelines. As numerous factors need to be taken into 
consideration, such as age and co-morbidities (Jabbour, Kantarjian, Koller & 
Taher, 2008), this potentially difficult decision may account for some of the 
variation in clinical practice surrounding BT (Bishop, Faithfull, & Allan, 2010; 
Hinka, Kosunen, Metsanoja, Puustelli, & Kellokumpu-lehtinen, 2002).  
 
1.5.3 Blood transfusion guidelines 
The UK National Institute for Health and Care Excellence (NICE, 2015) and 
NHS Blood and Transplant (2016) have recently suggested that, where 
possible, a single unit of blood should be administered in patients who are 
haemodynamically stable and who are not actively bleeding. Following 
administration of this transfusion, a reassessment of the patient’s haemoglobin 
should be made to determine if a subsequent unit of blood is required. NICE 
and the NHS Blood and Transplant guidelines recommend that a haemoglobin 
concentration of between 70-90g/litre is maintained post BT. The NICE 
guidance, which recommends a restrictive blood transfusion policy, does not 
specifically address patients who have an advanced disease (Carson & 
Kleinman, 2018; NHS Blood and Transplant, 2016). However, the NHS Blood 
and Transplant (2016) guidance suggests that the recommendation of 
administering one unit of blood and then the reassessment of the patient 
should be maintained in palliative circumstances. This recommendation is not 
applicable to those with chronic transfusion dependency.  
 
Carson and Kleinman (2018) advised a target range of between 80–100g/L for 
elderly patients; those with cardiac or renal dysfunction; and for haematology 
and oncology patients who have chronic transfusion dependency. In their 
recommendations they specifically note that when authorising BT, each 
patient’s physical and psychological condition be considered, to ensure that 
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patients receive individualised care appropriate to their needs (Carson and 
Kleinman, 2018). It has been argued that, in everyday clinical practice, 
individualized care is not happening as physicians have been seen to 
authorise BT based on haemoglobin level alone, rather than also considering 
a patient’s unique physical and psychological circumstances (Cheng, Sham, 
Chan, Li & Au, 2015, p. 224; Bishop, Faithful & Allan, 2011).  
 
1.5.4 The effect of the setting or place on blood transfusion authorisation 
The administration of BT has been shown to be five times higher in the hospital 
setting compared to the hospice setting, particularly in the six weeks prior to 
death (Watchel & Mor, 1985). Watchel and Mor (1985) suggest that patients 
with advanced malignancy were found to be transfused inappropriately in the 
hospital setting (twenty-seven percent) compared with the hospital-based 
hospice setting (eight percent) and home-care setting (four percent). A later 
study undertaken in Italy suggests that there is overuse of BT in the hospital 
setting and an incongruous withholding of BT in the hospice and home setting 
(Mercadante et al., 2009). 
 
In the UK, BT administered to haematology patients with a palliative diagnosis 
are generally performed in a day unit of a secondary care hospital, rather than 
in a hospice (Boyce, McHugh and Lyon, 2003) as patients are not referred to 
the palliative care team by haematologists (Cheng, Sham, Chan, Li & Au, 
2015). Several reasons have been suggested to account for the lack of referral 
by haematologists to the hospice setting:  
 
First, patients diagnosed with a HM can deteriorate very quickly with a 
concomitant drop in Hb level, platelet count and white blood cell count. A low 
platelet count predisposes them to the risk of a fatal bleed and a low white 
count to overwhelming infection, conditions thought to be difficult to deal with 
outside of the hospital setting (McGrath, 2014; McGrath & Holewa, 2007).   
 
Second, haematology patients have been shown to show signs of recovery 
even when close to death, thus the distinction between the curative phase and 
the palliative phase is not clear (McGrath & Holewa, 2007).  
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Third, treatment of HM may continue over many years which allows close, 
trusting bonds to be formed between patients, physicians and the 
haematology unit staff. Disrupting these bonds by transferring care to the 
palliative team and adopting a palliative approach in hospice is believed to be 
very difficult for all those involved (McGrath & Holewa, 2007; LeBlanc & El-
Jawahri 2015). Transferring the care of these patients to a hospice is 
recognised as especially difficult when patients and their families are reluctant 
to cease any active treatment (NICE, 2003).  
 
Fourth, there is a recognition that haematologists feel responsible for 
maintaining patients’ hope of survival (Bernacki & Block, 2014; LeBlanc & El-
Jawahri, 2015). Referral to a palliative care physician has the potential to 
shatter patients’ hopes and expectations, even though they want truthful 
prognostic information regardless of how dire the information is (El-Jawahri, et 
al., 2015; LeBlanc & El-Jawahri, 2015; McGrath, 2001).  
 
Lack of referral to the palliative care team (PCT) is thought to result in palliative 
services being used less often in haematological cancers than in solid tumour 
cancers (Cheng, Sham, Chan, Li & Au, 2015: McCaughan, et al 2018; 
McGrath, 2001; McGrath & Holewa, 2007; NICE, 2003, p.4). Although this 
situation is believed to be improving (Corbett, Johnstone, Trauer & Spruyt, 
2013; McCaughan et al, 2018), still only fifty-four percent of haematology 
patients are referred to the PCT (Corbett, Johnstone, Trauer & Spruyt, 2013). 
Indeed, as reported by McCaughan et al., (2018) who recently undertook the 
first UK study to explore palliative care specialists’ perceptions concerning 
referral of haematology patients to their services, this is an ongoing, complex 
situation. Many patients with a palliative HM may not therefore be receiving 
appropriate end of life care that addresses their psychological, emotional and 
spiritual needs, which may help them make important goal setting decisions 
concerning their treatment (LeBlanc & El-Jawahri, 2015; McGrath, 2001; 
McGrath & Holewa, 2007), although McCaughan et al (2018) suggest that this 
is something that needs to be determined. LeBlanc and El-Jawahri (2015), 
advise that palliative care should be integrated from the moment of diagnosis 
in those with a HM, however, they suggest that how to do this effectively needs 
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to be explored. Cheng, Sham, Chan, Li & Au (2015) suggest that joint ward 
rounds between haematologists and the PCT may promote more effective 
transition of haematology patients into the hospice setting (p. 221), while 
McCaughan et al, (2018) suggest that co-location of services provides an 
optimal way of promoting more integrated working relationships. 
 
Lack of referral of those with a HM leads to these patients dying in the hospital 
rather than in the hospice or home (Cheng, Sham, Chan, Li & Au, 2015; 
Howell, et al., 2013; McCaughan, et al., 2017). Indeed, research indicates that 
between sixty-one and seventy-nine percent of patients with a HM in the UK 
die in hospital (National Cancer Intelligence Network, 2011, p.2), despite most 
patients suggesting that they would prefer to die at home (McCaughan, et al., 
2017).  
 
1.5.5 Exploration of blood transfusions from the patients’ perspective 
Little scholarly attention has been given to the perspectives of patients who 
are diagnosed with a palliative haematological malignancy and who require 
regular BT in a day unit hospital or hospice. It is not known, therefore how 
patients perceive this procedure, what they expect from BT and what 
challenges they perceive to be associated with BT. An important consideration 
that was recognised by Cheng, Sham, Chan, Li & Au (2015) is that the burdens 
of treatment for patients at the end-of-life should not exceed the perceived 
benefits; however, little is known about patients’ burdens associated with the 
administration of BT.  
 
Orme, Still, Day, Evans, and Perkins (2013) undertook a phenomenological 
study to explore the views of ten palliative haematology patients regarding 
their views of living with anaemia and undergoing blood transfusions in a day 
hospice setting. They found that tiredness was the overwhelming symptom of 
anaemia, that participants preferred the hospice setting to the hospital setting 
because of easier parking, shorter waiting times and space to ask questions 
about their care. Most participants said they would like to return to the hospice 
for future BT. These researchers conclude that the hospice day unit is 
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associated with a good experience for patients with a haematological disorder 
and that the hospice service should be more commonly available (p. 171).  
 
Fitzgerald, Hodgkinson, and Thorpe (1999) undertook an interpretive 
phenomenological study in Australia to obtain participants’ experiences of 
preparing for and receiving BT. Their sample included nineteen participants of 
whom only two were haematology participants (it is not recorded whether they 
were palliative or not). They conclude that receiving BT is a relatively un-
stressful procedure compared to some other procedures in the hospital, 
minimal pain is experienced, patients knew and accepted the reason for BT, 
and although they remained anxious about acquiring HIV and Hepatitis 
infections from the BT, their anxiety was less than if they had not received BT 
(pp. 593-600).  
 
A study by Adams and Tolich (2011) explored non-palliative patients’ 
understanding of the role of BT in their treatment, and whether it caused them 
any discomfort. Their findings suggest that participants understood the role of 
BT in their treatment and that nurses were the healthcare professionals who 
gave them information about BT. They highlight that participants believed it 
was the physicians’ responsibility to prescribe BT, but alternatives to BT, such 
as erythropoietin, were not offered or discussed. Participants, in this study, 
were found to express concerns about the safety of BT but were reassured by 
the fact that the nurses adhered to safety checks at the bedside. 
 
A study by Szende et al., (2009) explored the perspectives of non-palliative 
patients with MDS who required regular BT. Their aim was to assess how 
patients valued life without BT compared to a life dependent on BT by using 
health-related QoL descriptor cards. They suggest that participants found 
being dependent on BT so overbearing that they believed a shorter life would 
be preferable, and a small number of participants found dependency on BT so 
challenging they considered it “worse than being dead” (pp. 1-2).  
 
Other studies shed light on the hardships of patients who attend regularly to 
receive BT, and have highlighted the necessary, frequent and prolonged 
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attendance at hospital, the excessive waiting times involved and the travel 
costs that patients with a HM and their families incur (McGrath & Holewa, 
2007; Craig, Milligan, Cairns, McClelland & Parker, 1999, p. 31), and also the 
lengthy hospital day that BT require (Engert, 2000; Gray & Craig, 1994, cited 
by Craig, Milligan, Cairns, McClelland & Parker, 1999).  
 
1.5.6 The ethical dimension of blood transfusion administration in 
palliative circumstances 
A Cochrane Review (Preston, Hurlow, Brine & Bennett, 2012) explored the 
effect of BT in patients with advanced cancer and found minimal effectiveness 
and shortened life expectancy. This caused scholars (Preston, Hurlow, Brine 
& Bennett, 2012; Smith, Cooling & Davenport, 2013) to question the medical 
futility of administering BT to patients who have a limited life expectancy with 
no possible chance or hope of getting better medically. According to Brody, 
Campbell, Faber-Langendoen, and Ogle (1997) and Ferrell, (2006, p. 922), 
medical futility may be defined as: “care that prolongs life but is unlikely to end 
in meaningful survival”.  
 
Medical futility is a challenging ethical concern as it is dependent on goals of 
care (Smith, Cooling & Davenport, 2013). Some researchers have noted the 
cost and scarcity of blood (Preston, Hurlow, Brine & Bennett, 2012: Smith, 
Cooling & Davenport, 2013), suggesting that these scarce resources should 
be used efficiently. Smith, Cooling, and Davenport, (2013, p. 699), for 
instance, suggest that in medically futile situations, BT should be avoided 
where possible, BT should not be given to patients at the end of life if a blood 
shortage develops, and rare blood types, which are particularly scarce 
resources, should not be given to those considered to be palliative. Using finite 
resources in futile situations, they suggest, may expend resources that could 
be administered to save the life of another patient (p.699). Smith, Cooling and 
Davenport (2013) recognise the ethical tensions that exist between an 
individual’s desire to prolong their life for just one extra day and the broader 
social dimensions.  
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1.6 Summary of the research problem 
Much of the research, to date, that has explored the administration of BT to 
patients in a palliative stage of malignancy have been quantitative, medically 
orientated studies that have assessed the efficacy of BT. These studies have 
employed positivist research methods, such as before and after studies which 
have sought to quantify the effect of BT on breathlessness, fatigue and quality 
of life. These studies have used a variety of standardised quantitative 
assessment tools, like Visual Analogue Scales and Edmonton Symptom 
Assessment System to enumerate effect. The population recruited into these 
studies have mainly been patients from an in-patient hospice setting who have 
been diagnosed with a solid tumour.  
 
Despite the volume of studies reviewed in section 1.5 none could be found 
that have asked haematology patients who are in a palliative stage of disease 
to describe their experiences regarding BT in profound detail. Thus, it is not 
known what patients expect to happen post-BT either physically or 
psychologically or both, what challenges they associate with BT and what 
factors affect their experience of BT. Gaining the perspectives of patients is 
viewed as important in evaluating health care (DH, 2012), as it is believed that 
patients’ experience of the NHS, can be improved by, “asking, monitoring and 
acting upon patient feedback” (DH, 2012, p.1). 
 
Gaining knowledge of patients’ experiences also allows disparities between 
patients’ perception of their experience and healthcare professionals’ 
perceptions of the same experience, to be illuminated (Gullick & Shimadry, 
2008). Improvement in the quality of clinical care and service provision can 
then be made from the patients’ viewpoint.  
 
Improving palliative and end-of-life care must be viewed as a priority, as care 
provided to these sick and vulnerable people has been shown to be 
inconsistent (National Palliative and End of Life Care Partnership, 2015). 
Some palliative patients have been shown to receive excellent care while 
others do not, and this inconsistency is unacceptable and needs to be 
addressed by healthcare professionals (ibid, p. 6). To ensure everybody 
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receives excellent care it is recommended that ‘person-centred care’ becomes 
standard clinical practice (National Palliative and End of Life Care Partnership, 
2015).  
 
Furthermore, most palliative patients with a HM who attend for BT are elderly. 
In the document “Compassion in Practice Nursing, Midwifery and Care Staff 
Our Vision and Strategy” (DH, 2012), it is stressed that to meet the needs of 
patients, and particularly the needs of older people, it is vital to look after 
people with “care, dignity, respect and compassion” (p. 5). To attain excellence 
in provision of healthcare it is suggested that six values (known as 6Cs), that 
is, compassion, care, communication, confidence, competence and courage 
that underpin the role of all nurses and healthcare staff, are adopted by 
everyone involved in commissioning, planning and delivering care (p. 5).  
 
In view of the gap in the academic literature, the aim of this thesis was to gain 
a deep insight into the everyday life experiences of participants who had a 
palliative stage HM and received regular BT in a day unit. The purpose of this 
study was to understand participants’ experiences surrounding this therapy 
and any challenges that they faced, and to use these insights to inform current 
clinical care.  
 
1.7 Research question 
The study research question was as follows:  
What are patients’ experience of receiving regular blood transfusions in 
a day unit setting whilst in a palliative stage of a haematological 
malignancy?  
 
1.8 Research objectives 
The study research objectives were: 
1. To explore participants’ expectations and challenges around receiving 
regular BT in a day unit setting.  
2. To explore healthcare professional’s role on participants’ experience of BT. 
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3. To explore the effect of the place or setting where the blood transfusions 
were administered on participants’ experiences of BT. 
4. To explore the change in participants’ experiences as disease progressed 
from an early palliative phase, to a late palliative phase, to the terminal 
palliative phase of a haematological malignancy. 
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Chapter 2: Research context  
2.1 Introduction  
This chapter introduces the research approach and methodology employed in 
this study to explore participants’ experiences. It includes a discussion of 
narrative inquiry (NI) as a research approach in the study of illness and 
healthcare, its limitations and the rationale for its utilisation. 
 
2.2 Research approach to understanding experience 
The aim of this study was to gain a deep understanding of participants’ 
experiences of BT and gain knowledge about the everyday challenges 
participants endured. This required a qualitative approach, as qualitative 
research revolves around people’s experiences and the stories they tell 
(Strauss & Corbin, 1990). The focus of qualitative investigators is to explore 
the social world of participants to gain a deep insight into how people 
experience or understand an event, process or a situation (Denzin and Lincoln, 
2011). Qualitative researchers recognise that “our knowledge and experience 
of the world cannot consist of an objective appraisal of some external reality 
but is profoundly shaped by our subjective and cultural perspective, and by 
our conversations and activities” (Yardley, 1997a, cited by Yardley, 2007, p. 
217). Furthermore, qualitative methodologies can bring fresh insights into 
health and illness (Yardley, 2000). Thus, a qualitative approach was deemed 
the most suitable choice to explore participants’ experiences of BT. 
 
An array of qualitative research methodologies can be employed to study 
‘experience’. In this study a narrative inquiry methodology was employed. Prior 
to discussing the study methodology, it is important to first clarify two key 
terms, story and narrative, which are employed throughout this study. 
 
The terms story and narrative are often used interchangeably in the public 
domain and within published academic literature, particularly amongst 
different disciplines. When difference is noted, it is generally to do with the 
personal meaning associated with the narrative. For instance, Smith (2016, p, 
204) highlights that people “tell stories, they do not tell narratives”. Patterson 
(2000) proposes that a story is an intellectual interpretation of the narrative 
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made by the reader or listener. Thus stories, Patterson (2000) suggests, are 
not stable constructs but tales that can constantly alter over time with each 
telling and retelling and are dependent on the listener, reader and context of 
the situation.  
 
In contrast, narratives are stable linguistic constructs which have a specific 
grammatical structure. They serve as a resource from which people frame their 
personal stories and understand the stories they hear. People make sense of 
their lives according to the narrative available to them. (Patterson, 2000: 
Smith, 2016). Indeed, other eminent, expert narrative researchers highlight 
that narrative is the principal manner by which individuals interpret and make 
meaning of their everyday life experiences, establish their identity and their 
place in the world and motivate their actions (Bruner, 1990; Crossley, 2002; 
Gee, 1986; Mishler, 1986; Murray, 2008; Patterson, 2000; Riessman, 1993; 
Smith, 2016; Squire, 2013). Narratives reflect the culture and social 
circumstances of the time, historical context, race and place (Smith, 2016), 
and are considered universal (Barthes, 1977). 
 
In this study narratives were defined as “all meaningful stories of personal 
experience” (Squire, 2013, p. 48) that participants delivered to me through 
their oral accounts. These narratives were specific episodes or courses of 
action (Kvale and Brinkmann, 2009) that involved “movement, succession, 
progress or sequence – usually, temporal sequences – and the articulation of 
development of meaning” (Squire, 2013, p. 48).  
 
2.3 Methodological approach employed to study experience 
The narrative research approach employed in this research study was guided 
by the Narrative Inquiry methodology proposed initially by educators Connelly 
and Clandinin (1990), and subsequently developed over the years (Clandinin, 
2006, 2013; Clandinin & Connelly, 2000; Clandinin & Rosiek, 2007; Connelly 
& Clandinin, 1990; 2006).  
 
The principal phenomenon of interest that researchers seek to explore in NI is 
‘experience’. Experience, thus stands as the ontological position from which 
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the research endeavour commences (Caine & Estefan, 2011; Clandinin, 2006, 
2013; Clandinin & Connelly, 2000; Clandinin & Rosiek, 2007; Connelly & 
Clandinin, 2006). The ontological philosophical foundation of NI is Dewey’s 
concept of experience. In this theory “Dewey sought to promote pragmatism 
by re-orientating philosophy away from abstract concerns and turning it 
instead to human experience” (Morgan, 2014, p. 1046). 
 
Dewey, an eminent philosopher in the study of experience, recognised 
principles of “continuity” and “interaction” in his renowned “transactional”, 
pragmatic, ontological theory of experience (Clandinin & Rosiek, 2007, p. 39). 
According to Clandinin and Connelly (2000), Dewey’s two criteria of 
experience, continuity and interaction, provide the grounding for exploring 
experience through an inter-related three-dimensional inquiry space: 
place/setting, temporality and sociality (personal and social dimensions), while 
acknowledging that these dimensions are ontological. This was in the 
recognition that all experiences are created by a link between a person and 
the world they live in, and these experiences are moveable, dynamic and 
continuous: they feed on each other, in that one experience leads to another, 
that leads to another, through past, present and future. They change with the 
individual’s personal history, social influences and material environment 
(Lemley & Mitchell, 2012; Wang & Greenwood, 2015; Clandinin, 2013; 
Clandinin & Connelly, 2000; Clandinin & Rosiek, 2007).  
 
In NI researchers gain an understanding of experience through story or 
storytelling (Caine and Estefan, 2011; Clandinin, 2000, 2013; Clandinin and 
Connelly, 2000; Clandinin and Rosiek, 2007; Connelly and Clandinin, 2006). 
From an epistemological perspective, the justification for this is that humans 
are by nature storytellers and that individuals make sense of their experiences 
by recounting personal stories of experience in an interconnected sequence 
which maintains temporal order (Bell, 2002; Clandinin, 2013; Clandinin & 
Connelly, 2000; Clandinin & Rosiek, 2007; Murray, 2008). During NI, 
researchers pay attention to participants’ experience as it goes through time 
and in situational context (Clandinin, 2013; Clandinin & Connelly, 2000).  
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Thus, NI is characterised by having a pragmatic, relational, contextual, 
temporal and continuous epistemology and methodology (Caine & Estefan, 
2011; Clandinin & Rosiek, 2007; Shaw, 2017), where attention is paid to the 
personal, social, place and temporality dimensions of stories. Stories are 
positioned and shaped by larger narratives that exist within the lives of 
participants and the lives of researchers and are influenced by cultural, social, 
and institutional elements (Caine & Estefan, 2011). The shape of stories we 
tell are thus formed by those we are told from birth, throughout our early years 
and throughout our time (Bell, 2002; Okri, 1997).  
 
The relational aspect of NI recognises that meaning is created by joint 
interaction between researchers and participants in certain sociocultural and 
institutional settings (Clandinin & Connelly, 2000; Tierney, Seers, Tutton, 
Reeve 2017). It is this relational aspect which shapes the stories told in 
interviews and in turn shapes the interpretations made by the researcher 
(Caine & Estefan, 2011). Meaning is made through a process of “narrative 
emplotment” (Ricoeur, 1991), which organises an array of events sequentially 
to create a narrative plot (Tropea, 2011) through which individuals make a 
point about an event or argue a certain perspective (Murray, 2008; Squire, 
2013). It is this point that the researcher interprets, and which allows an 
understanding of the participants’ perception of events or experiences and 
allows access to the identity of the storyteller and the culture in which they live 
(Clandinin & Connelly, 2000; Clandinin & Rosiek, 2007; Squire, 2013).  
 
Without plot a narrative is just a sequence of words with no meaning (Haydon, 
Browne, and van de Riet, 2018; Mattingly, 1994; Tropea, 2011). The plot 
accentuates tensions inherent within the narrative and moves the narrative 
forward through a unique “order of meaning which features time and sequence 
in relation to activity” (Crossley, 2002, p. 2). “Sequence” and “time” are 
acknowledged as playing a crucial part in allowing oneself and others an 
understanding of what happened in certain situations and making experiences 
meaningful (Crossley, 2002, p. 2). Humans define meaning in their own lives 
and make sense of their existence by looking backwards and into the future 
(Crossley, 2003). Humans are motivated to survive by considering their future 
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and following their ambitions (Crossley, 2003). As Frankl (1984), highlighted 
by Crossley (2003, p. 440) insists, “it is a peculiarity of man that he can only 
live by looking to the future”.  
 
Sequencing of time and looking to the future may be seen in the illness 
narrative employed by sick individuals, highlighted by Smith, (2016, p. 205),  
“Yesterday I was healthy, today I’m sick, but tomorrow I’ll be healthy again”.  
 
2.4 Narrative Inquiry as a research approach in the study of illness and 
healthcare 
NI has become popular as a methodology in illness and healthcare because 
sick individuals need to tell stories about their illness and treatments to make 
sense of what is happening to them (Murray, 2008). The recognition of this 
need and the acceptance of storytelling as a valid approach to knowledge 
production (Bury, 2001), has led to a post-modern explosion to the study of 
narrative within the healthcare arena (Andrews, Squire & Tamboukou, 2013; 
Murray, 2008; Riessman, 2005, 2008).  
 
Chronic illness, and life-threatening illness propels people into a state of 
disarray or incoherence (Bury, 1982; Charmaz, 1997; Crossley, 2000, 2002, 
2003; Murray, 2008; Riessman, 1993; Williams, 1984). Incoherence in 
chronically sick individuals Crossley (2002) notes, occurs because their 
normal temporal orientation of time, past-present-future, is shattered. Their 
prognosis can disallow contemplation of a future which, in turn, disrupts the 
conception they had of themselves, their everyday lives, indeed, their whole 
world (Crossley, 2002), a situation characterised as “narrative wreckage” 
(Frank, 1995, cited in Crossley, 2002, p. 10).  
 
Continuity and coherence are vital to a sense of self. When chronic or life-
threatening illness disrupts continuity and coherence, individuals need to 
construct a comprehensible story by a process of narrative emplotment. This 
allows them to make sense of the confusion and pandemonium in their 
everyday lives that the illness has wrought (Bruner, 1986; Del Vecchio Good, 
Munakata, Kobayashi, Mattingly, & Good, 1994; Good & Del Vecchio Good, 
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1994; Crossley, 2000, 2002, 2003). It is as if: “to bring order to disorder” 
(Murray, 2008, p. 26). Construction of a coherent narrative makes life appear 
meaningful (Ricouer, 1991; Mattingly, 1984), and allows individuals to try and 
establish a sense of normality back into their lives (Crossley, 2002).  
According to Bruner (1986) and Good and Del Veccio Good (1994), two 
elements are associated with chronic illness narratives: one is that individuals 
structure their narratives in a manner to draw an empathetic response from 
their audience; and the other is that individuals experiencing chronic illness 
express quest narratives which portray themselves to be in a “subjunctive 
world”, that is, a world in which there is always a possible hope of getting better 
(Good & Del Vecchio Good, 1994, p. 839). As such, their stories are not 
finalised, rather they are told in the “midst” of their ongoing story, their future 
is uncertain (Clandinin, 2013; Good and Del Vecchio Good, 1994).  
 
Physicians have been noted to collaborate with patients in this quest narrative. 
For instance, in their study of oncologist practice in America, Del Vecchio 
Good, Munakata, Kobayashi, Mattingly and Good (1994) suggested that 
cancer patients and clinicians work together during their clinical meetings 
through a process of therapeutic emplotment of illness, and the treatment 
regime associated with it. Therapeutic emplotment Del Vecchio-Good, 
Munakata, Kobayashi, Mattingly and Good (1994) postulated, describes how 
physicians caring for cancer patients employed metaphors of hope during 
discussions with patients that promoted a future. They did this by focussing 
their discussions around available therapies, treatment plans and side effects 
of treatment, in preference to discussing what the future held. In urging 
patients to receive chemotherapy treatment, the oncologists tried to preserve 
patients’ hope of survival, dispel feelings of despair and encouraged people to 
fight against “disease and death” (ibid, p. 856; Crossley, 2003; Murray, 2008).  
 
2.5 Conceptual approach  
Conceptually I explored, interpreted and presented participants’ storied 
experiences by framing them within Dewey’s three dimensions of experience: 
sociality, place and temporality. These dimensions are consistent with aspects 
of experience that I sought to explore in the research objectives (see Table 2).  
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These three metaphorical commonplaces of experience were employed as the 
conceptual framework throughout this study. Initially to frame my research 
objectives, to collecting storied data in the field with the aid of prompts, 
throughout the analysing phase and finally in the discussion of findings. This 
ensured a coherent and consistent flow throughout the study between the 
different components of the research process. 
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Table 2 Framing my research objectives 
 
Sociality commonplace:  
Personal Dimension 
Sociality commonplace:  
Social Dimension 
Place / Space  
Dimension 
Temporality / Continuity  
Dimension 
 
 
Objective one: 
To explore the expectations 
and challenges around 
receiving regular BT in a day-
case setting. 
 
 
Objective two: 
To explore healthcare 
professional’s role on 
participants’ experience of 
BT. 
 
 
Objective three: 
To explore the effect of the 
place or setting where the 
blood transfusions were 
administered on participants’ 
experiences of BT. 
 
 
 
Objective four: 
To explore the change in 
participants’ experiences as 
disease progressed from an 
early palliative phase, to a 
late palliative phase, to the 
terminal palliative phase. 
 
25 
 
2.6 Limitation of narrative inquiry approach 
During narrative inquiry, narratives ‘re-present’ experience, refashioning it 
during expression to display transformation or change (Squire, 2013). Thus, it 
was acknowledged that the narratives of personal experience employed as 
data may not have always been exact mirror images or replications of what 
had occurred (Smith, 2016; Squire, 2013). It is known that people may 
sometimes forget the details of an experience, tell untruths or get things 
muddled (Personal Narratives Group, 1989). They tell stories that defend how 
they interpret themselves and omit those that undermine their perceptions of 
self-identity (Bell, 2002). Participants’ narratives also change dependant on 
audience and the cultural and environmental situation patients find themselves 
in (Riessman, 2008; Squire, 2013).  
 
According to Bell (2002) it is irrelevant whether the stories are true or not, 
because NI allows the researcher to look deeper to explore the fundamental 
assumptions that shaped the stories. She explains: “no matter how 
fictionalised, all stories rest on and illustrate the story structures a person 
holds. As such they provide a window into people’s beliefs and experiences” 
(Bell, 2002, p. 209). It is acknowledged that personal narratives “do” still reveal 
truths in the manner that the teller wants to be understood (Personal 
Narratives Group, 1989, cited in Patterson, 2013, p. 36). 
 
In this thesis the personal oral accounts that participants provided were viewed 
as constituting reality, where they made sense of what was happening in their 
lives as they tried to adapt to their struggles (Crossley, 2003). It was believed 
that every narrative told was valid to some extent and contained important 
points that could be revealed through interpretation (Clandinin and Connelly, 
2000; Patterson, 2013). As Labov, (1972) maintained; narratives provide, “an 
imperfect, practical wisdom”, that may not have the generality of a “grand 
theoretical truth”, but never the less provides important truths (cited in Squire, 
2013, p. 51). 
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2.7 Rationale for utilisation of narrative inquiry approach 
To meet the aim and objectives of the study a pragmatic NI approach was 
adopted. NI, guided by Clandinin (2013), was deemed suitable for studying the 
narratives of patients receiving BT for several reasons: 
 
Firstly, the aim of this study was to explore participants’ experience and in NI 
experience is the phenomenon under study and is explored and understood 
through dimensions: sociality (personal and social dimension); place 
dimension; and temporality dimension. As such, NI allows a deep 
understanding of participants’ experience of BT and of their self-identity and 
allowed the objectives of the study to be met. NI provides a way of focussing 
on stories around experience that are important to patients such as their 
worries, concerns and hardships. Having a pragmatic philosophical foundation 
allows emphasis to be placed on practical application of findings (Kvale, 
Brinkmann, 2009). It allows practical knowledge to be developed from these 
stories, aspects which makes NI particularly suitable for healthcare research 
(Haydon, Brown & van de Riet, 2018). 
 
Secondly, NI is an established approach within nursing and since its inception 
multitudes of nurse researchers have chosen to use narrative inquiry (Chan, 
Jones & Wong, 2013; Haydon & van de Riet, 2014; Hsu & McCormack, 2011; 
Schick Makaroff, Sheilds & Molzahn, 2013; Wang & Geale, 2015). These 
academics recognise that NI has the capacity to capture important nuances of 
the personal, everyday life experiences of patients within the complex 
discipline of nursing and healthcare (Wang & Geale, 2015). NI has been said 
to reveal the “humanness of healthcare and nursing” (Lindsay, Schwind, 2016, 
p. 1).  
 
The approach grants access to understanding of experience through stories 
consciously told by participants, with an awareness that this permits access to 
deeper information that patients may not consciously have knowledge of 
themselves (Bell, 2002, p. 209). Stories can be oral, visual, written, or 
imaginary stories of personal experience (Clandinin, 2013; Clandinin & 
Connelly, 2000; Clandinin & Rosiek, 2007 Connelly & Clandinin, 2006).  
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In this thesis, exploration of participants’ experience was gained through the 
oral, personal stories of experience co-constructed between participants and 
me. I felt comfortable with the approach as stories are ubiquitous within 
nursing. Patients tell their stories to nurses about all aspects of their lives; their 
concerns about their illness, their problems related to their medications and 
lives, and the problems they cause for their families (Sandelowski, 1991). 
Thus, as a nurse, I gain knowledge about patients’ experiences and the 
hardships they endure through listening to their stories. It is what I do every 
day. Listening to their stories and understanding their problems allows me an 
understanding of the nursing and medical care that is most needed to suit their 
situation. Indeed, it is “the human impulse to tell tales that gives nursing 
scholars access to everyday life human experiences” (Sandelowski, 1991, p. 
165).  
 
Consistent with NI in this study narratives were employed as data and as 
representational form. To constitute the narratives, the stories told by 
participants were appropriated by me and transformed through interpretation 
into coherent narrative accounts during analysis. Appropriation meant that I 
gained an understanding of participants’ experience in effect by the 
experience it provoked in me, which I understood as being socially and 
culturally situated. Ricoeur (1972, p. 89) defines appropriation as the “ability 
to make one’s own what was initially alien” (cited in Murray, 2008, p. 43) 
 
Accepting the premise of narrative emplotment provides a strong rationale for 
employing a narrative inquiry approach to explore participants’ experience of 
BT. 
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Chapter 3: Research methodology 
3.1 Introduction 
This chapter provides a methodological overview. This is followed by 
discussion of the sampling, recruitment, data collection strategy and the 
interview protocol. The ethical considerations and the process of ethical 
approval are then reported, which is followed by the data analysis procedure. 
The chapter concludes with a discussion of “found poetry”, which is the 
approach employed to present the raw data and support the findings of this 
study 
 
3.2 Methodological overview 
Nested within a qualitative research tradition, the research approach 
employed in this study was an exploratory, longitudinal, narrative inquiry. 
Twenty-two in-depth interview transcripts from eight participants, as well as 
participant demographic information, and researcher’s reflective data were all 
collected between the 2nd of August 2012 and 30th July 2013. Unstructured 
interviews elicited the blood transfusion experiences of these participants who 
received a blood transfusion every two to three weeks while in an early, late, 
or terminal palliative stage of a haematological disease. The participants’ 
demographic and descriptor information were collected on a Case Report 
Form and qualitative, reflective information was captured in a study diary.  
 
The participants received blood transfusions in one of three settings: 
Haematology Day Unit; Hospice Day Unit; or the Day Unit of a community 
hospital. Data was analysed using a thematic narrative analysis method. 
Narrative plotlines (themes or threads) that weaved through participants’ 
stories were elucidated. Storied experiences are presented through storylines 
(overarching themes) which are situated within the dimensions of sociality, 
place and temporality. The words of the participants are presented in poetic 
form, in line with arts-based inquiry in qualitative research (Butler-Kisber, 
2005; Sjollema, Hordyk, Walsh, Hanley, & Ives, 2012).  
 
29 
 
3.3 Method of Sampling and Recruitment 
3.3.1 Sampling 
A purposive sampling method was used to determine the participants to be 
included in this study. Purposive sampling allows the researcher to 
consciously select their subject sample to fit with the purpose of their study 
(Patton, 2002). Typical case sampling was employed in this study whereby 
participants were chosen based on the following characteristics: they were all 
in a palliative phase of a haematological disease as assessed by a consultant 
haematologist using the palliative phase definitions shown in Table 3, and they 
all received BT on a regular basis in a day case setting. The participant sample 
therefore had characteristics which are pivotal to this research study and which 
allowed collection of pertinent data on issues central to the subject area being 
studied. 
 
Table 3 Palliative Phase definitions employed in this study (based on 
Dalgaard, & Thorsell, Delmar, 2010, p.88) 
 
Early Palliative Phase: 
The patient is incurably ill 
The condition typically lasts twelve months. 
 
Late Palliative Phase: 
The patient is incurably ill 
The condition typically lasts for six months. 
 
Terminal Palliative Phase: 
The patient is terminally ill and dying 
The condition leads to death within days/weeks/less than six months. 
 
3.3 2 Recruitment of Participants 
Recruitment of participants was from one of two settings: The Haematology 
Day Unit (HDU) of an NHS Hospital Foundation Trust, and the Day Unit of an 
NHS Community Hospital.  
Recruitment was carried out by three consultant haematologists who acted as 
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‘gatekeepers’ to protect the welfare of their patients. These consultants 
assessed patients’ suitability to take part in this study dependent on the study 
inclusion/exclusion criteria which is described in Table 4: 
 
Table 4 Inclusion and Exclusion criteria 
Inclusion criteria: 
Patients diagnosed in a palliative 
phase of a haematological 
malignancy. 
 
 
 
 
 
 
 
Were no longer receiving curative 
chemotherapy. 
 
 
 
 
 
 
Attended a Day Unit setting to 
receive their BT. 
 
This was viewed as crucial as the 
specific aim of the study was to 
explore the experiences of 
participants’ in a palliative stage of 
their disease. Furthermore, to 
explore if their experience changed 
as their condition deteriorated 
through the early, late, terminal 
palliative phases.  
 
One of the objectives was to explore 
participants burdens associated with 
BT. It may have been too challenging 
for participants to separate out the 
problems they encountered with BT, 
from the problems they suffered 
during chemotherapy treatment.   
 
Another aspect to explore was the 
effect of the day unit setting on 
participants’ experience of BT.  
Exclusions: 
Patients that were unable to provide 
informed consent due to cognitive 
impairment, or who were unable to 
speak or understand English. 
 
 
As face to face interviews were the 
primary data collection method it was 
essential that participants could 
communicate with me on a one to 
one level.  
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Patients who were below the age of 
18. 
 
 
The day-unit study settings were for 
adults only (that is, over the age of 
18). 
 
3.4 Patient flow pathway  
As shown in the patient flow pathway (Figure 1, p. 32) the consultant 
gatekeepers only spoke to their patients about the study if they believed that 
the patients were physically and psychologically able to take part in the study. 
When discussing the study, the consultants would inform their patients about 
the study objectives and the terms of participating in the study. If the patient 
showed interest and agreed to their details being passed to me, then the 
haematologists referred the patient to me so that they could learn more about 
the study. A letter of invitation (Appendix 2) and participant information sheet 
(Appendix 3) were given to the patient who then had a minimum period of 
twenty-four hours to consider participation in the study before being asked to 
sign the study participant consent form (Appendix 4).   
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Figure 1 Patient flow pathway  
KEY: Black Text – Routine Care Red Text – Additional Intervention 
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Interested                          Not Interested 
Referred to Researcher  
Pat Information sheet provided 
along with explanation of study 
Patient given a minimum of 24 
hours to make decision 
Routine care 
On day of blood transfusion patient attends Haematology 
Day Unit, Hospice Day Unit, or Community Day Unit. Patient 
Signs Study Consent Form. Filed in patient’s medical notes. 
Patient kept a copy. Patient’s demographic and descriptors 
obtained from medical notes and entered on to case report 
form. 
Participants interviewed to obtain stories about their 
experience of blood transfusions (3 maximum. Length of 
interview determined by participant). 
If medical consultants felt that patients fitted the inclusion criteria and were able 
emotionally and physically to participate they informed the patient about the 
study.  
All patients in a palliative phase of a haematological disease who attend a day unit 
setting to receive regular blood transfusions were screened for suitability to take 
part in this study by their respective consultant. 
Interviews were audio-taped and transcribed. All data coded 
to maintain strict confidentiality and anonymity. Transcribed 
data checked for accuracy of transcription by clinical and 
academic supervisor.  
Patients discharged from setting on completion of blood 
transfusion. 
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3.5 Patients referred but not recruited 
Out of twelve patients who were referred to me by a consultant haematologist, 
four were not recruited:  
 
One of those referred was receiving blood transfusions every six months and 
had not been diagnosed as being in a palliative phase of his disease, he 
therefore did not meet the inclusion criteria described in Table 3. 
 
A second patient asked me to interview her immediately following our 
discussion about the study. I explained that the study protocol requires a 
twenty-four-hour period to consider taking part prior to signing the Informed 
Consent Form. Sadly, the patient died before our arranged meeting.  
 
A third patient having read the Participant Information Sheet decided she did 
not want to participate. 
 
A fourth patient was transferred to another hospital which was out of the study 
recruitment area, prior to signing the participant consent form. 
 
3.6 Participants recruited into the study 
Eight participants were recruited into the study. Recruitment ceased at this 
point as no new stories or information was forthcoming. As researcher I also 
adopted the position that ten or less participants are considered a suitable 
number to sufficiently inform qualitative research studies (Polit, Beck, & 
Hungler, 2001), as the aim in this type of approach is not about representation 
of sample, or generalisability of findings. Rather the approach is concerned 
with participants having sufficient experience with the area under study; that 
is, their “appropriateness” (ibid, p.250), to provide applicable information to 
inform the study aim and objectives. 
 
Recommended sample size in narrative research approaches proved difficult 
to establish from the academic literature. Cresswell (2013) suggested that as 
few as one to two cases may be sufficient if the researcher is not aiming for a 
collective story to be developed. Guetterman (2015) highlighted that from his 
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review of NI studies, in health sciences, the sample sizes ranged from one 
participant to fifty-two participants. Bell proposed that in NI the “time 
commitment required makes it unsuitable for a large number of participants” 
(Bell, 2002, p. 210).  
 
Reviewing the work of other NI researchers suggests that between four and 
six participants were recruited into their studies: Chan, Jones, and Wong, 
(2013) for instance, employed five participants in their narrative inquiry study 
to explore the relationship between communication, care and time on 
registered nurses’ work; Haydon, Browne, & van de Riet, (2018) who explored 
person-centred nursing care, suggests that limiting the sample size to between 
four and six participants was appropriate. Their reasoning was the large 
amount of data produced from in-depth questioning between participants and 
researcher during NI, and because exploration of data via three dimensions of 
experience (sociality, place and temporality) creates a longer and more 
detailed presentation of findings (Ely, 2007). A sample of eight was 
considered, therefore, comparable with, if not more than, other published 
narrative inquiry studies. 
 
3.7 Demographic and descriptor information 
Out of the eight participants: six were male and two were female, with an age 
range of between 41 and 86 years old (six participants were over 65 years of 
age). Seven were married and one was widowed. All eight had been 
diagnosed with a haematological malignancy (HM) of which: 
five had Myelodysplasia (MDS)  
one had MDS and Non-hodgkins lymphoma 
one had Acute Myeloid Leukaemia (AML) and  
one had AML and Non-hodgkins lymhoma. 
 
Three participants (Kenneth, Ernest and Zavier) were in an early palliative 
stage of their HM. Two (Jim and lily) were in a late palliative stage and three 
(Harold, Helen and Bill) were in the terminal palliative stage of their illness:  
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Supplementary data was collected prior to each interview via a Case Report 
Form (CRF) (Appendix 5). The CRF contained demographic and descriptor 
information obtained from participants and their medical notes, and included: 
gender; date of birth; marital status; haematological malignancy (HM); 
palliative phase of the participants’ HM; the frequency participants attended 
the unit; the day unit where participants received their blood transfusions; the 
date of their first blood transfusion; the number of BT participants had received 
since their initial blood transfusion to the end of study; the date of last blood 
transfusion prior to death; and the number of days between transfusion and 
death. A summary of the information from the CRF is in Table 5. Date of death 
and date of last BT prior to death is not included for confidentiality reasons. 
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Table 5 Summary of information from case report form  
 
  
Names 
(All 
Pseudo
nyms 
 
Gender Age Marital 
Status  
Haematological 
disease 
Palliative 
Phase of 
disease 
Frequency 
of BT during 
duration of 
study 
Setting for BT and 
meeting 
Date of 1st 
BT 
Number 
of BT 
received 
between 
initial BT 
& final 
interview 
Number of 
days 
between 
BT & 
Death  
Kenneth 
 
Male 79 Married MDS Early 
 
Every 3 
weeks 
Haematology Day 
Unit 
18/05/09 46 9 
Jim Male 62 Married MDS Late Every 2 
weeks 
Haematology Day 
Unit 
02/10/07 34 16 
Harold 
 
Male 72 Married MDS Terminal Every 2 
weeks 
Community 
Hospital Day Unit 
14/09/06 55 30 
 
Lily Female 86 Widow MDS Late Every 3 
weeks 
Haematology Day 
Unit 
08/09/09 34 11 
Ernest 
 
Male 75 Married MDS Early Every 2 
weeks 
Haematology Day 
Unit 
12/09/07 121 4 
Helen 
 
Female 68 Married MDS/NHL Terminal Every 2 
weeks 
Haematology Day 
Unit for one BT and 
Hospice Day Unit 
for the other 
08/10/12 18 24 
Bill Male 74 Married AML Terminal Every 2 to 
every week  
Haematology Day 
Unit 
20/12/12 18 1 
Zavier Male 41 Married MDS/AML Early Every 3 
weeks 
Haematology Day 
Unit 
05/06/08 52 17 
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3.8 Data collection  
During the study four types of data were collected: Interview data, 
demographic and descriptor data, reflective data and self-reported health 
status data. The primary data collection method was through qualitative 
interviews. 
 
3.8.1 Qualitative interviews 
3.8.1.1 Settings  
Interview data was collected from participants in one of three settings: 
interviews with six of the study participants took place within a side room of 
the Haematology Day Unit (HDU); one participant was interviewed on the day 
unit of a community hospital; and one participant had one of her interviews on 
the HDU and another on the Day Unit of the NHS Hospice. Participants were 
offered a choice of day, time and place, including their own homes to be 
interviewed. All participants chose to be interviewed while their BT were being 
administered as they said this was more convenient for them.  
 
3.8.1.2 Frequency and timing of interviews 
Twenty-two interviews were undertaken. Six of the participants (Kenneth, Jim, 
Harold, Lily, Ernest and Zavier) were interviewed three times and two 
participants (Helen and Bill) were interviewed twice as sadly they died before 
a third interview could be undertaken. 
 
The frequency of interviews varied as they corresponded with the 
administration of their BT: four participants were interviewed every two weeks 
and three participants every three weeks. At the first interview with Bill he had 
been receiving his BT every two weeks, however, at the second (final) 
interview his blood transfusion requirements had been increased to weekly.  
 
Interviews took between 30 and 60 minutes depending on what participants 
wanted to share and how they were feeling. In consultation with the study 
steering group (see Section 3.9.1) it was decided that a maximum of one hour 
was the allocated time slot. This decision followed the experience of Melin-
Johansson, Odling, Axelsson, and Danielson (2008) whose study was 
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designed to elucidate the meaning of quality of life, narrated by patients with 
incurable cancer who were approaching death. These authors suggested that 
sixty minutes is not too long, on condition that patients were allowed short 
breaks.  
 
During each of the interviews I was extremely vigilant of each participants’ 
condition. I asked frequently throughout if they were comfortable and happy to 
continue; we stopped for breaks whenever they wanted to, and they could stop 
at any point during the interview without giving a reason. At no time did any of 
the participants ask me to stop the interview.  
 
All of the interviews undertaken were audio-recorded onto a password-
protected tape recorder and transcribed verbatim soon after each interview by 
a member of our haematology team. This person was chosen because of her 
excellent secretarial typing ability, her expertise in listening to audio tapes, her 
transcription skills, her familiarity with medical terminology, and her contractual 
obligation regarding issues of confidentiality. Having the right person to 
accurately transcribe this oral information into written text was crucial because 
these transcripts served as the primary data from which access to participants’ 
feelings could be gained, their experiences analysed, and their experience 
communicated to a wider audience, including academics, examiners and other 
healthcare professionals (Bamberg, 2012).  
 
Transcription of data was according to protocol influenced by McLellan, 
MacQueen and Neidig (2003). Essentially, everything that was said by each 
participant was transcribed verbatim. Transcripts included; mispronunciation 
of words and non-lexical utterances, such as, “erm”, “err”, “well”, “so”, and 
“like”. Laughs, and pauses were also included. The transcripts were labelled 
with the participant’s pseudonym, the date the interview took place, sequence 
number of the interview, and where the interview took place. The researcher’s 
text was labelled (R), and the participant (P). Every time either one of us spoke, 
our utterance was transcribed as a discreet unit of text and assigned the 
appropriate speaker’s label. A line space was inserted between my prompt 
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and the participants’ response. Identifying information about people and 
names of hospitals was removed.  
 
3.8.1.3 Interview approach 
The interview approach employed was an in-depth, unstructured, face-to-face, 
conversational, narrative interview approach that centred on participants 
stories (Mishler, 1986). Conversations were viewed as “a basic mode of 
knowing” (Kvale & Brinkmann, 2009). Conversations were unstructured and 
guided by study prompts which were based on the analytical framework and 
which allowed participants’ stories to be heard and developed in line with the 
purpose of the study. 
 
Using unstructured interviews for a narrative research study allows exploration 
of the participants’ ‘lived world’ (Kvale, 1996, p. 105). The approach promotes 
the concept of participants being experts in their lives and events that take 
place. Participants are encouraged to tell their own stories, to speak about 
what they want to discuss rather than the researcher imposing on them what 
they want to talk about. This allows aspects to be spoken about that may have 
been difficult to achieve by other data collection methods, such as 
questionnaires or focus groups where the researcher dictates the subject. 
Narrative interviews emphasise the temporal, the social, and the meaning 
structures of the interview (Kvale & Brinkmann, 2009). 
 
Longitudinal data (data that follows the same subjects over a period) was 
collected from each participant. The initial intention had been to interview each 
participant three times, during their first blood transfusion and during the 
administration of two subsequent blood transfusions. Carrying out prospective, 
repeated interviews with several participants about the same phenomena is 
commonly employed in narrative inquiry, enabling a deep understanding of the 
phenomena under investigation (Chan et al., 2013; McCracken, 1988). It 
allows for the smallest changes in experiences at an individual level to be 
identified and recorded (Ruspini, 2002). It also has the potential of enabling a 
more trusting relationship to develop between the researcher and participants, 
which in turn can promote more open conversations (Murray et al., 2009; 
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Seidman, 1991). Furthermore, the time between interviews is said to provide 
space for participants to reflect on and deepen their subsequent stories 
(Seidman, 1991).  
 
My interview approach was guided by the work of Atkinson (1998) who 
suggests that rapport between participant and researcher is developed if the 
researcher demonstrates warmth, friendliness, empathy, sensitivity, support 
and encouragement. This rapport was achieved by: smiling and nodding at 
appropriate moments thus demonstrating that I was keen to hear what 
participants had to say; keeping my own voice in the background when 
possible to allow participants to take the lead and discuss issues important to 
them; maintaining an iterative approach and actively listening and seeking 
clarification or elaboration when required. This meant that challenges and 
hardships identified in prior interviews were explored and revisited again in 
later interviews with reference to emerging experiences. Episodically, my 
understanding of what participants had told me was shared with them to 
confirm that my understanding was correct (McGrath, 2004).  
 
Generally, the interview started with asking how long the participant had been 
receiving blood transfusions. I started in this manner because it seemed to 
provide an informal entrance into our conversation. My aim had been to try 
and maintain a similar interview approach for each participant, however, this 
proved difficult to facilitate due to my prior nurse-patient relationship with them. 
Two of the participants, who I knew very well as I had placed their peripherally 
inserted central lines and taken their bone marrow biopsies, entered 
conversations easily with me, taking the lead throughout the interviews. As I 
had not met the other six participants prior to their involvement in the study, a 
different approach was required during the first interview, whereby I took the 
lead and employed study prompts as highlighted in Appendix 6 (Appendix 6. 
Initial conversation prior to first, second and third interview, and prompts 
employed in study).  
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3.8.1.4 Pilot interview  
There is conflicting academic literature concerning the need for a pilot 
interview in qualitative research studies. Holloway (1997) suggested that a 
pilot interview is not necessary because the research approach has the 
flexibility for the researcher to develop their interview technique as interviews 
progress. While others (Denzin & Lincoln, 2011; Robson, 1999) suggested 
that pilot testing is an essential part of the research process that allows 
refinement to study aspects prior to embarking on the main study.  
 
Following consultation with the study steering group, a decision was made not 
to undertake a pilot interview with participants as it was felt to be inappropriate 
in light of their poorly condition. Instead, the interview process and the prompts 
to be employed in the study were first discussed with my academic supervisor 
which resulted in minor revisions to the prompts. Using the revised study 
prompts, I then asked a member of our haematology team, who had received 
BT several years earlier, to tell me her stories about her experiences of 
receiving BT, following which amendments were made to the initial prompt. 
 
3.8.2 Reflective data 
Reflection and reflexivity are essential aspects of the research process. Bolton 
and Delderfield (2018, p. 9) highlight the difference between these two terms: 
Reflection, they suggest is an in-depth review of events either alone or with a 
supervisor to understand ‘why’ something happened under certain social and 
political contexts. These reflections of events may be recorded within a study 
diary during the research process (Bolton & Delderfield, 2018).  
 
Reflexivity, Bolton, and Delderfield (2018, p. 10) suggest, allows researchers 
to look inside themselves to question their own beliefs, position, suppositions, 
intolerances and characteristics and to understand the multifaceted 
relationship with participants and others in the research endeavour.  
 
Reflection-on-practice allows researchers to; “reflexively critique their personal 
values, ethics, prejudices, boundaries, assumptions about roles and identity 
decision-making processes” (Bolton and Delderfield, 2018, p.8). Duke and 
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Appleton (2000, p.1558) describe key skills necessary during the process of 
reflection-on-action: 
• Describe the experience 
• Identify salient features of the experience 
• Analyse the feelings evoked by the experience 
• Analyse the experience with respect to different sources of knowledge 
• Analyse the contextual factors that might have influenced the 
experience 
• Synthesize existing knowledge with the new knowledge gained from 
reflection 
• Evaluate the experience and the learning achieved and the implications 
for future learning and practice, and plan action to take the learning 
forward into practice and other learning activities.  
 
A study diary was maintained throughout the study period to record reflection-
on-practice and the research process that considered my values, my 
professional and personal life-experiences and any assumptions or 
preconceptions held that could influence how I understood and gave meaning 
to the data collected during the interview and data analysis process. I identified 
and noted striking features about issues raised and analysed the feelings this 
evoked in me (Duke and Appleton, 2000), and the emotions that I witnessed 
during each interview. Notes were written shortly after each interview while 
they were still fresh in my mind. These notes were helpful in that they retained 
in written form “bumping” places (Clandinin, 2013, p.63); that is, matters 
participants brought to light while telling their stories that I found difficult to 
comprehend from a clinical perspective. One example of a bumping place, for 
example, emerged during a conversation with Jim who told me that he had 
persuaded the doctors to change his blood transfusion prescription from every 
two weeks to every four weeks. His story did not make sense to me from a 
haematology nurse practitioner perspective since the frequency of BT is 
expected to increase rather than decrease as disease progresses, however, 
for Jim this was a perfectly coherent narrative. Analysis of the contextual 
factors that might have led to this experience (Duke and Appleton, 2000) led 
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me to understand what Jim was trying to achieve. He was trying to get his 
body used to managing with monthly blood transfusion support. Training his 
body in this manner, he believed, would get his body used to going four weeks 
without a transfusion. He thought this was necessary because he was 
preparing to go on a four-week holiday where access to blood would be 
impossible.  
 
Reflection on “tensions” (Clandinin, 2013, p. 107) that participants and I 
appeared to experience were also recorded in the study diary. These reflective 
notes served as an aide memoir of issues that required deeper exploration at 
subsequent interviews. Tensions were recognised by exhibitions of distress, 
anger or stoicism on the part of participants, which evoked tensions in me 
identified by feelings of guilt and sadness as I learnt of participants’ physical 
and psychological hardships.  
 
3.8.3 The self-report EuroQol EQ-5D3L Health Questionnaire or WHO 
performance status tool 
Participants were also asked to complete a EuroQuol EQ-5D-3L Health 
questionnaire prior to each interview (Appendix 7), and complete a Visual 
Analogue Scale, where the “best health state imaginable” was marked as 100 
and the “worst health state imaginable” was marked as 0. This data is 
presented in Appendix 8. As one participant was so unwell on the day of his 
third interview, the validated WHO performance Status tool was completed 
instead (Appendix 8). The health information, which was collected to provide 
a descriptive profile of health status as self-reported by participants, has not 
been discussed throughout this thesis since this supplementary data did not 
appear to add to a more complete participant description. 
 
3.9 Ethical considerations 
Much consideration was given on how to look after the best interests of the 
participants in this study as it was acknowledged that palliative patients may 
experience physical, psychological, social and spiritual distress which makes 
them a particularly vulnerable group in relation to participating in research. In 
addition, those with a life-limiting condition may not benefit directly from taking 
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part in research which means the cost of participating in research will always 
outweigh the benefits. Any research undertaken within an NHS hospital Trust 
must abide by the primary ethical principles of beneficence, non-maleficence, 
respect for human dignity and justice (Polit, Beck & Hungler, 2001).  
 
This research study obtained ethical approval on 22nd May 2012 by the NHS 
Health Research Authority, National Research Ethics Service Committee 
South Central – Portsmouth, Bristol Research Ethics Committee (Ethics 
reference number: REC 12/SC/0282) (Approval Letter, Appendix 9). Ethical 
approval to undertake the study within an NHS Foundation Trust hospital was 
also obtained. Following a Research Risk Assessment for Trust Sponsorship, 
approval was given by the Research and Development Office, who confirmed 
that the Trust were willing to act as a sponsor for the study under the terms of 
the Department of Health Research Governance framework for Health and 
Social Care, Second edition (DH, 2005) (RGF). R&D Ref. No: 2012/SUR/10. 
(Appendix 10. Research risk assessment for Trust sponsorship). 
 
3.9.1. Steering group  
A study steering group was established consisting of two lay members of the 
public and a group of healthcare professionals, including: a consultant 
haematologist (lead clinician in haematology who is also clinical supervisor for 
the study); the lead clinician of the NHS Hospitals Palliative Care Service who 
is also Associate Medical Director and end-of-life Consultant at the hospice; a 
haematology specialist/research nurse; the modern matron and divisional 
manager for cancer services at my employing trust; my academic supervisor; 
and me as Chief Investigator.  
 
Following an approach from the patient experience manager at my employing 
NHS Foundation Trust, it was decided to invite two members from the 
Hospitals NHS Trust's Patient Voice Forum and Cancer Partnership Group. 
The two lay members helped ensure that my original study proposal was 
sensitive to patients’ needs, that it was appropriate and acceptable to patients 
and that it was ethically sound. The two were actively involved in a 
collaborative manner at the initiation of the study. Initial feedback over the 
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study protocol was provided by members of the steering group following which 
amendments were made. Two suggestions incorporated were the need to 
involve the Trust Counsellor if participants became upset, and to invite family 
and friends to be present during the interview if the patient wanted them 
present. In this study, the support and advice from the Trust Counsellor was 
not required, and only one participant asked for her husband to be present 
throughout our two interviews.  
 
The purpose of the group was to discuss the management of the project and 
ensure adherence to best research practice as highlighted in the document 
“Research Governance Framework for Health and Social Care” (DH, 2005), a 
key element encompassing ‘respect for participants’ dignity, rights, safety and 
well-being’ (ibid, p.15). The steering group met quarterly.  
 
3.9.2 Confidentiality 
Participant confidentiality was safeguarded in line with the Data Protection Act 
(DPA, 1998). Each participant was given a pseudonym and a study number 
which populated all study documentation to ensure anonymity. Only the lead 
researcher and members of healthcare team had access to the Investigator 
Site File containing the participants’ initials, dates of birth, hospital numbers 
and designated study numbers. The coded Case Report Forms and transcripts 
are all kept in a locked cupboard at the researcher’s home. The recorded 
interviews and the reflective diary were kept on the researcher’s computer 
which is password protected. Participants confidentiality will also be protected 
in the final report and in any future publications. 
 
3.9.3 Positionality 
As both a nurse and an academic undertaking research it was important to be 
reflexive (Sheldon & Sargeant, 2009) about my positionality in this study as 
this dual role evoked personal ethical tensions.  
 
One challenge which revolved around my dual role as a nurse and as an 
academic researcher was the risk that patients might feel “obliged” to 
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participate in the study, just to show gratitude for the care they have received 
(Speck, 2009, p. 279). Participants were not coerced into taking part, indeed 
it was made clear during the Informed Consent process that there was no 
obligation to participate and that they were free to withdraw from the study at 
any point. Sheldon and Sargeant (2009) highlight several ethical issues in 
qualitative research which were encountered during this study. One of these 
issues related to the power that health professionals may hold over patients in 
their care because of their professional knowledge and their hierarchical 
position within the healthcare organisation. This issue cannot be avoided but 
measures were taken to minimise this effect during interviews with 
participants; for example, medical terminology was avoided, and neither my 
nursing uniform nor bleeper were worn.  
 
Another tension that featured was determining “who am I” (Sheldon and 
Sargeant, 2009, p. 166) a nurse or a researcher, as participants frequently 
asked me to undertake nursing care during our study interviews. Clinical 
supervision with the trust counsellor helped resolve this matter. My primary 
responsibility was to abide by my nursing and midwifery code of professional 
conduct, to provide care and to protect the interests of all patients (Nursing 
and Midwifery Code of Professional Conduct, 2015) as a priority over gaining 
data for the study.  
 
Supervision with my academic supervisor throughout the study period helped 
me to be reflexive on my personal and professional experiences which could 
create values and bias that influenced my interpretation of the findings. That 
is, as a nurse working within the area being studied preconceived ideas were 
held about blood transfusion administration. During the research process it 
was necessary to place these ideas in the background of my cognitive logical 
thoughts and allow my mind to “wonder” and to explore and understand 
participants’ experiences from their perspective. Wonder, according to Bolton 
and Delderfield, (2018, p. 22); “is the beginning of wisdom, because wonder 
is an open, enquiring state of mind when anything might be possible, when 
startling inspiration appears as a result of no cognitive logical thought”.  
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3.10 Data analysis: narrative analytical approach 
There are several approaches to narrative analysis of data: thematic, 
structural, dialogic and visual (Riessman, 2008). A thematic narrative analysis 
that focused specifically on content, that is, “what was said” rather than “how 
it was said” (Riessman, 2005, 2008) was employed in this thesis. Language 
was thus viewed as providing access to meaning, a resource rather than a 
phenomenon to be explored structurally (Reissman, 2005). Stories were kept 
intact during this analytical and interpretive processes. They were not 
fragmented or coded out of context, rather long narrative episodes were 
included that maintained the chronological pattern of the stories from 
beginning though to their resolution. The analytical steps employed were 
influenced primarily by the body of work of many researchers; Clandinin 
(2013), Clandinin and Connelly (2000), Connelly and Clandinin (1990) and 
Riessman (2005; 2008).  
 
The analytical process involved “narrative coding” of the transcripts influenced 
by Clandinin and Connelly (2000, p. 131). These authors proposed that to find 
narrative meanings the investigator needs to narratively code the data taken 
from the setting or field, denoted as “field texts”, to prepare “interim research 
texts”. Narrative coding involves sorting through all the transcripts of field texts 
to identify important themes (scenes, ideas, aspects) relevant to the purpose 
of the study then interweave these into the three-dimensional inquiry space. 
Scenes and ideas, for example included the people participants brought into 
their stories who have had an impact on their experience, the settings involved 
and the tensions that were exhibited and perceived.  
 
From the interim research texts, an individual research text for each participant 
was then created by seaming together the elements gained from each of the 
individual’s interviews and using the interpretive tools of “broadening” and 
“burrowing” (Clandinin & Connelly, 2000; Connelly & Clandinin, 1990, p. 11). 
Broadening brings to the research texts institutional, professional and cultural 
aspects, and burrowing allows the researcher to try and stand in the shoes of 
the participants to reconstruct a story of their experiences from their 
perspective. Finally, “re-storying” (Clandinin & Connelly, 2000; Connelly & 
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Clandinin, 1990) brought the research texts into chronological, coherent 
narrative accounts. These narrative accounts were thought of as a patchwork 
quilt (Clandinin, 2013) that consisted of many narrative themes stitched 
together to form the whole BT experience.  
 
Scanning across the eight narrative accounts resonant plotlines were 
discerned. Plotlines in this study were defined as aspects of significance to 
participants that wove through one or more of the stories that revealed 
individual perspectives of their blood transfusion experience, aspects that 
gave coherence and meaning to the stories.  
 
The process of data analysis undertaken was as follows: 
 
3.10.1 Step One: Hearing and feeling the stories 
The process of narrative analysis began as soon as participants started telling 
me their stories. Thoughts and feelings that arose during interviews were 
recorded immediately on completion of each interview. 
 
3.10.2 Step Two: Transcription of the data 
The audio-taped data (field texts) were transcribed as described earlier 
according to a protocol influenced by McLellan, MacQueen and Neidig (2003).  
 
3.10.3 Step Three: First reading of transcriptions - checking for 
discrepancies 
Once transcribed the transcripts were proofread. This involved me carefully 
listening to the audio-recordings whilst reading the transcripts to ensure 
accuracy of transcription, and to re-familiarise with what had been said during 
the interview. Very few corrections were necessary. Listening to the tapes 
raised emotions felt during our actual meetings, and these emotions were 
checked against what had been documented in the study diary but none of 
any significance were found.  
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3.10.4 Step four: Second reading of transcriptions - from field texts to 
interim research texts  
The next step involved an intense re-reading of the transcripts and ‘narrative 
coding’ (Clandinin & Connelly, 2000). At the end of this process, story scenes 
or ideas expressed (Frazer, 2004, p. 189) related to the study purpose were 
identified and recorded on a new document, considered as the “Interim 
Research Text” (Clandinin, 2013, p.47; see an example in Appendix 11). 
 
3.10.5 Step five: Third reading of transcriptions - categorisation of 
narrative scenes in the interim research texts 
During the following reading of the transcripts each of the identified scenes in 
the interim research text were organised within one of the three dimensional 
narrative commonplaces of experience: personal and social (sociality), place 
and temporality (past, present and future) (Clandinin, 2013; Clandinin & 
Connelly, 2000; see an example provided in Appendix 12). Organising scenes 
into this framework provided a lens that allowed distinct elements of 
participants’ experiences to be seen more clearly:  
Personal and social dimension: Participants’ feelings, understandings, 
expectations, challenges, relationships with healthcare professionals, and 
cultural aspects.  
Place dimension: The Haematology Day Unit (HDU), The Hospice Day Unit, 
The Community Hospital Day Unit and the Pathology Department.  
Temporality dimension: Blood transfusion history and changes in blood 
transfusion effect with disease progression. 
 
3.10.6 Step Six: Fourth reading of field texts – interim research texts to 
research texts 
The next step was to create a research text for each participant. The initial 
process involved weaving together the categories found in participants’ first, 
second and third interviews into a single document to create eight ‘research 
texts’. The tools of broadening and burrowing were employed at this stage to 
stitch together the narrative categories into research texts that portrayed the 
participants’ own perspective of their experiences within social and cultural 
contexts. The compiled research texts consisted of a collage of categories 
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under one of the three dimensions of experience. Many drafts of these final 
research texts were compiled until it was believed that an accurate 
representation of the experiences of each participant had been compiled.  
 
3.10.7 Step Seven: Creation of eight narrative accounts and identification 
of narrative threads or resonances (plotlines)  
The next step involved re-storying the categories into a chronological, 
coherent, individual participant narrative account for each participant that 
addressed the three dimensions of experience. Each account was organised 
in the following format:  
1. The account started with an introduction to the participant and 
included their age, HM, palliative phase, how long they had been 
receiving BT; 
2. The account then detailed personal and social aspects relating to BT, 
for example; how participants felt about BT, what they expected to 
happen following BT, any challenges they experienced associated with 
BT, and social aspects that included their relationships with healthcare 
professionals;  
3. The account detailed places associated with BT and the effect places 
had on participants’ experience of BT; and finally 
4. Temporal aspects were then detailed in the account which showed 
how participants experience changed over time. 
 
The process of re-storying helped me to discern similar narrative themes or 
characteristics that ran through each of the narrative accounts. These themes, 
which Clandinin (2013) refers to as “threads” or “plotlines” captured key 
features of each participants’ blood transfusion experiences. For example, 
their perspective of BT, their concerns, their fears, their expectations, their 
hopes and their revelations.  
 
Scanning across the eight narrative accounts, common plotlines emerged that 
resonated with receiving blood transfusions in a day case setting when 
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diagnosed in a palliative phase of a haematological disease. An example of 
how plotlines were derived is provided below. 
 
The plotline, Blood transfusions mean life was a thread echoed in all 
participants’ narrative accounts. Text box 1 presents a vignette from Kenneth’s 
narrative account to help demonstrate how his message “without blood 
transfusions it would be a box job”, provided the foundation for this plotline. 
Kenneth’s quotes are bold text. 
Text box 1. A vignette from Kenneth’s Narrative Account 
Kenneth’s story began when he was in an early palliative stage of his 
disease and he had been told by a consultant haematologist that they “can’t 
do anything else”. The only thing that the doctors can do, he understands, 
“is top your blood up because you’ve got immature red blood cells, 
simple as that”. He understands that “there’s no other tablets or magic 
pills or anything like that”, BT are the only therapy available for him that 
will keep him alive. Frequent blood transfusions he announces, “are part of 
my life. I have no choice, without blood transfusions it would be a box 
job”.  
 
3.10.8 Step Eight: Development of storylines 
The following step was to develop storylines, as they encapsulate and depict 
in a single line or phrase specific elements of participants’ everyday life 
experiences. As Brown and Addington-Hall (2008) suggest “storylines help 
make sense of complex narratives… and serve as organising threads to help 
patients, families and healthcare professionals better understand” (p. 200).  
 
Storylines, in this study, were thought of as overarching plotlines or themes 
which spoke across and within participants’ stories. Built from a foundation of 
plotlines, they represented a shared understanding of participants’ personal 
accounts of experience which had been informed by broader societal and 
cultural narratives. Development of storylines fashioned a way for me to 
present and discuss my findings academically and to my peers, in a way that 
would allow them to relate to the storylines as being applicable or non-
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applicable to their own practice. From the storylines they could draw their own 
conclusions regarding credibility, dependability, confirmability and 
transferability.  
 
3.11 Found poetry 
Initially, my plan had been to include direct participant quotes taken from the 
field to aid with trustworthiness of findings, presenting participant quotes 
exactly as they had been spoken. However, this approach did not recount 
participants’ experiences in the manner that I wanted. They seemed too long 
and did not invoke the empathy personally experienced when talking to 
participants. To address this presentation problem, “found poetry” 
(Richardson, 1994) was created to present the words of participants.  
 
Found poetry is a subjective interpretation of the words of participants by the 
researcher (Butler-Kisber, 2002) who “takes the words of others and 
transforms them into poetic form to re-create lived experience and evoke 
emotional responses” (Richardson, 1994, p. 521). Representing narrative 
findings in an arts-based form, such as found poetry, is becoming increasingly 
popular as researchers realise that poems can grasp and captivate the mind 
of the audience (Clandinin, 2013). Mishler (1999), decided to present his 
transcripts verbatim in a style close to poetic form, “where the poetic shape 
provides an accessible structure for the story” (Kvale & Brinkmann, 2009, pp. 
154-155). My decision to do this was greatly influenced by the work of many 
researchers, (for example, Butler-Kisber, 2002, p. 232; Clandinin, 2013; Duke, 
2007; Gee, 1986, 1991; Mishler, 1999; Reilly, Lee, Laux & Robitaille, 2018; 
and Richardson, 1994, p. 521).  
 
To display the words spoken by participants in a style close to that of a poem 
or stanza form the following guidelines were adopted (Butler-Kisber, 2002; 
Duke, 2007; Gee, 1986, 1991): 
• Each line of the poem was kept short and contained a new piece 
of information. There was generally a pause before the next line 
began  
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• Poetic stanzas were assembled by grouping sets of lines 
together that depicted a scene or image in the narrative  
• Each stanza was distinguished from other stanzas by a blank 
line. In creating these stanzas participants’ words were kept in a 
similar order to that spoken by them as generally their verbal 
accounts had a sequential, temporality associated with them. 
However, occasionally it was necessary to slightly rearrange the 
words in a line to create rhythm, pauses, emphasis and to keep 
themes together. This was achieved without changing the 
meaning of the text.  
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Chapter 4: Research Findings 
4.1 Introduction  
The findings presented in this chapter emerged from the analysis of stories 
told by eight palliative participants with a haematological disease, who 
between them had until the end of study received 378 blood transfusions. 
Throughout the chapter a recap of each participant is made, highlighting their 
age, which ranged from 41 - 86 years old, their haematological disease, and 
the frequency each received their BT.  
 
Four research objectives were established with the purpose of exploring 
participants’ experience. These objectives were met by undertaking a thematic 
narrative analysis of the storied data which addressed three dimensions of 
experience. This analysis led to common plotline findings which highlight 
challenges associated with blood transfusions which participants or I 
interpreted as having a detrimental effect on their care and everyday lives. The 
analysis was discussed with my academic supervisors and my clinical 
supervisor; however, it is appreciated that the interpretation of the data was 
subjective, as another researcher with a different set of experiences, from a 
different discipline could have interpreted the transcriptions differently.  
 
Nine plotlines were found to resonate with receiving BT when diagnosed in a 
palliative phase of a haematological disease:  
1. Blood transfusions mean life; 
2. Blood transfusions as a sustenance to life; 
3. An up and down everyday blood transfusion life; 
4. Life in the hands of physicians; 
5. Life in the hands of the nurses; 
6. Life in the hands of ward receptionists; 
7. Waiting in pathology for blood tests; 
8. Waiting on the haematology day unit; and 
9. Anxiety associated with places in the hospital setting. 
 
Three plotlines resonated with receiving blood transfusions within the Hospice 
Day Unit:  
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1. More individualised care; 
2. Hospice day unit perceived as a safer place to receive blood 
transfusions; and 
3. Hospice Day Unit perceived as a more tranquil place. 
 
Three plotlines resonated with the everyday lives of participants who were 
receiving BT in the late to terminal phase of their haematological disease:  
1. Somnolence overwhelms daily life;  
2. Adversities overpower everyday life; and  
3. Desperation to hang on to life. 
 
These plotlines provided the foundations for five overarching storyline findings 
that corresponded with the research objectives and presented throughout this 
chapter in three sections:  
Section 1 illuminates the personal and social dimension of experience. 
Section 2 illuminates the place dimension of experience 
Section 3 illuminates the temporality dimension of experience. 
 
Conveying the findings in separate sections, related to dimensions of 
experience might give the impression that these dimensions are not connected 
to each other. This is not the case. All the dimensions of experience were 
considered as being completely interrelated and pieced together like a jigsaw 
puzzle to provide an overall picture of participants’ everyday blood transfusion 
experience.  
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4.2 Section 1: Personal dimension of experience 
4.2.1 Storyline one: Everyday blood transfusion life hangs in the bag 
This storyline elucidates the personal dimension of experience and responds 
to objective 1: To explore participants’ expectations and challenges around 
receiving regular BT in a day unit setting.  
Three narrative plotlines provided the foundations for this storyline: blood 
transfusions mean life; blood transfusions as a sustenance for life; and an up 
and down blood transfusion life.  
 
These plotlines allow an insight into how participants felt about BT, what BT 
meant to them, their expectations, and the perceived effect on their day-to-day 
lives. Gaining an understanding of these aspects was one of the objectives of 
the study as there are limited studies that have addressed participants’ views 
about BT. Most researchers, appear to have undertaken positivist research 
that has focussed on the efficacy of BT in reducing symptoms of anaemia in 
patients with an advanced cancer, the financial cost of BT, and the futility of 
BT at the end of life. With the current emphasis in healthcare on costs and the 
suggestion that BT are a scarce resource that may be futile at the end-of-life, 
addressing participants’ feelings and understanding what blood meant to them 
was believed to be important.  
 
4.2.1.1 Plotline - Blood transfusions mean life 
Most participants in this study felt that receiving BT meant they could live a 
little longer. Without this essential supportive therapy, administered in the form 
of packed red cells, they recognised that they would die quite soon. As none 
were receiving any chemotherapy treatment all their hope of prolonging their 
lives lay in the bags of blood they received. As such, BT were viewed as a life-
line, an elixir of life that sustained and controlled their everyday lives. Like 
insulin for the diabetic patient or GTN for the patient suffering from angina, 
their lives became dominated by BT and the rituals associated with them. 
Participants spoke of their resignation to this situation and told how they were 
prepared to adjust their lives as required, so that they could attend the day unit 
for a day every two to three weeks to receive BT. This willingness to spend 
much of their time in the hospital was because they had been informed by their 
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consultant haematologist that there were no other treatments available, and 
BT maintained hope of survival.  
 
Kenneth (early palliative phase): Kenneth, for instance, articulated this 
plotline well. Kenneth was 79 years old and had been diagnosed with MDS. 
He was aware that the immature red blood cells in his bone marrow would not 
mature into healthy red blood cells, cells essential for life. He understood from 
a consultant haematologist that the administration of BT would provide him 
with the healthy red blood cells he required for survival. Frequent blood 
transfusions he said, “are part of my life”, he has “no choice”. With his reliance 
on BT to survive, he states he has resigned himself to attend the HDU of our 
District General NHS Foundation Trust, every three weeks to receive BT. He 
comments that he has got used to coming to the HDU frequently and it no 
longer causes him any worry, but stresses that this has taken time. His 
acceptance of the situation he suggests came about by toleration of the 
infusion time involved and by adjusting his circumstances to accommodate 
whatever needs to be done. 
 
There’s no choice 
I’ve got immature red blood cells 
it’s part of the problem I’ve got 
  
There’s no magic pills 
to keep me alive 
only thing they can do 
is give me a blood transfusion 
  
They keep me going 
cos without it 
it would be a box job 
you learn to live with that. 
 
Ernest (early palliative phase): Ernest was 75 years old and had MDS. 
Ernest had been receiving blood transfusions for over four years and had 
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received 121 since first diagnosed and up to the time of our final interview. He 
explained that the consultant haematologists aimed to keep his “normal Hb 
level” around “10”, which he understood was lower than that considered a 
“normal” Hb level for most people. But, he states, at this level he could still 
maintain a “normal life”, doing “normal things”, like playing “darts on a Friday 
night with friends”. To maintain this Hb level Ernest required frequent BT. 
When first diagnosed he had received them every eight weeks. However, over 
the past few months the frequency had increased significantly, from every 
eight weeks, to every six weeks, to three weekly and finally to every two weeks. 
Ernest associated this increased frequency with “the end of my life is 
approaching”.  
 
He knew that BT had kept him alive for the past four years but believed that 
he couldn’t go on living because BT were “not doing their job properly”. He 
judged the blood to be accountable for his increased requirement, rather than 
acknowledging it was down to a deterioration in his bone marrow function. As 
BT were the only treatment available for him, he said he wished that the 
haematologists could find another way to keep his Hb level at one compatible 
with life. It made him question me if there was an alternative to BT, misguidedly 
suggesting that he would be willing to try a “bone marrow transplant” as a 
“simpler option” to raise his Hb. As Ernest vocalised his worries, it became 
startlingly apparent that despite being in the final stage of his life, his medical 
and nursing care still lay wholly with the haematology team. He had not been 
introduced to anybody from the palliative care team. 
 
I need the blood to keep me alive  
if I don’t have it I don’t survive  
I worry that it used to be every 8 weeks 
then every six, then three,  
now it’s every two 
where do we go from here?  
 
There’s not much further 
the end of my life is approaching 
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nothing you can do about it 
 
I wish they could find another way  
of topping up my levels  
cos the blood transfusions 
they’re not doing their job properly 
 
If there was a simpler way 
of having my haemoglobin boosted 
by a bone marrow transplant or whatever 
I would be willing to go ahead with it 
to prevent me having BT. 
 
Zavier (early palliative phase): Zavier was 41 years old and had been 
diagnosed with MDS/AML. He had endured several attempts to cure his 
disease with intensive chemotherapy, but these had failed. During his final 
attempt with chemotherapy Zavier had almost died from overwhelming sepsis. 
Following this episode he had decided that he did not want any more 
chemotherapy. A consultant haematologist had informed him that he would 
require regular BT to keep him alive. Zavier had gone home and searched the 
internet for more information about BT. From this source Zavier understood 
that as he did not have “much blood in your system”, receiving BT would help 
him to survive. They would extend his life, he had “no choice”. As the frequency 
of his BT increased Zavier did not associate his increased need with disease 
progression, rather he was under the misconception that this was related to 
the level of physical activity he undertook at home. Zavier mistakenly believed 
that if he undertook strenuous physical activity this lowered his Hb level.  
 
I don’t have a choice  
I really need it  
if there’s no blood transfusion 
I wouldn’t survive any more 
 
Blood transfusions prolong your life  
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because every single moment  
my blood level is dropping 
 
If I make a lot of movements  
or do things in the house or outside  
I easily lower my haemoglobin. 
 
Jim (late palliative phase), Lily (late palliative phase) and Harold (terminal 
palliative phase): These participants had also been diagnosed with MDS. Jim 
was 62, Lily was 86, and Harold was 72. All stated that they really needed BT 
as they would die quite soon if they were stopped. Recognising that survival 
was dependent on BT was their paramount motivation for having them. Harold 
stated that the doctors strived to maintain his Hb level “as high as possible”, 
above “100” (10g/dL), but that he rarely attained this level despite regular 
administration of three units of blood. His understanding was that the 
haematology doctors would continue to prescribe BT for as long as they 
remained beneficial to him, which reassured him. 
 
Bill (terminal palliative phase): Bill was 74 years old and had AML. The 
intensive chemotherapy treatment that he had received in our inpatient facility 
to treat his disease had been unsuccessful so had been stopped. He now 
received supportive BT in our HDU. At our first interview Bill was receiving BT 
every two weeks, however, by the time of our second and last interview this 
frequency had increased to weekly. Bill was pragmatic about this burdensome 
requirement as he understood that BT allowed him, he stated, “to exist”. Exist, 
perhaps, was an appropriate word for Bill to have chosen, as he could no 
longer partake in any of the activities of daily living that he had previously 
enjoyed with his family and friends.  
 
4.2.1.2 Plotline - Blood transfusions as a sustenance for life 
Three participants (Kenneth, Ernest and Zavier) expected BT to provide them 
with some relief of their anaemia related symptoms. For them BT were 
considered a fuel that provided a source of strength that supported and 
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maintained them, even if the effect was transient. Two participants (Lily and 
Jim) stated during our first two interviews together that they expected some 
relief from their symptoms, however by the time of our final interview together, 
this beneficial effect was virtually non-existent. Three participants (Harold, 
Helen and Bill) expected no beneficial effect.  
 
As shown in the narratives below, those who did feel some benefits chose to 
stress how the effect of BT brought a sense of normality to their lives.  
 
Zavier (early phase): Zavier for instance, chose the words “Superman” and 
“normal person” to describe how he felt after receiving BT. Zavier insisted that 
they alleviated his physical symptoms of anaemia, that is his breathlessness, 
tiredness, lack of energy, tachycardia, and made him feel “much better”. 
Indeed, they allowed him to feel like “a normal person, doing the same things 
as normal people”. If his Hb fell below 80 he suffered chest pain, felt tired and 
breathless to the point he would be forced to slow down his activity level. 
 
Every time I have a blood transfusion  
my strength, my energy, comes back 
and I feel like I am a normal person 
doing the same things as normal people 
 
If my haemoglobin goes down to 80 
I can feel it 
I feel tired 
I can’t breathe 
my heart beats a lot faster 
and then I’m having chest pain 
so, I slow down. 
 
Ernest (early phase): Ernest was the most effusive of the participants when 
describing what he expected to feel post BT. He expected to experience a 
“good boost”, to get a “buzz”, a “little burst of energy”, to have “a little bit more 
breath in the early stages” and “to be slightly more elated”. He used the term 
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elated, he said, because “you feel freshened” and able to do more than you 
did before. Following his BT when his Hb had been increased he didn’t feel as 
if he was ill at all; indeed, he stove to be “normal”, he would go to the pub with 
his friends to play darts. 
 
I get a buzz  
I feel good  
I expect to have a bit more breath 
and to be slightly more elated  
because you feel freshened  
and able to do more than you did before  
 
When my blood levels are quite high  
I don’t even know that I’m ill 
I keep my chin-up 
I try to be normal.  
 
Lily (late phase): During our first two interviews, Lily told me that receiving BT 
made her feel much better physically. Lily used the word “marvellous” to 
describe the difference she felt post blood transfusion explaining that it 
“bucked her up” and gave her a “bit more oomph”, more energy to do a few 
more jobs. During these two interviews, Lily used humour to describe how she 
felt following her BT explaining, she could “run after a bus” after it, like that 
Road Runner’ character. However, during our last interview Lily was different. 
She was feeling very unwell, “really horrible”, “barely able to walk”. She 
described her everyday life as “just sitting in a chair”, sleeping a lot, unable to 
motivate herself to do anything, unable to concentrate enough to do the 
knitting or sewing that she loved to do. Lily put this down to the fact that she 
was “short of blood” as her haemoglobin level had dropped to “91”. She did 
not equate it to a deterioration in her condition. 
 
I do feel the benefit of it  
it makes an awful lot of difference  
it bucks me up a bit  
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I can do a bit more  
I could run after a bus after it 
like that Road Runner 
 
It takes it out of me going so low 
I can’t do anything 
I don’t want to do anything  
I just can’t concentrate 
everything comes to a standstill 
I am exhausted all the time  
I feel like a wet week.  
 
Jim (late stage): Jim did not expect any physical symptomatic relief from BT. 
However, he reported that they helped him mentally to “think a bit quicker” and 
to “feel a bit brighter”. In the past when in an earlier palliative stage, he said 
receiving BT had helped “a little bit” to relieve the breathlessness he 
experienced on exertion. However, by the time of our interviews when Jim was 
in a late palliative phase, the beneficial effect on his breathlessness had 
diminished almost completely. Equally, they did not relieve his fatigue as he 
became easily tired even after the administration of blood which led him to be 
relatively inactive at home.  
 
It doesn’t help so much, physically 
as it did before  
but mentally, you think a bit quicker 
which is quite good. 
  
Helen, Bill and Harold who were all in a terminal palliative stage of disease did 
not experience any significant beneficial effects. Although Harold (terminal), in 
our first two interviews together did suggest that he “sometimes” felt “slightly 
better”.  
 
Helen (terminal phase): Helen, did not think of blood as a sustenance. She 
explained that she held no hope that receiving a blood transfusion would 
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provide her with any beneficial symptomatic relief. Her optimism had been 
dashed because she had received blood on several occasions but only 
experienced benefit once. On this isolated occasion she had felt “so well”, “not 
quite so tired” and “more alert” the day after receiving a blood transfusion. 
Elaborating on her story Helen stressed that she had “more energy” and felt 
more-lively, she felt “good”. She remarked that she couldn’t believe what was 
happening highlighting that she had thought “if this is what it’s going to do this 
is wonderful to what I’d been feeling”. The symptomatic relief she experienced 
on this one occasion, however, had been short lived. She had hoped that this 
could happen again but had not felt any beneficial effects with subsequent BT. 
 
One transfusion I had  
made me feel well  
I had more energy 
I felt more lively 
I felt good 
 
I thought  
if this is what it’s going to do 
this is wonderful 
then the other transfusions I’ve had  
I haven’t felt much different 
 
Helen was unable to carry out many activities of daily living due to extreme 
fatigue and breathlessness. Even cleaning her teeth seemed a mammoth task. 
Helen brought the idea of hope into the two interviews we undertook together. 
Helen maintained hope that BT would help her to feel a bit more energetic and 
not so sleepy even though they had only helped on one occasion.  
 
Hopefully I’ll feel more energetic 
and not so sleepy 
it’s horrible not having any energy 
you can’t explain it to anybody 
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Everything just seems an effort 
even to clean your teeth 
you think oh I’ve got to do that 
even to do that I get so breathless 
 
So, we don’t do a lot 
I get up and have a bath every morning 
and that quite tires me out  
and I make the bed, usually  
sometimes I can’t do that anymore 
 
I don’t Hoover anymore which I used to  
I mean I can wash up and wipe up  
and I can do vegetables  
but I am so tired after it. 
 
Bill (terminal phase): Bill’s story was like that of Helen. Following his first 
blood transfusion he had found the beneficial effect unbelievable. Bill 
described the effect as a “super drug” that had given him a “big uplift”. He told 
a story to highlight why he felt this way. Essentially when he had arrived on 
the HDU he had been unable to walk, however following his blood transfusion 
he had walked out of the unit. He believed this transformation to be so 
“incredible” that he “felt like shouting out what a difference it made”. 
Seemingly, the blood he received on this occasion gave him energy to walk 
and helped with his breathlessness. Subsequent BT had not helped with his 
overwhelming symptoms of fatigue which made it impossible to do any 
physical activity.  
 
I couldn’t believe my first blood transfusion 
it was like a drug 
the big uplift, unbelievable  
I came in and I couldn’t walk 
the nurse got me a wheelchair 
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and when I’d had my blood transfusion  
what a difference it made  
I walked out 
it was incredible 
 
Since then I don’t do nothing  
I just sit in the chair or on the settee  
all day long watching the television  
I feel ill, I lack energy, I feel tired  
I don’t seem to have no strength  
I get very out of breath. 
 
Two weeks later during our second and final interview, Bill told me he had not 
wanted to attend the HDU for his blood transfusion that day as he had felt so 
ill. Crying frequently as we talked, Bill brought up the subject of his low mood 
telling me he felt really “low”. He had to “force”’ himself to come to the HDU, 
“felt compelled to come”, because he hoped that receiving blood would make 
him “feel a hundred percent better”. Bill had recently been referred to a 
Macmillan nurse. He had met up with her twice, but he felt she had not been 
able to help him in any way. He preferred he said to talk to the doctors and 
nurses on the HDU as he knew them better. Perhaps, if he had met one of the 
Macmillan nurses earlier in his disease trajectory he may have found it easier 
to communicate with her.  
 
I didn’t feel so good today  
and I didn’t feel so good yesterday 
or the day before that 
and I thought well I’ve got to go up there 
force myself to come up here 
because I’ve been feeling a bit low 
 
I seem to get low in mood 
little things can switch it on or off  
some days you’re just lower like  
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and I know I’m coming in here 
and hopefully it’s going to make me feel better 
just got to do it. 
 
4.2.1.3 Plotline - An up and down everyday blood transfusion life 
Kenneth, Ernest and Zavier explained how the good effect they experienced 
following BT was transient which led them to experience an ‘an up and down 
life’. They would reach an up and feel better, not immediately post transfusion, 
but two to three days later. Ernest who was receiving BT every two weeks 
would remain in this up state, feeling normal, it appeared, for four to five days. 
Kenneth and Zavier who were receiving BT every three weeks stated they 
would feel better for approximately fourteen to fifteen days. Then their 
symptoms of anaemia would return, and they would feel down physically and 
mentally until they received their next transfusion. It was during this ‘down’ 
time that they needed to come to the hospital for their blood tests and to 
receive their BT.  
 
Ernest (early phase): Ernest articulated his feelings about the up and down 
effect particularly well. He described how after each transfusion, which he 
received every two weeks, he would start to feel good two to three days post 
BT. When this happened, he did not think of himself as being ill, rather he felt 
normal. He would feel the beneficial effects for four to five days before he 
would start to slowly decline and feel sluggish, tired and breathless again. His 
concentration would be affected, and he would forget to do things, which he 
attributed to being too tired to remember things. Ernest said that this up and 
down effect was repeated time and time again. He reported that during the 
time he felt better, he had a clear week at home with no hospital commitments, 
however on the second week post blood transfusion when he was “on the 
slippery slope going down slowly”, he was “expected” to attend the hospital 
twice.  
 
I get an up and down situation 
after the blood transfusion 
you get a good boost  
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not at the time 
two to three days later 
and I feel good for about four or five days  
 
And then the whole thing starts to reverse  
to go downhill  
to making me feel tired and breathless  
to the stage when you don’t want to do anything 
listless in fact 
and that sort of repeats itself 
time and time again 
 
When my blood levels are quite high  
I don’t even know that I’m ill 
I keep my chin-up 
I try to be normal  
 
If I drop below eighties I feel weary and tired  
you sit in the armchair more  
and become more of a vegetable  
you are more of a hindrance than a help  
to the household 
 
My concentration tends to go as well 
and I can’t think clearly  
it’s not that I am forgetting to do things  
it’s just I’m too tired  
to remind myself that I should do it  
 
When I’m on the slippery slope going down  
I am expected to come  
and get blood tests on Tuesday  
and blood transfusion on Wednesday. 
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4.3 Section 1: Social dimension of experience  
4.3.1 Storyline two: Everyday blood transfusion life hangs in the hands 
of others 
This storyline which elucidates the social dimension of experience responds 
to objective 2: To explore healthcare professional’s role on participants’ 
experience of BT. That is, how cultural, institutional and social relationships 
with healthcare personnel influenced participants’ experience of receiving BT. 
This storyline was built from the plotlines: life in the hands of physicians; life in 
the hands of nurses; and life in the hands of ward receptionists. These plotlines 
illuminate how the lives of all those who took part in this study hung in the 
hands of their consultant haematologists, the nursing staff and the ward 
receptionists.  
 
4.3.1.1 Plotline - Life in the hands of physicians 
The lives of all those who took part in this study lay in the hands of their 
haematologists. Institutionally, these physicians were responsible for 
authorising their life blood. They determined how often BT should be 
administered and the number of units to be transfused. As highlighted below, 
this decision it appeared was often influenced by the participants’ Hb level 
alone, rather than alongside the symptoms they exhibited.  
 
Kenneth (early phase): Kenneth, for instance, spoke about the haematology 
consultants abiding by a “magic number” of 80. This magic number referred to 
the minimum threshold level which the haematologist strove to keep his Hb. 
Kenneth told of an occasion when he had met one of the haematologists in 
the corridor. The physician had told Kenneth that his Hb had dropped down to 
75g/dL and asked him when he was coming in to the HDU, as he needed 
another transfusion to top him up. Although Kenneth did not feel that his body 
needed another blood transfusion, he complied with the physician’s decision 
and attended the HDU to receive his transfusion.  
 
The doctors, they have this magic number 
if my haemoglobin falls below 80 
I have a blood transfusion  
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regardless of how I feel 
I can be feeling ok  
my body doesn’t feel it needs another blood transfusion 
but no, the doc says you have to come in  
 
I saw a doctor and he said  
when are you coming in for a top up  
because your haemoglobin dropped to 75  
I said Thursday  
and he said good because you need it 
so, he felt I needed it  
but I didn’t feel any side effects of it going down that low. 
 
Lily (late): Lily’s narrative also suggested that physicians authorised BT 
according to numbers, that is Hb level alone. Describing an event during one 
of our interviews together, Lily reported that the doctor had not authorised a 
blood transfusion when her Hb level was “101”. Lily believed that she had 
really needed the blood transfusion when her Hb level had been, at what she 
described as, “borderline” level. When she saw the doctor two weeks later her 
Hb had dropped to 91. Lily said she always knew when he Hb level fell below 
100 because she would experience significant symptoms of anaemia. Lily 
explained that between her two clinic visits to see the doctor, everything had 
come to a “standstill”. Lily had been dismayed that the doctors had let her Hb 
level fall to 91, reiterating many times her belief that the doctor should 
“prescribe” blood when the level is “borderline, so as to help support patients”.  
 
Despite her feeling that they were wrong in not authorising a blood transfusion, 
Lily did not feel she could query their decision stating “they’re the doctors and 
I’m the patient, no, no, I leave it to them”. This suggested that she believed 
that she should leave the decisions regarding her treatment to the physicians. 
She passively put her life in their hands with the understanding that they knew 
best what was right for her. 
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I really needed the blood last month 
my blood was 101 and they said 
it was a borderline case  
so they didn’t give it 
 
And it ended up I was 91  
so, the last week has been horrible 
I haven’t been able to walk at all  
I was like a wet weekend 
 
When they say it’s borderline 
they ought to err on the good side 
they should go on the good side to help you 
not leave you which was done this time 
 
I knew it was going wrong  
but they have their reasons 
there again, there we go  
they’re the doctors and I’m the patient 
No, no, I leave it to them. 
 
Helen (terminal): Helen also told a story concerning the haematologists’ 
authorising practice. She highlighted, unprompted, that there had been 
variation in the authorising of BT between a haematology registrar and 
consultant haematologist. According to Helen, the registrar “prescribed” blood 
according to her haemoglobin level whilst the consultant haematologist also 
ascertained and accounted for how she was feeling physically. Helen was 
unhappy that a blood transfusion had not been authorised by the registrar 
when her Hb had been 90. Although she believed she should have received 
blood to help with her physical symptoms of anaemia, she had not challenged 
the doctor about his decision not to transfuse. Instead, she requested to see 
a consultant at her next visit as she believed they would authorise her BT 
according to her symptoms. 
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We’ve seen the registrar for two weeks 
we weren’t very happy.  
and yesterday we saw the consultant  
and I was much happier 
 
Last week the blood was a little bit higher 
but I was still not feeling quite right 
but the registrar said no you don’t want a BT  
it’s like the consultant said  
some people cope on 9 and some people don’t 
perhaps I’m one that doesn’t cope on it  
 
The registrar did seem to go on figures 
more than feelings 
now when we told the consultant yesterday how I felt 
he said I think you need a transfusion.  
 
The haematology physicians are also responsible for monitoring blood ferritin 
(iron) levels, as patients who have received “ten to twenty” units of blood will 
generally have a raised level (Goa, et al., 2014). To help reduce the iron 
overload, a chelating agent, that is, either Desferrioxamine or Exjade may be 
prescribed by the physician. The decision to prescribe a chelating agent is 
influenced by the participants’ ferritin level, as excess iron in the blood deposits 
in and causes damage to vital body organs, such as the heart, liver and 
pancreas. Participants’ tolerance of the two agents is also considered. To learn 
of the hardships three participants (Kenneth, Harold and Ernest) experienced 
with chelating agents was enlightening and distressing.  
 
Kenneth (early): Kenneth brought to my attention without any prompting 
during both our first and second interview the difficulties he had experienced 
with chelating agents. The chelating agent he had initially been started on was 
subcutaneous Desferrioxamine. He reported that the drug was delivered by 
“this horrible pump you wear round your neck of a night and then you have to 
put it into your own stomach”. Finishing this story with the comment “and that 
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really upset my kidneys, really upset my kidneys and the doctor picked that 
up”. Kenneth stressed several times that he had to inject himself. He appeared 
to abhor the process of self-administering this drug subcutaneously into his 
abdomen. He was also concerned about the negative clinical effect it had on 
his kidneys. Despite these challenges, Kenneth continued to self-administer 
this drug until he was told by a haematologist to stop. 
 
The next time I saw the doctor  
he said we’ve got to concentrate on your iron  
we’ve got to get it down it’s higher than it should be 
 
First, they gave me this horrible pump  
you wear round your neck at night  
and you have to put the needle into your own stomach 
 
You have to do it yourself 
and that really upset my kidneys 
and doctor said stop taking that stuff.  
 
Due to the problems he experienced with Desferrioxamine his treatment was 
changed to Exjade an oral chelating agent. Initially he was prescribed two 
tablets to take at night and two in the morning. Kenneth describes this drug as 
a “white, chalky, horse table”’. He highlights that when the haematologist tried 
to increase the dosage of Exjade as a means of reducing his iron level “a bit 
quicker” this had made him feel unwell. His stomach had become congested 
which caused him some discomfort and he had become “quite down in the 
dumps because of it”. Kenneth had at this point taken the matter in his own 
hands. He told the doctor that he would not increase the dosage because of 
the problems he experienced. The Haematologist, he said, had been “very 
blasé about it” and advised him that it was okay to keep to his original dosage. 
He had also said “simply stop taking it for a couple of days” if any problems 
were experienced. Kenneth did not worry about taking this action because the 
haematologist had informed him that Exjade was secondary to his BT. Simply 
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stopping it for a few days when it caused him to feel unwell made taking the 
drug more tolerable for him, his coda was “you learn to live with it”.  
 
Now they’ve got me on Exjade  
it’s a horse tablet about that size 
its white, its chalky  
they tried to increase that to four a day 
and that really upset my stomach, 
so, we knocked that on the head  
 
Well I knocked it on the head 
I said I’m not doing this because it’s upset my stomach  
I had a terrible time last weekend  
I was down in the dumps 
with stomach problems due to the Exjade 
 
I said I’m going back to two a day  
and that seems to be doing what it needs to do 
but sometimes I knock it on the head  
for a couple of days 
 
It’s what the doctor told me to do last time 
just don’t take it because it’s a secondary thing  
the blood transfusion is more important  
Again, you learn to live with it. 
 
Ernest (early): Ernest also went to great lengths via several long stories to 
explain the concerns he encountered with chelating agents. This topic he 
brought early into our conversations, unprompted. Ernest’s serum ferritin level 
was extremely high due to the large amount of blood he had received. To try 
and reduce it he had tried both Desferrioxamine and Exjade. Ernest described 
the administration process of Desferrioxamine in huge detail, before going on 
to say he had developed a problem. He reported that despite cleaning himself 
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with sterile pads before putting the needle into his abdomen he had developed 
a very large ulcer at the injection site. This had proved to be “very difficult to 
clear up”. Ernest showed me the site where the ulcer persisted. He stressed 
emphatically that he had cleaned his skin prior to injecting himself, seemingly 
anxious for me to know that it was not his fault, afraid that I may assume that 
the ulcer had developed due to poor hygiene. The Desferrioxamine had been 
discontinued. 
 
Exjade was subsequently tried. Ernest had initially started on two tablets, but 
the dose had been increased to five, which meant it was necessary to split the 
dosage into two glasses of water to make a drink that was a “lot looser type”, 
and thus more palatable. Ernest reported that while on an inpatient ward the 
previous year, a nurse had dissolved all five tablets in one glass of water and 
had presented him with “a great big thick porridgy lump”. Ernest had explained 
to the nurse that he always dissolved them in two glasses of water but 
apparently the nurse had refused to do this and told him, “tablets you take in 
one go and not separate goes”. Ernest had asked to speak to the consultant 
haematologist. The nurse had telephoned the doctor who had told her to 
discontinue the drug.  
 
Ernest was concerned that he had not received any chelating agent for over a 
year. Labouring the point, on several occasions during all three interviews he 
quite unprompted told me of his concerns. He was aware that his current 
ferritin level was significantly raised and that it was getting higher with each 
unit of blood he received. He was afraid because a haematologist had 
informed him, “with too much iron in my system other parts of my body 
functions will start to shut down”. Ernest did not know at what point this would 
happen. Ernest poignantly labelled this concern as his “catch 22” situation. He 
did not, however, question the haematologists about it. He trusted their 
decision to cease treatment believing that it was because Exjade had been 
ineffective.  
 
Harold (terminal): The subject of chelating agents also appeared to be a 
pressing concern for Harold, who similarly appeared to find the administration 
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of these two drugs quite challenging, indicated by the fact that he peppered 
our first two interviews with this topic. For instance, almost immediately into 
our first interview together, Harold brought the topic of Desferrioxamine 
unprompted into our conversation. He reported having to wear the 
administering pump four times a week, each time for approximately ten hours. 
The pumps which are big and bulky, Harold suggested, were more “intruding” 
than the BT. Harold was aware that he could infuse overnight whilst he slept, 
but he worried about the needle coming out as he was a “restless sleeper”. 
 
The concern Harold felt became most apparent during our second interview. 
He provided a long story to enable me to understand what it was like for him 
to manage his situation with Desferrioxamine day-by-day. His story detailed 
challenges and adversities which were articulated so well that it brought a 
picture to mind. I imagined him; sticking the needle into his emaciated 
abdomen four mornings each week; the difficulties he encountered with vision 
and dexterity as he tried to secure the needle in place with Micropore tape and 
plasters to ensure that the needle stayed in place for the next ten hours; the 
multiple bruised injection sites on his emaciated abdomen which he said were 
sore for a few day; his struggles with a tube that was “so long” he said it needed 
to be wrapped round his neck; the conspicuous lump in his trouser pocket; the 
bright orange urine that had initially shocked him; and the inconvenience of 
having to keep 12 sizeable administration pumps filled with Desferrioxamine 
in his fridge at home. These hardships associated with administration of 
Desferrioxamine Harold had to endure whilst in the terminal palliative phase 
of his disease.  
 
The other major treatment I have 
is to get rid of the excess iron in my system  
that is done by using a Desferrioxamine pump 
via a subcutaneous needle  
it won’t ever get down to normal levels  
but it will keep it under control 
 
I put that together myself and stick it in my stomach  
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I have experimented with ways to put the needle in  
it’s subcutaneous so, you put it in there  
I try and pick different spots  
and then I use a couple of lengths of micropore 
round the plaster that surrounds the needle  
and that helps keep it in place 
it’s maybe sore for a day or so and then its fine 
 
These pumps are much more obtrusive 
let’s say than transfusion  
but I have worked out ways of handling it 
and sorting out somewhere to put the pump  
tucking it away where it isn’t a nuisance or anything 
 
The pump goes in my left trouser pocket  
the tube to the needle goes around my neck  
as it’s a bit longer than its intended to be  
the spare length of tube I tuck inside my shirt 
where it might not get tugged by anything 
 
I wear the pump for about ten hours  
four days a week  
I know some people wear it overnight 
but I am a restless sleeper  
so, I think it’s safer to do it during the day.  
 
Harold had originally been prescribed Exjade but he had not liked taking it as 
the tablets had caused him to experience nausea and vomiting. This had 
adversely affected his appetite which, he said, had resulted in significant 
weight loss. Exjade had also been unsuccessful in reducing his ferritin level. 
Due to the problems he endured, and the lack of efficacy associated with 
Exjade, a haematologist had changed to Desferrioxamine.  
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During our final interview together, Harold had been extremely unwell and had 
been brought to the Community Day Unit by ambulance. He had been vomiting 
on the way in. On arrival the nurse had rung the haematologist for advice. She 
had been told not to give the blood and to discontinue the Desferrioxamine. I 
was with Harold when he received this news. Although distressed not to 
receive his blood transfusion, he was overwhelmingly “relieved” that the 
Desferrioxamine had been stopped, sharing what a “nuisance” it had been for 
him to administer “four pumps a week”. Harold died 30 days later. 
 
From a social perspective, all participants in this study were dependent on 
haematologists to involve the palliative care team (PCT) as they were all at 
“the end-of-life” stage with twelve months or less to live (GMC, 2010). The 
findings from this study indicate that most of the participants were not referred 
to the PCT. Only two participants, Helen and Bill, met a Macmillan nurse and 
this only shortly before their deaths.  
 
4.3.1.2 Plotline - Life in the hands of the nurses 
All the participants in this study praised the nurses who cared from them. They 
spoke about “how wonderful” they all were, highlighting that “nothing was too 
much trouble” for them. Five of the eight participants, however, spoke about 
the speed their BT were administered. Helen and Harold expressed concern 
about the rate the nurses had administered their BT, while Kenneth, Lily and 
Ernest simply suggested that their BT had, sometimes, been put through a bit 
quicker than usual. Lily qualified this by suggesting it happened on the 
occasions she received three units of blood. As a senior nurse responsible for 
clinical nursing practice, this participant experience concerned me. Particularly 
as I learnt about variation in administration rates over two sites and a 
suggestion that nurses were putting the blood through quicker to complete the 
BT within their working day and the opening hours of the HDU.  
 
Nurses, when administering BT, do so according to medical authorisation, but 
they are allowed by protocol some slight discretion over the rate at which they 
administer the blood. Increasing the rate of BT is not without risks. The risk of 
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administering blood too quickly, especially in older people, is developing 
Transfusion Associated Circulatory Overload (TACO), which can be fatal.  
 
Ernest (early): Ernest thought it was a good thing for him when the nurses put 
the blood through quicker as it meant he was not going to get home late. He 
also thought it was good for the nurses, as it meant that they would not be 
delayed at the end of their working day. They would finish between four and 
five which was, he stated, their contracted time for finishing work.  
 
It’s never been that quick before  
but it’s good  
because I know that I’m not going to be late  
finishing at the end of the day 
 
And It’s good from the staff point of view  
because they start going home at four, or five  
and by then I am going to be done  
so, they don’t have to worry about me, good for them. 
 
Harold (terminal phase): Harold told of the variation in the blood transfusion 
process between the main hospital and his local community hospital where he 
had received BT for the last three months. He stated that he did not think about 
the blood that was being transfused into him apart from to ask the nurses how 
big the bag of blood was. He was interested in the number of millilitres (mls) 
of blood in the bag as this determined the rate at which his BT were 
administered on the Day Unit of his local community hospital. He explained 
that the community hospital had a different procedure for administering BT 
than that followed on the HDU. In the community hospital the nurses would 
administer the blood over two hours. That is, if the bag of blood held 340mls 
the rate set on the pump would be 170mls per hour and if it was 360mls the 
rate was set for 180mls per hour. 
 
In the main hospital, Harold explained, the protocol was to administer the blood 
between two to three hours, as medically authorised on the pre-printed blood 
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prescription charts. This allowed the nurses discretion to alter the rate set on 
the pump to allow the blood to be given during this time. Harold said that the 
nurses on the HDU always set a pump rate of 140mls per hour for him. This 
meant that if it was a 340mls bag of blood it would take approximately 2 hours 
and 25 minutes to transfuse. Harold preferred the longer infusion time, 
highlighting that it didn’t matter if it took longer as what was important was that 
he knew he could cope with blood being administered at this rate. He had 
received blood administered at 140mls/hour for many years and was 
concerned he could encounter problems when the rate was set higher than 
this. He did not mention his concerns to the nurses as he believed that each 
place had a different transfusion protocol and he would have to accept that.  
 
I only ask how big the bag is  
and, therefore, how long it’s going to take  
here they set it to infuse over two hours 
so, if it is 340 millilitres  
that would mean a flow rate of 170  
 
I don’t think that’s really a good idea 
even if it takes longer than two hours 
I would rather see the flow rate at 140  
which I know I can tolerate  
rather than 170 which might cause problems  
 
In the hospital they did it differently  
they did it by flow rate  
they would set it to 140  
if it was a small bag  
it would take less than two hours 
and if it was a big bag  
it would take a bit more  
 
But they concentrated on flow rate 
rather than the length of time 
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and I think honestly that’s better 
but you know each place has its protocol.  
 
Helen (terminal): Helen’s story about rate of infusion of BT was the most 
disconcerting. Helen held an ongoing belief that there was a risk that she 
would die from life-threatening heart problems brought on by the 
administration of BT and explained how this fear had arisen. For her first ever 
blood transfusion, Helen had been prescribed three units of blood. Each unit 
had been administered over two hours at the discretion of the nurses on the 
HDU. She had been discharged home feeling well. However, at five o’clock in 
the morning, Helen had experienced significant tachycardia and feelings of 
impending doom. An ambulance had been called and she had been rushed to 
the Accident and Emergency department. The doctors at the hospital, she 
stated, were not convinced that her heart rate of over 300 beats per minute 
had been related to the administration of blood. She had been prescribed 
additional heart medication.  
 
Helen, however, was convinced that this episode had been caused by the 
blood being administered “a bit too quick”. She was certain of this because “it 
was the very next morning and ‘that’s why it’s slower now”. She stressed she 
had never experienced her heart “going out of rhythm before”, not following 
chemotherapy treatment or having a heart valve replacement. Since this first 
occasion, Helen had suffered recurrences of these “heart turns” following her 
BT. This was even though during subsequent BT the rate had been slowed 
down to administer the blood over three hours instead of two. These disturbing 
experiences clouded Helen’s perceptions of BT and caused her to worry each 
time she received blood that “it’s going to happen again”. 
 
The first time I had a blood transfusion 
it was three units of blood over two hours each 
and the very next morning at 5 o’clock 
my heart went all out of rhythm  
and I was rushed in here  
it was going up to 300 beats per minute. 
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I thought I was dying 
 
They can’t say it was definitely the blood transfusion 
but I feel it was  
because it was the very next morning  
and all the chemo I’ve had 
I never had any problems 
the heart replacement valve in 1999  
and I have never had any problems with that  
until that blood transfusion  
 
We think it might have been a bit too quick  
that’s why it’s slower now 
now it’s two units and roughly over six hours. 
but I’ve had several of those turns in the hospital since 
so, each time I have blood now I worry 
I’m worried now that it’s going to happen again  
but they have got me on extra heart pills now. 
 
4.3.1.3 Plotline - Life in the hands of the ward receptionists 
The HDU ward receptionists were responsible for booking all the blood 
transfusion appointments. Generally, patients would come back on the same 
day, two or three weeks later. Kenneth, Lily, Ernest and Zavier reported that 
the day on which they received their BT had been changed on several 
occasions. Kenneth reported that this was not a good thing for him and his 
wife, as he put all their appointments in his diary, and having to change his 
day caused them much inconvenience. Ernest also explained why it made him 
unhappy when this happened. He said that having the same day was important 
as it allowed him to plan and organise his lifestyle around this day. However, 
the day he received his BT had been changed on many occasions “to fit with 
the demands on the unit”. When this happened, he felt that it was “a bit of a 
push around” where “ad-lib” changes were made. He stressed that patients 
were not given a choice regarding the day, the day was chosen by the 
receptionists who were governed by the bed spaces available on the unit. 
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Ernest made a valid point about the change in day that was important from a 
clinical perspective. He pointed out that even if his blood transfusion was 
delayed by just “a couple of days”, the tiredness and shortness of breath he 
experienced were exacerbated. This in turn caused him to experience more 
difficulties with his mobility and self-care activities while at home; and it 
affected his everyday life. 
 
4.4 Summary of research objective 1 and 2 
4.4.1 Research objective 1  
First. Participants’ felt that BT were essential for life, they had no choice as 
there was no other therapy available. This belief was influenced by 
communication with physicians.  
 
Second. Participants’ adjusted their everyday lives to accommodate the 
administration of BT.  
 
Third. Some participants became cognisant that their disease was 
deteriorating when their need for BT increased; others did not. 
 
Fourth. Participants’ expectations in terms of relief of anaemia-related 
symptoms were variable. Some expected beneficial effect, either physical in 
terms of less fatigue, or psychologically to think a bit quicker. However, 
beneficial effects were short lived which led to up and down lives. This meant 
many days when participants were down. During their down period they were 
required to come to the hospital for blood tests and to receive their BT.  
 
4.4.2 Research objective 2:  
1. Participants placed their lives in the hands of the haematology doctors, 
nurses and receptionists which caused hardships and anxiety. 
 
2. The authorisation of BT by more junior physicians who relied on Hb levels 
alone rather than taking a holistic approach.  
 
3. The administration of chelating agents caused hardships.  
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4. The rate at which BT were administered to suit hours of HDU opening and 
the variation in rate between the acute, secondary care hospital and the 
community hospital.  
 
5. The disruption to diary planning when the dates of BT were changed to fit 
with demands of the HDU.  
 
6. The inadequate communication between participants and healthcare 
professionals which led to misunderstandings about BT. 
 
7. The poor communication about chelating agents in that participants had not 
been warned of the bright orange urine which had caused shock, and reasons 
for discontinuation had not been discussed with Ernest, and he was left to 
worry that iron would accumulate in his organs and cause them to shut down.  
 
8. The lack of referral to the Palliative Care Team.   
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4.5 Section 2: Place dimension of experience 
Storylines three and four elucidate the ‘place’ dimension of experience and 
respond to research objective 3: To explore the effect of the place or setting 
where BT were administered on participants’ experiences of BT. The storylines 
illuminate how ‘place’, as a dimension of experience, lightens or creates 
burdens experienced by participants receiving regular BT while in a palliative 
stage of a HM.  
Storyline three reveals how the hospital setting created burdens for 
participants receiving regular BT, while storyline four sheds light on one 
participant’s experience of receiving a blood transfusion within a Hospice Day 
Unit. 
 
4.5.1 Storyline three: Everyday blood transfusion life involves waiting 
and anxiety 
This storyline was developed from three plotlines: waiting in Pathology for 
blood tests; waiting on the haematology day unit; and anxiety associated with 
places in the hospital setting. These plotlines demonstrate that most places 
related to the administration of BT were found to negatively affect the blood 
transfusion experience. For instance, the primary resonant plotline related to 
place that all participants voiced was that they spent much of their time 
queuing or waiting. They queued in the Pathology Department to have their 
blood tests taken and they queued on the HDU to be cannulated, or between 
bags of blood. Waiting for long periods in several environments, usually twice 
a week on a regular basis, when so unwell with a limited life expectancy, 
caused them much distress. Participants associated waiting with poor quality 
of service.  
 
4.5.1.1 Plotline - Waiting in Pathology for blood tests 
Waiting or queuing in Pathology for one to two hours to have their blood tests 
taken every two to three weeks was a usual occurrence that most participants 
complained about. It was a hardship voiced by Kenneth, Ernest, Jim, Lily, Bill 
and Zavier.  
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Kenneth (early palliative phase): Kenneth, for instance, believed the 
frequent, long waiting time he was required to endure in Pathology were both 
“unacceptable and inconvenient”. He highlights that on one occasion he had 
to wait two hours “just to have my blood taken”. Kenneth suggested that 
“waiting” was an example of “poor quality service” that led to dissatisfaction 
with the care he received. He points out that, as there is no appointment 
system within the Pathology Department, patients need to know the best time 
to come to avoid the wait. He stressed that at certain times of the day there 
may be twenty to thirty people waiting for their blood to be taken. Kenneth 
stated that he never comes late morning or early afternoon because it is 
exceptionally busy at these times. Instead, he gets up early to arrive in the 
Department at seven thirty in the morning. It is a hardship for him having to 
attend at this early hour, but he feels he has no choice. He has tried to have 
his blood tests done at his General Practitioner’s surgery as it was more local 
to his home and he can book a timed appointment, however, on the occasions 
he has tried the nurses or phlebotomist there had been unsuccessful. Frequent 
venepuncture and intravenous infusions had made his veins difficult to access. 
Thus, he had made the decision to always come to the hospital because he 
believed that the phlebotomists in the hospital had more experience, “they 
know what they are doing more, they’re doing it full time all day long”.  
 
Ernest (early palliative phase): Ernest, like Kenneth, highlighted that he 
waits a long time in Pathology. He pointed out that he waits between an hour, 
to an hour-and-a-half for his blood tests, in an uncomfortable chair, in an 
uncomfortable place. Ernest found the Pathology setting to be oppressive, 
“hair raising, and absolutely manic at times”. This stifling, distressing situation 
he found was exacerbated by his poor health. He suggested that the service 
should be more streamlined to avoid the long wait he, of late, had no choice 
but to endure twice a week, every two weeks. 
 
It’s a terribly hot situation in there 
it’s even a hot place on a cold day  
there’s no air 
which is an uncomfortable situation 
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when you are not feeling too good 
 
It’s hair raising 
absolutely manic at times  
you can wait 
I have waited about an hour 
an hour and a half 
 
It’s a long time to be sat 
in a not very comfortable chair 
it’s an area somebody could look at 
they need to streamline it more.  
 
Lily (late palliative phase): Lily who was the oldest participant at 86, was in 
the late palliative stage of her disease. On the day Lily attended for her blood 
tests she would also see the haematologist which meant she waited at least 
three-and-a-half hours at different places around the hospital every three 
weeks. She would arrive at eleven o’clock and wait an hour in Pathology to 
have her blood taken. She would then go to the café and wait there until two 
fifteen. From there she would go to the haematology clinic for her two thirty 
appointment with a haematologist. This physician would review her medical 
condition and blood test results and authorise a transfusion for later that week. 
Lily stated that on the days she attended the hospital, she had to get up earlier 
than on other days of the week to get herself ready. She did not grumble about 
waiting, “more or less two hours to kill” between her blood test and being 
reviewed by the doctors; rather she explained she was “a patient sort of 
person”. She argued, “you can’t expect to go in and have it done and come 
out again, you know”. Perhaps what made Lily believe that it was okay to wait 
was her overwhelming conviction that “it is important to be grateful for the NHS 
care one received”, and her mantra that it didn’t matter if she enjoyed it or not, 
as the treatment was “free”.  
 
I come up on a Tuesday  
I get up here about eleven  
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to have the blood match done  
it’s a long wait 
a long wait of an hour  
but you can’t expect to go in  
have it done  
and come straight out again 
 
Then I go and have a cup of tea  
as my appointment with the doctor is about two-thirty  
my daughter always comes with me 
to see the doctor on a Tuesday 
but there’s no sense in her coming up at eleven  
because we’ve got two hours at least to wait 
before we see the doctor 
and she’s got other things to do. 
 
4.5.1.2 Plotline - Waiting on the haematology day unit  
Waiting on the HDU was a hardship reported by five of the participants in this 
study: Zavier, Kenneth, Ernest, Jim and Bill. It revealed aspects of care related 
to their blood transfusion experience that they believed should be addressed.  
 
Zavier (early palliative phase): Zavier was vehement when he informed me 
about his problems of waiting on the HDU for his BT. This wait he found to be 
particularly unnecessary and depressing. Explaining the situation, he reported 
that it was commonplace for the nurses to ask him to come to the HDU early 
to receive his BT. This meant he had to wake up earlier than usual to arrive on 
the HDU by nine o’clock. He emphasised the point by telling of one occasion 
when he had arrived at nine and had not received his blood transfusion until 
two o’clock in the afternoon. The delay in starting the transfusion meant he 
was not finished until late in the evening. As the HDU closed between five 
thirty and six o’clock this meant he was transferred to the haematology 
inpatient ward area to complete his transfusion, and discharged home from 
there at “nine” in the evening.  
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Zavier said he became upset and aggrieved when he arrived early to be told 
his blood was not ready. He had a young family which made getting to the 
hospital by nine in the morning difficult for him and his family. Sometimes, 
when this situation arose, Zavier would ask the nurses if he could go home. 
He would then wait at home until the nurses phoned to say his blood was 
ready. This solution, he said, was preferable to him, it was “better than waiting 
around” on the HDU. Zavier suggested that the nurses should ring patients to 
let them know their blood would not be available until later, rather than asking 
them to come in early, have them wait for long periods of time and then be 
transferred to the inpatient ward to complete their transfusion. 
 
They’ve asked me to come early  
so, I came at nine o’clock  
but the blood was not ready  
I had to wait until two o’clock in the afternoon  
 
So, you need to wait  
for a long, long, long time 
and then finish at nine o’clock in the evening  
so, I need to stay over there on the ward 
 
It’s a bit depressing  
because you need to wake up early 
prepare yourself and then  
when you get to the unit your blood is not ready  
 
Sometimes I ask the nurses if I can go home 
and wait for a while  
and come back when my blood is ready  
 
The thing that they need to do 
they should tell the patient  
that their blood is not ready  
so that they are not waiting.  
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Waiting on the HDU in the morning for a nurse to cannulate them to commence 
their BT infusions was another problem mentioned by Kenneth, Jim, Ernest, 
Bill and Zavier. It caused some of them distress because waiting made them 
feel “unimportant”. Ernest suggested that patients having their chemotherapy 
treatment were more of a priority for the nurses to deal with. This hardship of 
waiting, the participants ascribed to the nurses on the HDU being too busy or 
short staffed. 
 
There has been a couple of occasions  
when it’s been slow in the morning  
getting the cannula in to start off with  
that’s because they are so busy 
or they are short of staff.  
 
These participants also articulated a complaint about waiting between bags of 
blood for a “quarter of an hour or so” between each unit. 
 
Ernest (early palliative phase): Ernest verbalised his discontent about this 
issue best. He was upset that once the blood transfusion had been started it 
was not a continuous process, rather there were breaks during administration. 
The lack of continuous flow occurred when one unit of blood finished and there 
was a wait before the nurse commenced the second unit. Ernest found it 
difficult to understand why the nurses couldn’t keep it flowing properly.  
 
The only thing I can say is  
when a bag has run out  
it takes quite a while before they come up 
with the next bag of blood  
 
It used to be a continuous thing  
between the units of blood  
now there are some delays  
that sort of thing upsets you  
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You think why don’t they try  
and keep it flowing properly 
because you need a regular flow  
to finish by five o’clock. 
 
Several hardships were associated with delays in waiting on the HDU for 
nurses to cannulate or between bags of blood. One was that if the participant 
was receiving three units of blood, this meant that sometimes their transfusion 
had not finished by six pm. As the HDU closed at this time, this meant that 
patients would be transferred to the inpatient ward to be cared for by the 
nursing staff there. This had happened on several occasions to Zavier and 
Ernest.  
 
It had not worried Zavier to go and sit on the inpatient ward, perhaps because 
he had been an inpatient there for many months and knew the nursing staff 
well. Ernest, on the other hand, had been distressed on the occasions this had 
happened to him, primarily because he had been made to sit in the “foyer” of 
the ward where everybody could see him. Ernest had felt out of place sitting 
in the foyer. He described how it had made him feel as if he was not as 
important to the nursing staff there as the inpatients. This feeling arose 
because he would sometimes have to sit there with his pump bleeping until 
the nurses were free to come and attend to him. He believed that the nurses, 
“rightly”, prioritised the inpatients who were being treated on the ward with 
chemotherapy as he felt they were more poorly than he was. However, the 
situation left him feeling as if he was a hindrance to the nurses, “in the way”, 
“somebody not worth looking at”. During these episodes, it appeared that 
Ernest, perhaps, lost his feelings of self-worth, dignity and privacy, areas 
conducive to compassionate nursing care. 
 
It’s happened, in the past 
that they were still transfusing at six o’clock 
when the ward was locked-up 
so, they have walked me down with my pump 
to the other end of the main ward  
92 
And I used to sit down there  
next to the vending machines 
so that everybody could see me  
sat in the middle of the foyer 
and there I sat until the blood transfusion was finished 
and that could be anything up to seven thirty 
 
Down there on the ward 
the nurses they’ve got their priorities to do  
before they can attend to some blood patient sat there 
so, consequently if my pump was bleeping for attention 
mine was the last on the list to get looked at 
that made me feel as if I was in the way  
as if I wasn’t anybody worth looking at.  
 
The second hardship associated with waiting for the nurse to cannulate to 
commence the infusion or between bags of blood was elaborated on by each 
of these five participants. Each told me, unprompted, that they were required 
to get up much earlier than they would on normal days of the week. The early 
morning start and waiting around for the nurses on the HDU exacerbated their 
“long day” spent on the day unit.   
 
Kenneth for instance arose one hour forty-five minutes earlier on his BT days 
and Jim, Ernest, Bill and Zavier an hour earlier. They did this because they 
needed to prepare themselves to come in and allow time for parking to arrive 
on the HDU between eight-thirty and nine, the time at which they had been 
asked, by the nurses, to arrive. What appeared to be burdensome for them all 
was that despite their efforts to arrive by the specified time, they were made 
to wait until the nurses were ready to cannulate them.  
 
Ernest highlights what he believes was the unfairness of the situation: 
 
On a transfusion day  
I always get up at least an hour earlier  
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six thirty in the morning 
to be here for eight thirty  
 
One is requested not to get here before that  
as the girls don’t get here until half past eight now  
which sometimes feels a bit unfair  
as the girls used to be here at eight o’clock 
 
When I do get on the unit  
the girls won’t cannulate until nine o’clock  
which puts me at least an hour behind  
on transfusion of three units of blood  
 
And three units of blood takes  
seven sometimes eight hours  
So, I feel that’s a bit of a hindrance 
 in lots of ways.  
 
The need to get up much earlier in the morning was a theme also raised by 
the other three participants. Harold, Helen and Lily all reported that they got 
up about two hours earlier on the day of their blood transfusion day to arrive 
on the HDU early as requested. Kenneth believed the long day would be “more 
tolerable” if he was prescribed two units, rather than three as the day would 
be much shorter. He could be home early in time for dinner and he could also 
rest at home as he became more tired in the afternoons. 
 
Lily (late palliative phase) highlighted that it was a long day as her daughter 
picked her up at 07.30hrs. In her usual, acquiescent manner, Lily said she can 
“put up with it”, as “it’s for my own good”, “the thing that’s going to make you 
better”. 
 
Jim (late): Jim, however, found the long day on the HDU and the challenges 
he endured there almost impossible to bear. He found the long day ‘just sitting 
there all day’ on the unit hard to cope with mentally. He stressed that by the 
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end of the day he had “had enough”. Unprompted, he said that he would have 
preferred his BT to be administered in his own home rather than on the HDU. 
On being asked what made him feel this way, Jim explained that he would 
prefer not to have BT at all, however, as he needed them it would be much 
more tolerable for him if he was offered the choice to have them at home. 
Having them at home, he believed, would make an enormous difference to 
him because he would have his home comforts. It would also be more 
convenient for his wife, he stated, as it would “save her coming all the way up 
from the front and that”.  
 
I’d rather not have them but  
well if I had them at home  
it would be ok  
if there was a choice 
You could sit and watch your own telly 
obviously, you can’t do that here.  
 
Once the idea of home BT had been mentioned by Jim, I brought the topic up 
in conversations with the other seven participants. Of these only Bill thought 
that “it might be worth a try”. 
 
4.5.1.3 Plotline - Anxiety associated with places in the hospital setting 
So far in this section of the chapter, a description of waiting in specific places 
has been presented with the aim of highlighting participants’ anxieties and 
hardships. I would like also to highlight how the HDU environment itself caused 
anxiety for participants Kenneth, Ernest, Jim, Lily and Zavier.  
 
The HDU is a noisy, busy, crowded environment where up to forty patients a 
day receive their treatment as a day case patient in one of two large bays. In 
one of the bays eight chairs are arranged, and in the other bay eight beds. 
Treatments administered here include BT, platelet transfusions, administration 
of chemotherapy and administration of antibiotics. Most of the participants in 
this study found the day spent in this place terribly difficult as multiple 
hardships were encountered that provoked anxiety. 
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Kenneth (early palliative phase): Kenneth found being on the HDU 
challenging commenting “you see it all in that ward”. Being situated in an 
environment close to patients who were receiving chemotherapy, he found 
saddening and distressing. He told a story to indicate why he felt this way. 
Basically, Kenneth’s lack of symptoms meant that he felt well. So, when he 
witnessed a young mother of a small child receiving chemotherapy to treat her 
breast cancer, he believed her condition to be graver than his own. It made 
him feel as if he did not need any treatment when compared to her. This 
episode, he said, made him “feel a fraud”. Considering that he was in a 
palliative stage of his illness with a limited life expectancy, this was a 
misapprehension that gave an indication that he was not aware of his own 
prognosis. 
 
I come up here  
and I see people coming for chemo  
and I feel a fraud 
I don’t feel as if I need it at all 
 
A lady came who had breast cancer 
and they pulled the curtains around  
and I felt sorry for her  
and thought you are worse off than I am  
 
And after she finished her chemo 
her husband came in with their four-year old 
that finished me off 
 
You realise how lucky you are 
cause you’re not really suffering like they are 
you see it all in that ward.  
 
Ernest (early palliative phase): Ernest, like Kenneth, also found being in the 
same proximity as patients receiving chemotherapy saddening and 
uncomfortable. The anxiety he felt had come about following an incident on 
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the HDU. Ernest explained that while talking to a patient who was receiving 
chemotherapy for a solid tumour he had inadvertently made her cry. As she 
talked, Ernest came to learn that the young lady had only a short time left to 
live. Learning that she had only three to four weeks left to live had made him 
feel very distressed “to the point of tears”. It had shocked him as he had not 
anticipated what she was going to say to him. This incident, he reported, made 
him wary of talking to patients who were having chemotherapy. He described 
this situation as having to be “like a cat on hot bricks”, desperately afraid of 
saying the wrong thing. Being afraid to talk to others on the HDU was isolating 
for him and perhaps a difficult predicament for him to be in as he was known 
on the HDU as a cheerful, social man who liked to talk.  
 
Ernest reiterated several times that it was “an uncomfortable situation to be in 
when you don’t know how far down the line these people are”, “you know, 
younger people, who have a shorter time left to live than you have yourself”.  
Ernest, like Kenneth, was aware that his disease was progressing, but he did 
not know how long left he had to live. His prognosis had not been discussed 
with him by the haematology team.  
 
It’s uncomfortable for them 
and for me as a blood patient  
because I am desperately frightened 
of saying something 
that might upset them 
 
I was talking to a nice young lady  
who had lost her hair  
and suddenly she began to weep  
I said I’m ever so sorry 
if I have offended you  
 
She said you haven’t  
I’ve been given notice that  
I’ve only got 3 to 4 weeks to live 
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So, when you are in there  
you don’t know how far down the line these people are 
who are having treatment 
you have to be like a cat on hot bricks  
in case you upset someone  
 
That day I felt really upset myself  
I was virtually in tears 
because I had done something  
that might have offended someone.  
 
Jim (late): Compared to Kenneth and Ernest, Jim expressed a different 
problem associated with other patients on the HDU. He did not want to talk 
with others around him. Jim described how being around people chatting made 
him feel extremely anxious and depressed. Unprompted, he expressed a 
strong desire for quiet, peace and solitude, “to be able to sit and think of 
nothing in particular”. Patients situated around him talking led him to get 
“irritable”, he wanted them to “just shut up”. The peace, quiet, solitude, to be 
alone with his own thoughts, unfortunately this was not something that could 
be acquired on the noisy, busy HDU.  
 
Some days it’s okay 
other days I find it hard  
to cope mentally 
just sitting there  
and other days  
well I cope with it  
 
Like, it’s not too bad today  
but other times I find it hard 
like the lady next door was yack, yack, yack, yack 
just gets you down a bit  
you just want her to shut up for a minute  
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I know it’s not her fault, it’s just me 
your brain gets tired 
you just want to sit there  
and think of nothing much.  
 
There were three places within the hospital that were associated with fear, 
which also caused much anxiety. Zavier was afraid when on the HDU, in 
Pathology and in the lifts and Helen was afraid when she was on the HDU, 
and in Pathology.  
 
Zavier (early phase): Zavier found the long day, lack of privacy and hustle 
and bustle on the HDU challenging. This was because of the number of 
patients who attended the HDU. Zavier explained that during his intensive 
chemotherapy treatment to treat his acute myeloid leukaemia he had been 
nursed in isolation. During this period of chemotherapy treatment, he had been 
warned not to be in the same place as people with coughs and colds due to 
his neutropenic state, a state that put him at great risk of acquiring an infection 
that could become overwhelming and fatal. Although Zavier was no longer 
receiving chemotherapy, he remained neutropenic. This made him feel afraid 
of being on the HDU, travelling in the lift to the HDU and being in Pathology, 
all places where there were many people, some of which he feared might be 
infectious. His wife also feared him getting an infection and had advised him 
to wear a mask. His fear of infection led Zavier to suggest that patients having 
chemotherapy should be separated from those whose “system is a bit low”, 
that is, neutropenic. This, alongside his feelings that he did not have enough 
privacy on the HDU, appeared to indicate that he thought this place the wrong 
setting to receive his BT. 
 
The level of privacy 
it’s fifty, fifty  
if you are having a long day  
you want a quiet place to relax  
but what can you do 
because lots of patients need to come into the hospital 
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If your system is a bit low 
I think it is much better  
if you can separate them from 
patients having chemotherapy 
 
If I go in the elevator and other areas 
where there are many people 
my wife told me wear a mask  
especially now because I am neutropenic. 
 
Helen (terminal): Helen held the same fear of the HDU and Pathology as 
Zavier. She articulated her fear so well, I came to truly understand her 
substantial fear of infection associated with these two places. Helen had in the 
past been treated with intensive chemotherapy for non-Hodgkins lymphoma 
at a hospital in London. During her treatment there she had been nursed in 
isolation, in an air filtered room and warned by healthcare professionals that, 
because she was neutropenic, she was at risk of getting life-threatening 
infections. On her discharge from the ward she had been advised to stay away 
from crowded areas and people with obvious infections. Helen had not 
required any BT during her treatment in London, however she had gone on to 
develop MDS. As she was terminally ill at this point, she had been referred 
from London to our Haematology Department to receive supportive blood 
transfusions. Although our hospital was twenty miles from her home, it was 
more local and convenient for her.  
 
Like Zavier, being in close contact with other patients on the HDU filled her 
with apprehension. Helen described a scenario she had experienced 
concerning a visitor of a patient who was receiving chemotherapy. The man 
who had “the most awful cough and cold” had been given a mask by the 
nurses. Appallingly, the man had discarded the mask on the floor next to 
Helen’s bed as he left the unit. This had caused Helen immense fear and 
anxiety as she was aware of her neutropenic state. 
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Helen reported that she did not mind being around patients having their 
chemotherapy treatment, but she did not want to be around people with 
infections. Her unprompted comment brought an awareness that she was no 
longer eligible to receive this active treatment for her disease. It brought into 
consideration that, perhaps, it was not compassionate to nurse her in the same 
environment as people who were receiving curative therapies and who 
maintained hope of cure.  
 
When I was an inpatient in the hospital  
I was in a room on my own  
because of infection risk 
 
But when we came for the first blood transfusion 
I worried about the environment  
we did say about it  
but there was no single room for me to go in  
 
They gave me a mask 
because the visitor at the next bed  
had the most awful cough and cold  
and when he went he threw his mask down  
next to where we were  
 
Things like that really worry me 
I don’t mind being around chemotherapy patients 
it’s cold and things that worry us 
 
It really does concern me 
because I don’t know  
if I’d be able to fight the infection.  
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4.5.2 Storyline Four - More individualised care associated with the 
hospice day unit and everyday blood transfusion life 
This storyline also elucidates the place dimension of experience and responds 
to research objective 3: To explore the effect of the place or setting where the 
blood transfusions were administered on participants’ experiences of BT. 
The storyline sheds light on one participant’s experience of receiving a blood 
transfusion in a hospice day unit. It was developed from the plotlines: more 
individualised care; hospice day unit perceived as a safer place to receive 
blood transfusions; hospice day unit perceived as a more tranquil place. These 
aspects associated with the hospice day unit setting Helen brought to light in 
her stories.  
 
Most patients with a HM will die in the hospital setting (Cheng, et al., 2015; 
Howell, et al., 2013; McCaughan, et al., 2017; National Cancer Intelligence 
Network, 2011). Sadly, they do not die in a hospice or their own homes which 
may be their preference. Many reasons are given by healthcare professionals 
to explain this situation. For example, it is frequently purported that these 
patients, due to the nature of their disease, require intensive therapies 
including BT, intravenous antibiotics and platelets until the last weeks of their 
lives. Without these treatments they may succumb to unmanageable and 
frightening situations at home, situations their families or home-care health 
professionals may have difficulty in dealing with (McGrath, 2014; McGrath & 
Howlena, 2007). A further reason why haematology patients die in the hospital, 
it is suggested, is that they are not referred to the hospice or palliative care 
team by their haematologist (Howell, et al., 2013; McCaughan, et al., 2017).  
 
A hospice day unit service was established after this study began to provide a 
blood transfusion and phlebotomy service to patients with a palliative 
haematological or oncological disease. The hospice is within the hospital 
grounds and is housed in a glass conservatory overlooking gardens on each 
side. Palliative medical and nursing care is on hand. Generally, only one or 
two oncology patients are in the day unit of the hospice, a place where 
chemotherapy is not administered.  
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Only one participant, Helen, received a blood transfusion in our hospice day 
unit. Being aware of Helen’s fears associated with the HDU and her terminal 
diagnosis, I asked her during our first interview together if she would like to try 
the day hospice. Helen agreed to have her next blood transfusion there. My 
next interview with her, therefore, took place on the hospice day unit during 
her final blood transfusion. The familiarity with both the HDU and the hospice 
day unit environment enabled Helen to compare and report her experiences 
of receiving BT in these two places.  
 
4.5.2.1 Plotline - More individualised care 
Helen attributed many positive aspects to both places. For instance, she 
praised the physicians and nurses in both areas. She pointed out, however, 
that the nurses based in the HDU were far more rushed due to the number of 
patients they “had to cope with”, which left them with little time to talk. Whereas 
the nurses in the Hospice, Helen reported, had a lot more time to concentrate 
on her as an individual, and to sit and talk. Helen felt this made a positive 
difference, as she felt she was getting more individualised nursing care. Her 
healthcare in the hospice resonated with more compassionate care provision.  
 
They are wonderful over in the hospital  
but they are much more rushed  
they have such a lot to do  
a lot more patients to cope with  
 
Here they concentrate on me 
whereas over there 
there are other patients  
that’s the difference 
 
4.5.2.2 Plotline – Hospice day unit perceived as a safer place to receive 
blood transfusions 
Another aspect Helen mentioned was that she felt safer receiving her blood 
transfusion on the day unit of the Hospice. She came to this conclusion for two 
reasons. First of all, on the day she received her blood transfusion in the 
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hospice there were no other patients, and only her husband was present. This 
was in complete contrast to her experiences on the HDU. Helen perceived that 
having no other patients around reduced her risk of infection, stating “it’s the 
risk factor of infection, it would be a lot less having it done here”. Secondly, 
she commented that she felt safer having her blood transfused in the Hospice 
as the rate of transfusion was much slower. In the hospice each unit of blood 
was transfused over four hours and not three as she had recently experienced 
on the HDU. Helen reported that she was going to be on the hospice day unit 
for the whole day as “they are doing it very slowly”. “It’s a bit slower than what 
it was over there”. Helen didn’t mind the blood transfusion taking a long time 
as she felt it was safer. However, although she said she felt safer, she 
remained scared. She reiterated several times that she was still nervous that 
her heart rhythm might be affected, and she didn’t know how she was “going 
to feel by the end of it”. 
 
Because of what happens with my heart rhythm 
they are doing it very slowly 
I am going to be here all day. 
two units over four hours each 
 
It’s going to be a long time 
I don’t mind  
but I don’t know  
how I’ll feel by the end of it. 
 
4.5.2.3 Plotline - Hospice day unit perceived as more tranquil place 
Making an evaluation between the two places, Helen determined that the 
hospice environment was “nice, just lovely and peaceful”. When asked which 
environment she would prefer to receive her BT in the future, Helen initially 
said she did not mind. However, she then concluded that the hospice day unit 
would be her preference next time, highlighting “it has been so lovely here 
today”. Comparing the two places Helen emphasised the tranquillity of the 
hospice ‘without all the pump buzzers going off’ as in the HDU. She employed 
a variety of words to describe the hospice environment: lovely, tranquil, calm, 
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relaxing, peaceful and nice to be in “with the garden and everything”. She 
wondered how it would look in the summer with “all the flowers and 
everything”.  
 
I don’t feel good  
but it’s nice to be able to sit here  
it’s lovely with the garden  
it’s so peaceful 
it’s so tranquil  
instead of hearing all the buzzers going off. 
 
Zavier (early): Understanding Zavier’s fears associated with the hospital I 
asked him how he would feel about having his BT in the hospice day unit. 
Initially Zavier said he did not want to receive his BT there, explaining he had 
been attending the HDU for many months which meant he now felt at home 
there, “part of the family”, “loved” by the medical and nursing staff. If he went 
to the hospice to receive BT, he said he would have to familiarise himself with 
a new environment and the healthcare professionals there. He was loath to do 
this he said, because of the affection he had been shown on the HDU and 
inpatient ward. 
 
I want to come here to the hospital  
I know everybody here  
I know all of them 
doctors, nurses and everything 
 
I seem to be part of the family here 
it’s like home 
I can see people, nurses, doctors, everyone  
they look at me and I see their love   
 
Going over there  
at the Hospice would be entirely different  
I need to meet new people again 
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the doctors, the place and everything. 
 
The next time I saw Zavier he had changed his mind and decided that he would 
like to try the hospice for his BT. He reasoned “the place might be nice, there’s 
a car park” and he would not need to use the lift or other places where there 
were lots of people while he was neutropenic. An appointment to visit the 
hospice day unit was made for him. Despite feeling that the hospice might be 
a good place to receive his BT, Zavier did not visit the hospice and chose to 
receive all his BT on the HDU.  
 
4.6 Summary of research objective 3 
This section has addressed research objective 3: to explore the effect of the 
place or setting where the blood transfusions were administered on 
participants’ experiences of BT. A summary of findings follows: 
 
4.6.1 Hospital setting 
First, there was a dissatisfaction with healthcare provision in the hospital as 
most places linked with BT were associated with waiting, anxiety and distress. 
Long waiting times were experienced frequently in a variety of places 
throughout the hospital. Waits were equated to poor quality of service. Waiting 
in Pathology, for instance, was reported by most participants. They queued for 
one to two hours in an environment that was found to be manic, stifling and 
distressing. The large number of patients attending Pathology was reported to 
provoke fear of infection in those who were neutropenic. Participants 
recognised their GP practice took blood tests, however this was not 
considered a good option as the healthcare professionals there found it difficult 
to take blood due to participants’ poor venous access. Waiting on the HDU 
was found to be “depressing and unnecessary”. It intensified the “long, boring 
days” which were exacerbated by the need to get up much earlier. Being made 
to wait to be cannulated for their BT, or between bags of blood, caused 
hardships for participants because it delayed them going home. It meant that 
they sometimes had to go to the inpatient facility to complete their BT. Being 
nursed on the inpatient ward was associated with feelings of being unimportant 
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and less of a priority to the nurses as they were not receiving active 
chemotherapy treatment.  
 
Secondly, anxiety was associated with HDU for several reasons. It was said 
to be noisy and busy which proved challenging when solitude and peace was 
desired. Some participants found being cared for in the same place as younger 
patients, who were receiving chemotherapy treatment and who had a poor 
prognosis, upsetting. A participant reported he felt unable to talk to other 
patients for fear of causing distress which, perhaps, was isolating for him as 
he was a social person who liked to talk.  
 
Thirdly, participants reported that staff on the HDU were too busy or short 
staffed to talk. 
 
Fourthly, participants who were neutropenic experienced fear of infection due 
to the large numbers of patients in the unit, and which caused Zavier to 
suggest it was the wrong place for his BT to be administered. 
 
4.6.2 Hospice day unit setting 
Firstly, the hospice day unit was associated with more individualised care, as 
nurses had more time to spend talking with patients. 
 
Secondly, life in the hospice was perceived as more tranquil, more relaxing 
and peaceful with a garden. Helen also felt safer being nursed in the hospice 
day unit due to the slower rate of administration of the blood transfusion and 
the lack of others around her. 
 
Thirdly, Zavier declined receiving his BT in the hospice day unit because he 
felt part of the family, loved by medical and nursing staff on the HDU. The 
affection proffered made him loath to change, as going to the hospice day unit 
he associated with having to familiarise to a new environment and different 
HCP.  
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4.7 Section three: Temporality dimension of experience 
4.7.1 Storyline five: An everyday SAD life during the late to terminal 
palliative phase of a haematological malignancy 
This storyline which elucidates the temporal dimension of experience 
responds to objective 4: To explore the change in participants’ experiences as 
disease progressed from an early palliative phase, to a late palliative phase, 
to the terminal palliative phase.  
 
Looking across the stories of those in the early palliative stage (Kenneth, 
Ernest and Zavier), to those in the late (Jim and Lily) and those in the terminal 
palliative phases (Harold, Helen and Bill), allowed an insight into how 
experiences surrounding BT changed with disease progression.  
As participants’ haematology malignancy progressed through the palliative 
stages, everyday blood transfusion life resonated with three plotlines:  
Somnolence overwhelms daily life; Adversities overpower everyday life, and 
a Desperation to hang on to life. This led to the acronym SAD. 
These plotlines which emerged from participants’ stories were not distinct from 
each other, rather they melded together to provide the building blocks for this 
storyline.  
 
4.7.1.1 Plotline - Somnolence overwhelms daily life 
One of the striking differences between participants in the early palliative stage 
of disease compared to those in the latter stages related to the profound 
sleepiness experienced by those with more advanced disease. Overwhelming 
somnolence was a symptom reported by all five participants who were in the 
late to terminal palliative stage of their haematological disease: Jim (Late), Lily 
(Late), Harold (Terminal), Helen (Terminal) and Bill (Terminal). 
 
Jim (late): Jim reported on several occasions that he slept virtually all the time. 
He told me that he had been surprised to learn that his haemoglobin had fallen 
to 54g/dL, as he had not been aware of being more breathless. He had felt 
more tired and weaker limbed, but he had not felt “too bad”. Jim suggested 
that he hadn’t really noticed the effect of his Hb being so low because he’d 
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been “sleeping a lot at home” and as such had not been participating in much 
physical activity.  
 
Even with the transfusions 
I still get easily tired  
so, I’m not doing much  
I sit down 
I go to sleep  
I wake up  
and then I go to sleep.  
 
Excessive day-time sleeping for these participants did not appear to offer the 
usual restorative benefits that individuals expect from sleep. Participants felt 
just as tired post sleep as they had before they went to sleep. The 
administration of BT did not appear to help with this incapacitating condition, 
a condition which hindered their everyday lives.  
 
In the past, during the early palliative stage of their disease, they had not 
experienced this overwhelming sleepiness. Indeed Kenneth, Ernest and 
Zavier who were still in the early phase spoke of being tired and lethargic, but 
they never spoke of somnolence. In comparison, they talked about striving to 
be “normal”, “trying to do everything they had done before”, “trying to do the 
same things as other people do”.  
 
4.7.1.2 Plotline - Adversities overpower everyday life  
As participants’ disease deteriorated over time to the late and terminal 
palliative phase adversities overpowered their everyday lives. Each of the five 
participants presented overriding burdens, burdens which mostly related to an 
incapacity to undertake activities of daily living. For example, all expressed an 
inability to walk even the smallest of distances; none could dress themselves 
or wash themselves or travel to the hospital independently. These challenges 
are perhaps consistent with the problems any individual at the end stages of 
a deteriorating illness could expect. Importantly for this study, however, was 
that administration of BT did not help. In fact, many of the tribulations 
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associated with BT identified earlier in the chapter were exacerbated as 
participants’ disease worsened with time. This happened simply because they 
needed to come more frequently to receive blood. Rather than every three or 
four weeks as they had when in an early palliative stage, they were now 
required to attend every week or two weekly. So, the burdens of, for instance, 
leaving their beds, homes, families, getting to the hospital, waiting around at 
the hospital, and being in the hands of others all occurred more frequently 
which made the impact on them worse. This could be described as 
uncompassionate healthcare.  
 
Bill (terminal): Bill, for example, was leaving his home every week to spend 
a whole day on the HDU to receive his BT. Getting to the hospital was a 
mammoth task for him and his wife. Bill was totally dependent on his wife at 
this stage of his disease. His wife helped him to dress, she drove him to the 
hospital and then transported him in a wheelchair to the HDU. Attending for 
BT enforced him to leave his bed and home comforts to suffer these burdens 
on a weekly basis. Bill admitted to feeling “low in mood” and having to “force” 
himself to attend for his BT. 
 
Harold (terminal): Harold in the past had been a strong, independent man, 
serving as a senior officer in the armed forces. For most of his life he had been 
the person people depended on. As Harold’s condition deteriorated to the 
terminal palliative phase, he reported that he spent his time in bed “almost 
constantly”. His debilitated, frail, condition made him become totally 
dependent on his wife and family to support him with all his activities of daily 
living.  
 
I used to do the cooking 
But now I’m feeling very tired and sick  
and I’m fairly immobile and frail  
So, the wife has to do things for me now.  
 
Jim (late): Jim also demonstrated that he had been self-reliant until his 
disease had deteriorated to a late palliative stage. Jim had been self-employed 
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throughout most of his life. He prided himself on his independence, his work 
achievements and his ability to provide for his family. Indeed, his work 
appeared to be a vitally important aspect of his life demonstrated by the many 
stories about his employment that he reiterated, unprompted, throughout our 
meetings. On one occasion Jim relayed the story of his refusal to have a bone 
marrow transplant and splenectomy several years previously. He declined 
what could have been potentially life-saving procedures because he had been 
informed that he may not have been fit enough to work for twelve months post 
procedures. Being unable to work and having no money to support his family, 
he said, was an intolerable thought to him. Until this point in his disease, he 
had asked not to be told anything about his prognosis. He said he chose not 
to think too deeply about his plight, acknowledging that his manner of dealing 
with distressing or unpleasant news and managing his illness situation was to 
“bury his head in the sand”. Sadly, during our third interview Jim asked, “I 
suppose it’s too late for the spleen to come out now isn’t it”. His everyday life 
had become so constrained by the overwhelming somnolence, tiredness and 
weakness he experienced that he was desperate to try any treatment 
available.  
 
When Jim and I met at our first interview, his grossly enlarged abdomen 
caused by a massive spleen made walking difficult for him. Jim was, however, 
still able to walk from the front of the hospital to the HDU, albeit “very slowly”. 
At this point, he reported that he could walk 50 metres on the flat although he 
could not manage to walk an incline as he became breathless and felt 
overwhelming fatigue the next day. He was still able to drive. By our third 
interview, Jim’s condition had deteriorated so much that he could no longer 
drive or walk from the car park to the HDU or Pathology Department. He 
needed his wife to bring him in a wheelchair. Getting the chair out of the car 
was very difficult for her. The effect on his wife worried him and caused him to 
tell the haematologists that, as he was attending the hospital three times in 
one week (twice for blood tests and once for BT) every two weeks, he needed 
to reduce the frequency of his visits. It was organised that Jim attended only 
once a week, every two weeks. He first attended Pathology, then he came to 
the HDU to wait for his blood test results to be reviewed by a haematologist 
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and have his blood prescribed, then later in the day his blood transfusion was 
administered. Prior to leaving the unit Jim would make his subsequent 
appointment at the reception desk. Although much waiting was involved with 
this one stop service, Jim believed this arrangement to be much better. Like 
Lily, he used humour to make light of his situation. He joked that as he no 
longer needed to come so frequently to the hospital it saved him money in the 
hospital café. Bringing his situation to light made me wonder if this 
arrangement would be better for all haematology patients in this end-of-life 
situation. 
 
It’s a bit of a problem now  
getting into the hospital 
my wife needs to take the wheelchair 
out of the car  
which is not good for her 
 
So, I’ve changed it round 
I get the blood test when I get here 
then see the doctor 
then have the transfusion 
then book the appointment  
all in the one day  
 
So, it saves coming three times 
in one week 
which will be useful 
coz it cost me a fortune in Costa. 
 
By the time of our last interviews, all five participants with advanced disease 
had become different individuals from those whom I had met during our first 
meetings. They were no longer autonomous individuals, rather dependency 
on family, friends and healthcare professionals had become the norm. In 
comparison, participants in the early palliative stage did not suffer with these 
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burdens. They remained autonomous in their self-care and daily living 
activities; they felt normal, “able to do the things normal people do”. 
 
4.7.1.3 Plotline - Desperation to hang on to life 
Harold, Jim, Lily, Helen and Bill who were in the late-terminal palliative phase 
of their disease illustrated an unquestionable desperation to hang on to their 
lives through the administration of BT. Despite the challenges they faced every 
day all remained stoic trying each day to do a little something, retaining hope 
that BT would keep them alive a little longer. 
 
Harold (terminal): Harold, on the day of our final interview, told me that he 
had been putting off coming into the hospital to receive a blood transfusion as 
he had been feeling so unwell. However, he had made the decision to come 
in as he had “thought it would be worth giving it another try”. Harold stated that 
he didn’t know if the blood transfusion was going to help him, but he did not 
“feel it would do any harm”. So, despite being in dreadful physical condition, 
he had asked his wife to call an ambulance to bring him to the hospital to 
receive his blood transfusion. Harold knew that he would need to spend the 
whole day on the day unit of his community hospital, however this did not deter 
him.  
 
The hope of prolonging his life through BT provided him with the emotional 
resilience, strength and stamina to keep going. Harold was therefore 
distressed when told by the nurses that they were not going to give him his 
blood transfusion. He had been so desperate to receive it that he had endured 
the dreadful ambulance journey to reach the hospital. Harold, in an 
unaccustomed manner, accepted their decision not to transfuse on that day. 
He had been too ill to persuade the doctors to give it a try. He was, however, 
under the illusion that it had been a postponement, to wait and see if he was 
well enough the following week to receive blood. He did not acknowledge that 
the doctors might not want him to have BT in the future.  
 
I thought it would be worth trying 
to have another one today 
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I don’t know if it will help 
I don’t feel it would do any harm 
I honestly don’t know  
 
We’ll see what the doctor advises 
The delay, it’s really a one off 
see how I am next week. 
 
Jim (late): Jim, for a long time in his usual stoic manner resisted the doctors’ 
attempts to increase the frequency of his BT from every month to every two 
weeks. Jim had been trying, he told me, to accustom his body to receiving 
monthly BT to “get his body used too” a four-weekly regime. It had been 
important to him as he had planned a twenty-four-day holiday away during 
which time he would be unable to receive BT. With his disease deterioration 
and his desperation to stay alive, Jim reluctantly accepted the physicians’ 
advice to have them every two weeks. He was, however, under the 
misapprehension that by increasing BT to every two weeks his Hb level might 
stabilise at an acceptable level sufficient for him to go on his holiday. 
 
The doctor said about  
having the blood a bit more often 
I said yes, and then we can see how things go 
if I do get to the holiday 
its twenty-four days 
we’ll know how things are panning out by about June  
and things might just stay at that level 
mighten it? 
 
Bill (terminal): Bill was desperate to hang on to his life, he told me, for the 
sake of his wife and family. Bill’s wife was his “rock” and regardless of how 
difficult he found attending the HDU, he somehow found the emotional spirit 
to force’ himself, to do it on a weekly basis. This frequent attendance, perhaps, 
deprived him of a more peaceful time with his family at the end of his life.  
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Helen: Helen likewise clung to life. She travelled forty miles to get to the 
hospital and back home. She made this journey to receive her BT despite 
extreme fatigue and feeling so poorly she could not do anything. She could 
not dress or walk unaided, and her husband helped her with all her activities 
of daily living. Even though BT were not helping, they allowed her to maintain 
hope that they would keep her going a little longer for her husband’s sake. 
Indeed, each of those in the terminal palliative stage stated that they wanted 
to survive for their spouse.  
 
Section Three has illustrated the effect of temporality on participants’ 
experience. These findings are summarised below.  
 
4.8 Summary of research objective 4 
The findings that addressed objective 4 highlight that as participants’ diseases 
deteriorated into a late or terminal palliative phase, their everyday lives 
changed dramatically, and their lives became SAD.  
 
First, they experienced overwhelming somnolence and BT did not help with 
this symptom.  
 
Second, adversities overwhelmed their lives to such an extent that they were 
incapable of undertaking activities of daily living, even cleaning their teeth 
became an effort. As such they became totally dependent on their family and 
HCP.  
 
Third, their stories of experiences were vitally different to the experiences of 
those in an early palliative stage of their haematological disease who felt 
normal following their BT, able to do things normal people do.  
 
Fourth, these participants in the late to terminal palliative stage held a 
desperation for BT. Regardless of how poorly they felt, how dreadful their 
physical condition, or how dependent they became, they exhibited a 
desperation to hang on to their lives at any cost. It appeared their desperation 
to receive BT revolved around their beliefs that BT were an elixir of life. They 
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were the life-blood that allowed them to survive and as such all their hope hung 
in the bag of blood.  
 
Fifth, regardless of their dire situation, two participants employed humour to 
disguise their concerns during our interviews. The stoicism they all exhibited 
was demonstrable and unmistakeable through the emotional fortitude they 
exhibited.  
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Chapter 5: Discussion 
5.1 Introduction 
This study set out to understand the experiences of palliative patients who 
received regular blood transfusions in a day unit setting. The key findings from 
this research study are embedded throughout this discussion chapter and 
illuminated via five storylines which are interpreted in the context of the 
academic literature and in relation to compassionate clinical practice. The 
structure of the chapter links together the research objectives, the storyline 
findings and the three dimensions of experience, sociality (personal and 
social), place and temporality, as follows: 
 
First, addressing the personal dimension of experience allowed the first 
research objective to be met: to explore participants’ expectations and 
challenges surrounding receiving regular BT in a day unit setting and this is 
personified by findings in storyline one - everyday blood transfusion life hangs 
in the bag.  
Second, addressing the social dimension of experience allowed the second 
study objective to be met: to explore healthcare professional’s role on 
participants’ experience of BT and this is personified by findings in storyline 
two - everyday blood transfusion life hangs in the hands of others.  
Third, addressing the ‘place / setting’ dimension of experience allowed the 
third study objective to be met: to explore the effect of the place or setting 
where the blood transfusions were administered on participants’ experiences 
of BT, and this is personified by findings in storyline three - everyday blood 
transfusion life involves waiting and anxiety, and storyline four - more 
individualised care associated with the hospice day unit and everyday blood 
transfusion life. 
Fourth, addressing the temporality dimension of experience allowed study 
objective four to be met: to explore the change in participants’ experiences as 
disease progressed from an early palliative phase, to a late palliative phase, 
to the terminal palliative phase of a haematological malignancy, and this is 
personified by findings in storyline five - an everyday SAD life during the late 
to terminal palliative phase of a haematological malignancy. 
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5.2 Research objective 1: To explore participants’ expectations and 
challenges around receiving regular blood transfusions in a day unit 
setting  
5.2.1 Storyline one: Everyday blood transfusion life hangs in the bag 
This storyline elucidates the personal dimension of participants’ experiences 
of BT, as such it complied with the first research objective. 
 
5.2.1.1 Plotline - Blood transfusions mean life  
This plotline stood as the core theme that illuminated participants’ feelings, 
understanding and expectations of BT. Participants’ feelings were that BT 
mattered to them as it kept them alive. “Without them I couldn’t survive”, most 
participants said. This feeling was the thread which ran through all the 
participants’ stories. It connected all the other storyline findings and set the 
scene of everyday blood transfusion life. The centrality of this narrative 
storyline helps explains why participants put themselves through the burdens 
they voiced.  
 
It is unknown whether BT allowed the participants who were in a terminal 
palliative phase to live longer. Goksu et al., (2014, p. 4251) suggest that 
patients who receive BT when close to death live significantly longer than 
those who do not (15 days vs 8 days), but other authors report that BT 
administered at this late stage may be associated with increased mortality 
(Preston et al., 2012; Woodwark & Dean, 2017). However, it was a eureka 
moment for me when it became apparent that participants’ primary aim in 
receiving BT was not to reduce their anaemia-related symptoms of 
breathlessness and fatigue. They were putting themselves through the 
hardships which they associated with BT simply to stay alive and to lengthen 
their lives for as long as possible. Thus, they were willing to spend a whole 
day in a day unit every two to three weeks to receive this elixir of life because 
BT maintained their hope of survival.  
 
Hope has been recognised as an important concept in everyday life, and one 
that underpins the foundation of palliative care principles in terms of providing 
realistic life aspirations (Herth, 1990, cited in Woods, Beaver, & Luker, 2000, 
118 
p. 318). According to Woods and Beaver, ‘hope’ may often be associated with 
unrealistic ambitions of extending the “quantity” rather than the “quality of life”. 
In these circumstances patients frequently tolerate the many hardships 
associated with hospital care, for example, the need to comply with hospital 
appointments (Woods, Beaver, & Luker, 2000, p.318) and the annoyances 
associated with the long waits in outpatient clinics (ibid, p. 321). 
 
The findings from this study appear to suggest that physicians upheld 
participants’ hope of prolonging their lives through the process of therapeutic 
emplotment (Crossley, 2003; Del Vecchio Good, Munakata, Kobayashi, 
Mattingly, & Good, 1994, p. 855; Murray, 2008). That is, rather than discuss 
“death” and “dying” during their clinical encounters, haematologists preserved 
patients’ hope by focussing in on the benefits of BT, in terms of prolonging 
their lives, and detailing practical aspects of the procedure. Authorising BT 
until the week a participant died, perhaps, exemplifies this point. Bill, for 
example, was in the terminal stage of his disease, in authorising BT weekly 
the doctors instilled “an emphasis on temporality and on experience for the 
moment […..] the horizon of the future is deliberately blurred, even as patients 
may struggle to live into the future” ( Del Vecchio Good, et al., 1994, p. 857). 
Collaborating with Bill in his “quest” to survive physicians portrayed a 
“subjunctive world, one in which healing is an open possibility, even if miracles 
are necessary” (Good & Del Vecchio Good, 1994, p. 839). Receiving BT 
perhaps encouraged Bill ‘to struggle against his death’ (Crossley, 2003; Del 
Vecchio Good, et al., 1994, p. 856; Murray, 2008, p.22). 
 
It may be that therapeutic emplotment in Bill’s situation was not an unkind act 
as healthcare professionals were aiming to maintain his hope of surviving a 
little longer. However, promoting hope by continuing futile treatment with blood 
transfusions at this stage of his disease may have added to his suffering as 
“the creation of an experience of hope…. is often fraught with great anxiety for 
patients, who seek knowledge of prognosis and certainty of illness course” 
(Del Vecchio Good et al, 1994, p. 857). Breier-Mackie (2001) presents an 
eloquent argument concerning the nurse’s role in treatments viewed as futile 
in end of life situations. She argues that nurses are in a good position to 
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advocate on behalf of patients in ethical circumstances but highlighted that 
ultimately the patient must be allowed to decide whether a treatment is futile 
for them or not (p.514).  
 
In this study all of the participants coveted BT, which is in contrast to the 
findings of Szende, et al. (2009). These authors found in a study of participants 
with non-palliative MDS, that some rated blood transfusion dependency as 
“worse than death” (2009, p. 1-2). By comparison, participants in this study did 
not feel this way, even though study participants voiced anxieties and 
hardships, none suggested that the problems they experienced with BT were 
intolerable.  
 
On the occasions when participants held a different opinion to their 
haematologist, they still followed their physician’s advice and placed their lives 
in the hands of their doctor. For instance, when Kenneth believed he had not 
required a blood transfusion because he was asymptomatic, he would not go 
against the physician’s advice. When Lily believed she really needed a 
transfusion and the doctor did not authorise one, she would not argue with the 
doctor. This was, perhaps, because they believed that the physician knew 
what was best for them, as in the case of Lily, or perhaps by doing what the 
doctor suggested Kenneth demonstrated that he was taking responsibility for 
his own health (Charmaz, 1997).  
 
With knowledge of participants’ feelings about BT, it appears unthinkable to 
me as a nurse who is committed to providing compassionate care for all 
patients to imagine discontinuing BT. Even when administration of blood 
appears futile, when minimal or no beneficial physical effects are experienced, 
withdrawing this lifeblood support does not feel appropriate or reasonable so 
long as participants’ faith persists. There is strong support among nurses for 
this assertion as demonstrated in a survey assessing medical and nursing staff 
attitudes regarding the administration of BT to terminally ill patients (Leibovitz, 
et al., 2004). The majority of the 500 healthcare professionals surveyed 
believed that BT should be administered to terminally ill patients (p. 542). More 
recently, Hayward, Hiersche and Watson, (2012), also suggested that the 
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majority of healthcare professionals surveyed, during an on-line questionnaire, 
did not think that BT should be withheld in palliative circumstances. 
 
However, as will be seen throughout this chapter, the clinical service 
associated with administration of BT to those in a palliative phase of a 
haematological disease warrants much consideration. That is, healthcare 
professionals need to give much thought to: the place blood transfusions are 
administered, the rate blood is administered, the application of chelating 
agents, their relationships and communication with patients and involving the 
palliative care team earlier in the patients’ disease trajectory.  
 
5.2.1.2 Plotline - Blood transfusions as a sustenance for life 
Three of the eight participants (Kenneth, Ernest and Zavier) considered BT a 
sustenance to life as it helped to relieve their symptoms of fatigue. This relief 
of fatigue enabled them to carry out everyday activities of daily living and 
engage in outdoor activities. Kenneth, for example, reported that post BT he 
did not “even know he was ill at all”. However, in the final interview with the 
other five participants, none thought of BT as a sustenance to life, as following 
BT they were still unable to participate in normal activities of daily living due to 
extreme fatigue. 
 
Fatigue is one of the most overwhelming symptoms of anaemia in patients at 
the end-of-life (Brown, Hurlow, Rahman, Closs, & Bennett, 2010; Orme, Still, 
Day, & Evans, 2013; Woodwark & Dean, 2017). The varied beneficial 
response in relieving fatigue in these patients found in this study is comparable 
to that of other researchers (Orme, Still, Day, Evans, & Perkins, 2013; 
Woodwark & Dean, 2017; Preston, Hurlow, Brine, & Bennett, 2012). 
Woodwark and Dean (2017) for instance, found that thirty-nine percent of 
patients at the dying stage of life found some benefit from BT in relieving the 
symptoms of anaemia. While a Cochrane Review (Preston, Hurlow, Brine, & 
Bennett, 2012, p. 7) found that seventy percent of participants with advanced 
cancer achieved some relief of their fatigue, even though this relief lasted only 
up to fourteen days. The discrepancy between the findings of these two 
studies relates perhaps to the palliative phase of the population involved in 
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their research. That is, Woodwark and Dean studied only participants who 
were at the dying stage of life while Preston et al. explored all participants who 
had advanced cancer, that is, those in the early, late and palliative phases 
(although differentiation into palliative phases in the Cochrane Review is not 
specified).  
 
Stratifying patients into different palliative phases to explore the effect of BT 
appears to be a novel approach, as no other studies could be found that have 
employed this method. Due to the small sample size and narrative 
methodology it is impossible to categorically point to a definite cause and effect 
in the findings, however, grouping participants in this manner in this thesis 
allowed a greater insight into the effect of BT at the end-of-life and allowed for 
clinical observations to be made. For example, an interesting observation that 
adds to the knowledge base around this topic is that those participants who 
stated that they felt normal following BT, were in an early palliative phase of 
disease, albeit still recognised as at the end-of-their-lives as defined by the 
General Medical Council (2010). But those participants in the late or terminal 
palliative stage did not experience any feelings of normality following a blood 
transfusion as they were unable to participate in everyday activities of living.  
 
5.2.1.3 Plotline - An up and down everyday blood transfusion life 
From the stories told it appears that any positive effect, following the 
administration of BT, was transient and led the participants to experience what 
might be described as an up and down life in relation to the BT they received. 
For example, Kenneth, Ernest and Zavier reported that they generally started 
to feel better between one to three days post blood transfusion, but that this 
beneficial effect started to diminish quite quickly and appeared to be 
dependent on the frequency of transfusion. For example, Ernest, who was 
receiving BT every two weeks, stated that he would feel better for about four 
to five days but then he would slowly start to decline and feel sluggish, tired 
and breathless again. Ernest reported that this up and down effect was 
repeated time and time again. For Kenneth and Zavier, who received their BT 
every three weeks, the decline in beneficial effect would happen at about day 
fourteen to fifteen. From the narrative findings, it appeared that Ernest would 
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feel better or ‘up’ for between four to five days, while Kenneth and Zavier on a 
three-weekly blood transfusion regime remained feeling up for about fourteen 
days. These findings are coherent with those noted by Preston et al, (2012), 
who found that the beneficial effect is felt from “day two and begins to wane 
from day fourteen” (2012, p. 7). An important finding not previously expressed 
in the academic literature is that when the effect of BT diminishes these 
participants spent much time feeling ‘down’, physically, mentally or both.  
 
From participants’ narratives it appears that on the up days, participants could 
engage in normal activities of daily living and their everyday life felt normal. 
However, what was striking from participants’ narratives was that those in the 
late or terminal palliative stages did not report any up days, they only reported 
down days. On these down days, which was most days for Harold, Jim, Lily, 
Helen and Bill, their illness took over and they could not function normally. 
Their activities of daily living ceased, and they sat in the chair or lay in bed 
most of the day. They were unable to do even the simplest of tasks, anything 
that required physical strength became too much of an effort. However, on 
these down days, they were required to come to the hospital for their blood 
tests and to receive their BT.  
 
The stories participants told, in this study, to describe their up days and down 
days resonated with the terms “good days” and “bad days”, described by 
Charmaz (1997, p. 49-53) who used these terms to explain meticulously what 
it is like to live with a chronic disease, a state all patients in this study found 
themselves to be in. A good day, according to Charmaz, means that that the 
effects of illness are minimal, individuals manage to maintain everyday 
activities and they rarely engage in thoughts of symptoms. On a good day they 
feel “relatively normal between exacerbations” and are able to be the person 
they recognise as “self” (Charmaz, 1997, p. 51). A bad day means that their 
illness takes over their whole lives and they lose sight of who they were, their 
normal “self” (p. 51). Other researchers too have noted that patients with 
cancer suffer “up’ and ‘down” days, suggesting the effects of disease and its 
treatment on everyday life are relentless (Crossley, 2003; Murray, 2008). 
123 
5.3 Research objective 1: Summary of key findings 
First, the central point in participants’ narratives was their overwhelming 
expectation that BT would prolong their lives. This expectation, perhaps, was 
influenced by their discussions with the haematologists who strive to maintain 
hope during consultations with patients through a process of therapeutic 
emplotment (Delvecchio-Good et al., 1994, p. 855). While patients retain this 
expectation, BT should continue to be administered to this population 
(Leibovitz, et al., 2004; Hayward, Hiersche & Watson, 2012), as part of 
providing compassionate care.  
 
Secondly, as shown in Table 4 half of the participants in this study died within 
fourteen days of receiving a blood transfusion. It is unknown if BT contributed 
to their mortality through increased circulatory overload (Preston, Hurlow, 
Brine, & Bennett, 2012). 
 
Thirdly, the challenges associated with BT were not considered by 
participants to be so overwhelming that they considered death to be “a better 
option” (Szende et al., 2009). 
 
Fourthly, three participants expected a beneficial effect from BT, but they 
expected this positive effect to be short lived.  
 
Finally, those in the early palliative phase experienced a sense of normality 
following BT. Those in the late or terminal stages did not experience such 
sense of normality post BT. The up and down days experienced post BT were 
consistent with the good days or bad days described by Charmaz (1997).  
 
 
 
 
 
 
124 
5.4 Research objective 2: To explore healthcare professional’s role on 
participants’ experience of BT. 
5.4.1 Storyline two: Everyday blood transfusion life hangs in the hands 
of others 
This storyline corresponds with the social dimension of participants’ 
experiences of BT. As such it complied with the second research objective as 
it illuminated the effect the healthcare professionals’ role had on participants’ 
experiences of BT, which in turn was influenced by personal, cultural and 
institutional aspects. This storyline was developed from plotlines: life in the 
hands of physicians; life in the hands of the nurses; and life in the hands of 
ward receptionists.   
 
5.4.1.1 Plotline - Life in the hands of physicians 
This theme appeared in all participants’ stories and is, perhaps, an obvious 
plotline as participants were dependent on physicians to authorise their BT. 
However, participants’ lives were found to lie in the hands of their physicians 
in several other ways. One example, revolved around the variation in the 
physicians’ authorising of BT, which caused confusion and distress for some 
participants. Some physicians, for example, would prescribe BT to reach a 
target haemoglobin (Hb) level of 8g/dL, whilst others aimed for a target level 
of 10g/dL.  
 
According to the literature this variation in target Hb levels is acceptable in 
patients with haematological malignancies like MDS. For instance, Fenaux, 
Haase, Sanz, Santini and Buske (2014), on behalf of the European Society for 
Medical Oncology working group, recommend that blood should be 
administered to reach a target of “8g/dL, 9g/dL, or 10g/dL” (p. iii64) in patients 
with MDS. They did, however, add a proviso to suggest that physicians, when 
authorising BT, should pay attention to patients’ subjective factors, (those who 
are elderly and those who are unable to carry out any physical activities) and 
authorise transfusions according to these factors rather than on Hb level alone.  
 
A finding in this study was that there appeared to be a variation in the 
authorisation of BT between junior and consultant physicians. Two participants 
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suggested during our interviews that the more junior physicians did not always 
take account of their subjective factors, that is, how they were feeling 
physically when the BT was authorised. Rather the junior doctors appeared to 
authorise to haemoglobin levels alone. This clinical practice of authorising BT 
according to Hb level alone has been previously noted by Bishop, Faithful, & 
Allan, (2011) and by Cheng, Sham, Chan, Li, and Au (2015) who analysed the 
level of medical care received by haematology patients who were dying in a 
hospice and suggested that; “in daily practice blood products were given 
empirically, when doctors responded to figures from complete blood picture 
rather than patients’ individual needs” (Cheng et al., 2015, p. 224). 
 
The discrepancy between junior doctors and their senior consultant 
haematologists is perhaps understandable due to the lack of experience the 
more junior physicians have, and the time pressure involved with reviewing 
numerous patients in the day care setting and the temptation to go on figures 
alone. However, the apparent lack of holistic assessment which was observed 
in this study and which is reflected in participants’ narratives needs 
addressing. Provision of education in relation to the authorisation of BT on an 
individualised, case by case, clinical assessment basis (Gray, et al., 2016), 
could be a starting point and could suggest that further examination of junior 
doctors’ busy working schedules in day units and clinics is indicated.  
 
Two participants said they found the experience concerning variation in the 
prescribing practice of BT amongst haematology doctors distressing and 
confusing. An observation made from the study findings was the divergent 
manner that these two participants, Lily and Helen, chose to address the 
situation. Lily at 86 years of age chose an acquiescent, passive route allowing 
the doctors to take a dominant role, while Helen who was much younger chose 
to be more active in her approach. Lily believed that “the doctors know best”, 
while Helen knew what was best for her.  
 
Addressing the literature, it appears there could be several reasons for the 
deference Lily portrayed throughout all her stories, and Helen’s ability to 
advocate for herself. Lily, perhaps, was more familiar with a society where the 
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relationship between physician and patient was unlike that today. According 
to Agarwal and Murinson (2012), in the past it had been believed by patients 
that doctors alone boasted specialist medical knowledge and experience of 
treating their illnesses. This understanding made patients obedient to their 
doctors’ decisions while disregarding their own feelings. In more recent times, 
and perhaps in those younger like Helen, this situation has changed. Patients 
are now much more likely to challenge a physician’s decisions and want to 
take an active role in clinical decisions. Agarwal and Murinson (2012) argue 
that to ensure patients are allowed to make autonomous decisions about their 
care, it is vital that healthcare professionals take special care to communicate 
with their more elderly patients (Agarwal & Murinson, 2012). Allowing all 
patients to be involved in the decision-making process would help provide 
compassionate blood transfusion healthcare where patients’ rights are upheld.  
 
The administration of chelating agents was a further aspect that illustrated 
participants’ lives lay in the hands of their haematology physicians. It is a 
doctor’s responsibility to prescribe this treatment if they believe it is necessary, 
and to choose between Desferrioxamine or Exjade as part of treatment. The 
findings from this study highlight that this decision was influenced by the 
participants’ diagnosis, their ferritin level and their tolerance to these two 
agents. Four participants with MDS had been prescribed these therapies, but 
at the time of this study, one of these participants (Ernest) had ceased 
chelating treatment entirely due to the difficulties he experienced tolerating 
either Desferrioxamine or Exjade. Two of the other participants spoke, 
unprompted, in enormous detail of the hardships they experienced that were 
associated with the administration of these drugs. For example, Harold, who 
was in the terminal phase of his disease, explained the challenges he 
experienced with injecting himself subcutaneously four times a week with 
Desferrioxamine and infusing the drug for ten hours. He also explained the 
difficulties he experienced with the storing of twelve large diffuser pumps in his 
fridge at home. In view of the hardships participants in this study experienced 
with both Exjade and Desferrioxamine, administration of these drugs in 
patients with a palliative diagnosis is perhaps debatable. 
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There is confusing and contentious research evidence in recent literature 
concerning the use of iron chelation therapy (ICT) in patients with MDS who 
are at the end of their lives (Mast & Field, 2012; Zeidan, Pullarkat, & Komrokji, 
2017). Indeed, according to Killick, (2017, p. 375) “there is little so hotly 
debated within the MDS community as iron chelation therapy, with two camps 
being created, the believers and the non-believers”. Gattermann (2008) 
presents a summary of the recommendations proposed by an international 
working group of experts which demonstrates differing approaches to ICT in 
participants in a palliative stage of disease. The Italian group suggests 
providing ICT if life expectancy is greater than 6 months and the Japanese 
guidelines, and those of the MDS UK Foundation suggest administration if life 
expectancy is greater than a year.  
 
Participants were also dependent on the haematologists to refer them to the 
palliative care team (PCT) as they were all at the end-of-life phase (GMC, 
2010). Only two participants, Helen and Bill, met with a Macmillan nurse, and 
this meeting occurred only weeks before their death. The lack of referral of 
patients diagnosed with a haematology malignancy to the PCT has been noted 
by other researchers (Howell, et al., 2011; McCaughan, et al., 2017; McGrath, 
2002; McGrath & Holewa, 2007). This lack of referral to the PCT earlier in their 
disease trajectory meant that these participants may not have had the 
opportunity to discuss the dying process with a healthcare professional 
specialised in discussing death. This appeared to be the case with Helen who 
asked me during our final conversation, in the presence of her husband, “how 
will it happen, how will I die”, “what will cause me to die?” Helen, who sadly 
died shortly after this interview it appeared was deprived of the psychological, 
spiritual, holistic, compassionate care that the PCT can offer.  
 
Participants’ narratives suggest that communication between participants and 
haematologists about their prognosis was lacking. Although some participants 
associated the increased frequency of their BT as a sign that the end of their 
life was approaching, others did not. Jim, for instance, whose stance until our 
final interview was to “bury my head in the sand”, did not appear to connect 
the relationship between increasing blood transfusions and his prognosis, as 
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he had paid the deposit on a holiday scheduled for eight months later. Details 
of the dying process and what to expect had not been discussed with him by 
the haematologists. A further example was Helen’s final conversation with me 
that showed she was aware that she was seriously ill but the subject of her 
dying had not been raised by any healthcare professional. During our final 
conversation, Helen had wanted to talk about her forthcoming death. She 
wanted to know what would cause her to die and what should she and her 
husband expect to happen. Helen had been referred to a Macmillan nurse, but 
this was only shortly before her death. 
 
According to McGrath (2002), if patients are referred to the PCT earlier in their 
disease trajectory this could allow these patients and their families to say 
goodbye and finalise their affairs in preparation for death. McGrath, (2002) in 
her study of haematology patients dying in an intensive care setting, suggests 
that patients were instinctively aware that they were terminally ill but had not 
been told by physicians that they were dying. McGrath suggested that 
participants revealed that they needed HCP to specifically communicate the 
fact that they were dying to help them and their families through the dying 
process. 
 
5.4.1.2 Plotline - Life in the hands of the nurses 
This plotline highlights that the everyday lives of participants were affected by 
the nurses at the bedside who held the responsibility for administering their 
BT. The plotline emerged from the stories of five participants who each 
reported that nurses working on the HDU sometimes increased the rate of their 
BT. Participants suggested that nurses increased the rate of their BT when 
they were receiving three units of blood. Increasing the rate of BT can 
predispose patients to transfusion associated circulatory overload (TACO), a 
potentially fatal condition that can arise when a large volume of fluid, such as 
three units of blood, are administered too quickly, although it can happen when 
just one unit is transfused (Bolton-Maggs, & Cohen, 2013: Gray, et al., 2016). 
TACO is a condition grossly under-diagnosed and underreported (Alam, Lin, 
Lima et al, 2013; 2015; Bolton-Maggs, & Cohen, 2013), but remains a serious 
and frequent complication that occurs following the administration of BT, 
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despite the restrictive blood transfusion practice advised by NICE (2015) and 
BSH (2012) (Roubinian, et al., 2018). Recently TACO has been recognised as 
the most frequent cause of “blood transfusion mortality and major morbidity” 
(Robinson, et al., 2017, p. 7). 
 
Patients’ lives lay in the hands of nurses because nurses are responsible for 
administering the blood to patients and monitoring the patient as the 
transfusion is being administered. Inadequate monitoring of patients, by 
nurses at the bedside, has been shown to cause avoidable complications of 
BT (Robinson, et al., 2017). Thus, nurses hold a crucial role in the prevention 
of TACO by ensuring that a slow rate of infusion is set on the infusion pump 
and there is close monitoring during the transfusion (Henneman, et al., 2017; 
Robinson, et al., 2017). These preventative measures are especially important 
in patients known to have a cardiac dysfunction history, and in the elderly 
(Robinson, et al., 2017). Nurses can also help prevent TACO by ensuring that 
patients have a mandatory weight check prior to transfusion (NHS Blood and 
Transplant, 2016), as it has recently been documented that patients with low 
body weight are predisposed to this condition (Robinson, et al., 2017).   
 
5.4.1.3 Plotline - Life in the hands of ward receptionists 
Half the participants (Kenneth, Lily, Ernest and Zavier) reported that they were 
given no choice over the days their BT were administered as the day of 
transfusion was frequently changed by the ward receptionists. One participant 
reported that the day change was done in an “ad hoc fashion to fit with the 
requirements of the ward”, another spoke about how he and his wife put his 
blood transfusion days and associated appointments in their diaries and 
changing the day caused them distress. Changing the day of their BT, the four 
participants said, resulted in them feeling frustrated, possibly because the 
need to change their plans deprived them of the small amount of choice and 
control they still had left in their lives. Charmaz (1997, p.134) appreciates how 
the thoughts of people with chronic illness become immersed in “planning, 
scheduling, and timing”, and how “frustration and anxiety” arise when their 
plans are thwarted.  
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Planning their next few weeks allowed the participants to maintain a level of 
autonomy and some command over their lives (Charmaz, 1997). Taking away 
participants’ autonomy demonstrates a lack of respect for them as individuals 
and is not commensurate with compassionate care. Alternatively, their anxiety 
and frustration may have been caused because the delay in receiving their BT 
exacerbated their hardships. Ernest reported that if his blood transfusion was 
delayed by just a few days, this meant that the anaemia-related symptoms he 
experienced were exacerbated and this made his life at home more difficult.  
 
Considering the short amount of time left to live for all the participants in this 
study, allowing this delay to happen appears uncompassionate. It does not 
follow two of the key aims set in the document “Every moment Counts” (2015), 
which suggests that all HCP should allow people near the end of their lives to 
maintain as much control as possible in their lives, and that those involved in 
their care should ‘make a special effort to understand the patients’ life’ 
(National Council for Palliative Care, 2015). The National Council for Palliative 
Care shapes healthcare for patients in a palliative condition based on patients’ 
voices and discovering what matters to them. The council employs as the 
cornerstone for NHS England’s “Actions for End of Life Care: 2014-16” (NHS 
England, 2014, p. 4), the following narrative, “You matter because you are you, 
and you matter to the end of your life” (Dame Cecily Saunders, 1919-2005). 
 
This narrative, first proposed by Dame Cecily Saunders who was a nurse, 
physician, writer, and founder of the hospice movement, stands as the 
foundation for the care of all sick people.  
 
5.5 Research objective 2. Summary of key findings  
Firstly, participants in this study suggested that junior doctors did not take into 
consideration how they were feeling physically when they prescribed their BT. 
Rather, junior physicians prescribed BT according to haemoglobin level alone 
without considering other factors like the fatigue participants were 
experiencing or their inability to undertake any activities of daily living. The 
variation in care between junior doctors and consultant haematologists led 
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some of the study participants to be dissatisfied with the blood transfusion care 
they received.  
 
Secondly, in the case of this study, communication between participant and 
HCP appeared to be poor as participants did not appear to know their 
prognosis or be involved in decisions about their blood transfusion care.  
 
Thirdly, participants who received chelating agents to reduce the iron level in 
their blood that had occurred because of the large number of BT they had 
received, experienced several hardships with both oral and subcutaneous 
administration. One participant reported that he was relieved when told by the 
physician that he could stop administering the Desferrioxamine, as injecting 
himself frequently and maintaining a needle in place for ten hours had been a 
nuisance to him and caused pain. His Desferrioxamine treatment was 
discontinued shortly before his death.  
 
Fourthly, all the participants in this study were in a palliative phase of their 
disease but most were not referred to a member of the PCT, something which 
potentially could have helped them and their families through the dying 
process. 
 
Fifthly, participants reported that on occasion, the nurses on the day unit 
would speed up the rate of their BT which caused them concern as they 
worried that they may not be able to tolerate the faster infusion; indeed, one 
participant suggested it might cause her death.  
 
Finally, the participants BT experience was also negatively affected by HCP 
because they were sometimes thwarted in their ability to plan their schedules 
which resulted in frustration and anxiety.  
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5.6 Research objective 3: To explore the effect of the place or setting 
where the blood transfusions were administered on participants’ 
experiences of BT 
5.6.1 Storyline three: Everyday blood transfusion life involves waiting 
and anxiety 
This storyline elucidated the place or setting dimension of participants’ 
experiences of BT, and so complied with the third research objective as it 
illuminated the effect of the hospital on participants’ experiences of BT. This 
storyline was developed from the following plotlines: waiting in Pathology for 
blood tests; waiting on the HDU; and anxiety associated with places in the 
hospital setting. The study findings related to the hospital settings were 
believed to be of utmost importance because they caused all participants to 
experience distress and dissatisfaction with the healthcare they received. 
 
5.6.1.1 Plotline - Waiting in Pathology for blood tests 
A common plotline recognised in the stories of most participants was the 
theme related to queuing in Pathology for blood tests. Waiting in this 
department was believed to demonstrate a lack of compassionate care for 
these individuals. Participants who were in a late or terminal palliative phase 
of a HM with less than six months left to live attended Pathology twice in the 
same week, generally every two weeks. In Pathology they had to wait in 
uncomfortable, hectic situations for one to two hours. This equates, 
approximately, to between fifty-two hours (six and a half working days) to one 
hundred and four hours (thirteen working days) over a twelve-month period. 
Charmaz (1997) highlights the potential tragedy of this wasted time; “wasted 
days, wasted time, time that could never be recovered, they were moments 
lost forever” (Charmaz, 1997, p. 248).  
 
Some participants became so distressed by the ordeal of waiting to see a 
healthcare professional and the subsequent effect it had on their lives, that 
they took matters into their own hands to avoid waiting. Most of the study 
participants however believed that they had no choice but to wait to see a 
healthcare professional, and so they lost control over their time.  
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Charmaz (1997, p. 30-33) discusses ‘waiting time’ for individuals with chronic 
disease, perfectly capturing the meaning of this wasted time on patients’ 
experience:  
 
‘Waiting becomes dead time. Lying undercover alone in a chilly 
examination room for half an hour wastes time. Standing in long lines 
at a clinic is frustrating and grating. The meaning of waiting lies in the 
irritating concrete experience of it. Waiting time means lost time and a 
loss of control over time’ (Schwartz, 1975, cited in Charmaz, 1997, p. 
31). 
 
In the past, Craig, Milligan, Cairns, McClelland, & Parker (1999) highlighted 
the waiting time associated with blood tests that patients endured. These 
authors suggested that the employment of a home nurse practitioner, who 
assessed patients clinical condition and took patients’ blood tests while they 
were at home, reduced clinic attendance and was preferred by patients. 
Indeed, many researchers have highlighted that keeping patients waiting in 
the hospital setting results in them being dissatisfied with the care they receive 
from HCP (Charmaz, 1997; Bleustein, et al., 2014; von Plessen & Aslaksen, 
2005; Street, Khan, Tong, & Shanbhag, 2017; Thomas, Glynne-Jones, & 
Chait, 1997: Trimm & Sanford, 2010). Moreover, the NHS Patient Experience 
Framework (2012) highlights the importance of not keeping patients waiting. 
Despite this knowledge, waiting in clinical environments is still recognised as 
an area of healthcare practice that begs serious improvements (Bleustein, et 
al., 2014).  
 
To provide compassionate care for vulnerable, palliative patients, this “waiting” 
situation in Pathology, where the wait time was described as ‘unacceptable 
and inconvenient’, must be addressed. Patients have “the right to excellence 
in treatment and care to support them in their lives to live as well as possible 
until their moment of death” (GMC, 2010, p. 1).  
 
5.6.1.2 Plotline - Waiting on the haematology day unit 
Participants also reported that waiting was a problem associated with the 
HDU. Although most participants stated that all the nurses working on the HDU 
were “wonderful” and “nothing was too much trouble for them”, waiting on this 
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unit caused them much distress and dissatisfaction with the care they 
received. Some participants were able to reorganise their lives to avoid the 
waiting, but this too caused inconvenience as it involved them adjusting their 
everyday life routines. Other participants believed that they had no choice but 
to sit and wait until the nurses were ready to cannulate them as they believed 
that patients receiving chemotherapy were more important than they were. 
This belief made them feel as if they were less worthy than patients who were 
receiving chemotherapy. These feelings were exacerbated for Ernest if he had 
to go to the inpatient ward to complete his blood transfusion. During these 
episodes of waiting, it appeared that Ernest, perhaps, lost his feelings of self-
worth and dignity, areas key to compassionate nursing care. Participants 
believed that the waiting they endured on the HDU was due to the nurses 
being over-stretched because of the number of patients each nurse had to 
care for. However, in terms of providing compassionate care, this waiting 
situation and the feelings it evokes in patients is unacceptable and requires 
attention.  
 
The findings from this study associated with waiting for blood transfusions to 
start has been previously highlighted in the literature (Craig, Milligan, Cairns, 
McClelland, & Parker, 1999). The findings also strongly echo those of McGrath 
(2002) who studied the end of life care for haematology patients being nursed 
on an ITU. McGrath suggested that the staff working in ITU were too busy 
providing physical care to be able to sit and talk and provide the emotional 
support required by these terminally ill patients: “Although the health 
professionals were viewed as caring and dedicated, they were seen as too 
busy to be emotionally supportive [….] the physical demands of patient care 
had to be prioritised over psychosocial and spiritual issues” (McGrath, 2002, 
p.110). Robinson, et al., (2015, p. 17), also suggest that when nursing staff 
caring for palliative care patients are ‘too busy’ and patients are “left waiting 
for care, patients feel like they are an inconvenience, invisible, forgotten”.  
 
Extensive personal experience of working as a senior nurse over the past 
twenty years, in four busy HDUs in four large hospitals, has furnished me with 
a deep insight into the enormous pressures placed on nurses to treat the large 
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number of patients during each day shift. Much of the nurses’ time in cancer 
day units is spent on administering intravenous, bolus chemotherapy. This 
means that each nurse is tied up with an individual patient, on a one-to-one 
basis for long periods. They cannot be distracted by other patients or nurses 
during this time to prevent the risk of extravasation. Whilst administering 
chemotherapy, the nurse has time available to show humanity and talk through 
concerns with the patient. However, it leaves the nurses with very little time to 
talk to those who are receiving BT, a therapy considered to be “more 
ubiquitous and of low hierarchy in the cancer setting” (Bishop, Faithful, & Allan, 
2011, p. 203). Showing kindness and empathy while undertaking clinical 
procedures has been demonstrated to make patients feel, “reassured, safe, 
and cared for as an individual” (McCabe, 2004, p. 46). However, under the 
busy working conditions inherent to a day unit, and the commonplace and 
relatively low concern associated with BT (Bishop, Faithful, & Allan, 2011) in 
comparison to chemotherapy administration, it may be difficult for the nurse to 
deliver excellent nursing care to those receiving BT.  
 
5.6.1.3 Plotline - Anxiety associated with places in the hospital setting 
Exposure to certain places within the hospital caused anxiety for most 
participants. For example, both the Pathology Department and the HDU 
caused Helen anxiety, while the Pathology department, the lifts and the HDU 
settings provoked distress for Zavier. This anxiety arose because of the 
perceived risk of infection associated with these places due to the crowded 
and cramped conditions. However, the setting that caused the most distress 
was the HDU, where patients receiving BT were nursed in a multi-bedded ward 
which cared for both haematology and oncology patients. 
 
Helen and Zavier were both neutropenic which made the extremely 
susceptible to acquiring an infection. Being nursed close to other patients and 
patients’ relatives on the HDU made them afraid because they feared 
contracting an overwhelming infection from them. This fear was 
understandable as they had been nursed in isolation during their 
chemotherapy treatment and warned to stay away from people who may be 
infected with colds and flu.  
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Kenneth and Ernest stressed fervently that being nursed in a proximity close 
to young patients receiving chemotherapy made them feel ill at ease as they 
were intensely saddened by their plight. This led to Kenneth feeling a fraud, 
as he believed that the young people’s plight was worse than his own. Ernest 
found it difficult to talk to other patients who were in the next bed or chair, in 
case he said the wrong thing and upset them. Not being able to socialise with 
patients close to him led him to feel isolated. The situation, however was 
different for Jim as he wanted solitude, he found the close presence of other 
patients challenging. 
 
Charmaz (1997) recognises how for some individuals, being able to socialise 
with others allows them to maintain “self”, who they are. Others prefer to 
maintain an aloofness:  
 
‘even superficial sociability can assume weighty symbolic significance 
to an isolated ill person. Such sociability affirms that the self remains, 
that illness has not claimed all of ones being. The significance of social 
contact lies in its meaning. Many ill people, especially elders welcome 
social contact from whoever they can get it [...]. Other people remain 
aloof Charmaz’ (1997, p. 97). 
 
Other studies have explored the effect of the hospital or hospice environment 
on the experience of participants with advanced disease, their findings adding 
support to the findings of this thesis. Robinson, et al., (2015) undertook a 
qualitative study in New Zealand to explore the impact of the acute secondary 
care hospital environment on palliative patients’ experience of care. They 
found that when participants were nursed in close proximity to other patients 
who were near to death or who were infectious, it caused them distress. 
Rowlands and Noble (2008) studied the effect of a cancer centre environment 
on the quality of life for participants with advanced cancer, and Williams and 
Gardiner (2015) assessed patients’ preference for a single room in a hospice 
compared to a shared room in a hospice setting. Both studies concluded that 
most participants favoured being in an environment that allowed them to 
mingle with other patients when they felt well enough, but preferred being in a 
single room when they felt extremely unwell or were dying. The need for both 
types of setting was recommended in their findings.  
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Sadly, the opportunity to nurse patients who are having BT as a day case in a 
single room is neither available nor appropriate as most are elderly and need 
frequent monitoring, and single rooms are generally not found in day units. 
However, the findings made me wonder whether nursing those who are no 
longer eligible to receive active chemotherapy treatment in the same place as 
those who are receiving potential curative therapies is unkind. In light of the 
findings, I would argue that it is not compassionate care to nurse these two 
populations of patients in the same environment. As the following storyline 
suggests, providing nursing care for these patients in the day hospice unit is 
believed to provide more individualised and compassionate care.  
 
5.6.2 Storyline four: More individualised care associated with the 
hospice day unit and everyday blood transfusion life 
This storyline was also consistent with research objective 3: to explore the 
effect of the place or setting on participants’ experience of BT.  
The effect of the hospice day unit was gleaned from the stories told by Helen 
who voiced the following plotlines: more individualised care; hospice day unit 
perceived as a safer place to receive BT; and hospice day unit perceived as 
more tranquil place.  
 
5.6.2.1 Plotline - More individualised care 
The hospice day unit, which is in the grounds of the acute secondary care 
hospital, is where one study participant (Helen) received one of her BT. She 
reported that this was her preferred place to have any future BT because the 
care she received in this environment was more individualised. Inside there 
are large, squashy chairs and a television, there is a dining table where people 
can go and join other patients if they want to chat, and there is space to allow 
patients to be alone if that is what they want. The unit allows for patient-centred 
care to be delivered that focuses on the individual needs of each patient and 
allows for patients to receive the palliative blood transfusion care they require 
while still living at home. Within the hospice day unit much emphasis is placed 
on allowing patients to retain their dignity and privacy, and to grant access to 
psychological, emotional, practical and spiritual support from the palliative 
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care team who are specialised in the provision of palliative care. The World 
Health Organisation (2014) defines palliative care as: 
 
‘An approach that improves the quality of life of patients and their 
families facing the problem associated with life-threatening illness, 
through the prevention and relief of suffering by means of early 
identification and impeccable assessment and treatment of pain and 
other problems, physical, psychological and spiritual’ (WHO, 2014, p.5). 
 
Of paramount importance to palliative care principles is to help relieve patients’ 
distress and suffering and to offer a support system that affirms life, and which 
regards dying as a normal process. 
 
5.6.2.2 Plotline - Hospice day unit perceived as a safer place to receive 
blood transfusions 
Of importance was that Helen said she felt safer in the hospice day unit 
because her blood transfusion was administered more slowly. She also said 
she felt safer from acquiring infection because the hospice day unit was not 
overcrowded with other people from whom she could, potentially, catch an 
infection. In fact, the only other person present throughout her transfusion was 
her husband. 
 
No prior research could be found that has reported patients “feeling safer” 
when cared for in the hospice setting. It is an interesting concept and raised 
the possibility of addressing this subject in future research, as potentially if this 
suggestion is shared by other patients with a HM, it could provide a way to 
encourage future haematology patients to have their BT in the hospice day 
unit. 
 
5.6.2.3 Plotline - Hospice day unit perceived as more tranquil place 
Comparing the hospice and HDU, Helen associated the hospice day unit with 
tranquillity. She felt the garden setting added to this tranquillity and imagined 
what it would look like in the summer. In comparison she associated the HDU 
with noise, from the pump alarms constantly bleeping, and hustle and bustle 
because of the busy environment.  
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The findings from this study associated with the hospice are consistent with 
those found by Hopkinson and Hallett (2001), who undertook a 
phenomenological study to explore patients’ perceptions of a hospice day care 
unit. All participants had an advanced cancer (type not specified). They 
suggested that when nursed in the hospice participants felt valued and less 
isolated because the care offered to participants was “humanistic” (p. 117). 
That is, participants were given time to share and receive input about their 
personal concerns, feelings and understandings. In addition, the environment 
was flexible enough to assist participants to manage their illness in the way 
they saw fit. The findings are also strongly endorsed by other researchers. 
Orme, Still, Day, Evans, & Perkins (2013), highlighted participants’ preference 
of the hospice day unit, over the hospital, because of the benefits of easier 
parking and the time available to chat with HCP, while others recognised that 
patients feel more comfortable in the hospice due to the homelier and relaxing 
environment (Evans, et al., 2006; Brereton, et al., 2012; Robinson, Gott, 
Gardiner, & Ingleton, 2015).  
 
5.7 Research objective 3. Summary of findings 
Firstly, waiting was a common hardship that participants experienced while 
being nursed on the HDU and in the Pathology Department. Waiting in these 
settings, which was associated with lack of privacy and noise, caused 
participants much anxiety, distress and dissatisfaction with the healthcare 
services they received. 
 
Secondly, patients who were neutropenic found exposure to the HDU, the lifts 
and the Pathology Department frightening due to their fear of contracting an 
overwhelming infection.  
 
Thirdly, participants experienced anxiety and fear when being nursed in 
proximity close to other patients. 
 
Finally, the hospice day unit was believed to offer more individualised, safer 
and more tranquil care where the nurses had more time to provide more 
holistic care.  
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5.8 Research objective 4: To explore the change in participants’ 
experiences as disease progressed from an early palliative phase, to a 
late palliative phase, to the terminal palliative phase of a haematological 
malignancy 
5.8.1 Storyline five: An everyday SAD life during the late to terminal 
palliative phase of a haematological malignancy 
This storyline elucidates the temporality dimension of participants’ 
experiences of BT, and so addressed the fourth research objective as it 
illuminated how participants’ experiences changed with time and disease 
progression. It was developed from plotlines: Somnolence; Adversities; and 
Desperation, which resonated throughout the stories told by Harold, Jim, Lily, 
Bill and Helen.  
 
5.8.1.1 Plotline - Somnolence overwhelms daily life 
In the late and terminal palliative phases of disease, participants experienced 
overwhelming somnolence. BT did not help relieve the tiredness and 
sleepiness that these participants experienced.  
 
5.8.1.2 Plotline - Adversities overpower everyday life 
As participants’ conditions deteriorated they found it difficult to undertake 
many activities of daily living. Despite experiencing these challenges in their 
everyday lives, they remained stoic. Helen, for instance, kept on trying to help 
do the dishes and make the bed although she found it difficult “even” to clean 
her teeth; Jim found a way to get to the HDU regardless of his disability caused 
by his grossly distended abdomen; and Bill forced himself to attend the HDU 
although he was obviously very depressed, crying frequently as we talked.  
 
5.8.1.3 Plotline - Desperation to hang on to life 
Despite being in dreadful physical condition these participants in the late – 
terminal palliative stage of disease maintained a desperation to have BT. 
Despite their dire situation, most participants retained a sense of humour to 
describe their experiences. None expected BT to cure them, but they hoped 
BT would enable them to live a little longer. Even to spend one extra day alive, 
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to spend time with their families was important to them (Smith, Cooling, & 
Davenport, 2013). 
 
This situation that these participants in the late to terminal palliative phase of 
disease found themselves to be in is explained articulately by Charmaz (1997) 
who suggests that, when suffering with chronic illness, individuals do not hope 
for a complete recovery, rather they just hope to resume some small amount 
of performance ability: “ill people will trade efficiency for being able to function 
at all” (p. 147).  
 
Maintaining hope is believed to provide a way for those at the end of their lives 
to persist and manage their suffering (Duggleby, 2000). According to 
Groopman (2006), hope allows people to prevail in the face of illness, because 
“every disease has an uncertain outcome and in that uncertainty we find real 
hope, because a tumour has not read the text book and a treatment can have 
an unexpectedly dramatic effect” (p. 210). 
 
This study appears to suggest that those participants in the early palliative 
stage (Kenneth, Ernest, and Zavier) were, as Charmaz (1997, p. 178) 
described, “living one day at a time”. They managed their lives and their 
regimes associated with their BT on a day to day basis. They were not 
overwhelmed by constant struggles to survive and were able at times to have 
a normal life. Rather than dwell on the future, these participants in the early 
palliative stage coped emotionally and physically in their everyday lives by 
taking things one day at a time (McGrath, 2002).  
 
Those in the late or terminal palliative phase (Harold, Jim, Lily, Helen, and Bill) 
simply existed “from day to day”. (Charmaz, 1997, p. 185). Their ability to 
partake in everyday normal life activities had been lost as they had lost control 
of their health. They existed by simply getting through each day in the best 
way they could. Harold’s family read to him; Jim watched television all day; 
Lily on occasion still tried to knit; Helen pottered around the house as best she 
could; and Bill had his friends visit him or his wife would take him for “little 
drives in the car”. The adversities that beset their daily lives and their 
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desperation for BT overwhelmed their lives at this point in their disease. BT 
did not help to make life better for these individuals, it simply, as Bill suggested, 
allowed them to “exist”.  
 
Despite all participants being in a palliative stage of disease, only two 
participants, Helen and Bill, both of whom were in the terminal stage of 
disease, met with members of the PCT. This delay in referring palliative 
haematology patients to the PCT has been something recognised in the recent 
literature (Cheng, Sham, Chan, Li, & Au, 2015; McCaughan, et al, 2018; 
McGrath & Holewa, 2007). It occurred in this study, perhaps, because it is 
difficult to estimate accurately an individual’s prognosis, as there may be no 
clear distinction between the curative and palliative phase (McGrath & Holewa, 
2007). However, it has been suggested that people approaching the end-of-
life should be identified early (NHS, 2014). McCaughan, et al (2018) highlight 
that due to prognostic uncertainty it is difficult for haematologists to identify the 
most appropriate time to start talking about end-of-life care. They suggest that 
“the development of ‘indicators’ or ‘triggers’, based on diminishing response to 
treatment” (p. 8) could help determine when an appropriate time for referral to 
the PCT should be made. An indicator that was gleaned from this research is 
that patients may need to be referred to the PCT once their blood transfusion 
requirement increases to every two to three weeks, as it appeared that 
increased frequency to this level of blood support was consistent with disease 
deterioration and overwhelming symptoms of anaemia. An increase in regime 
to two weekly, or even three weekly BT, could provide an indication that 
patients have reached a palliative phase and indicates that this is the right time 
to commence discussions around end-of-life care.  
 
The publication “Every moment counts: a narrative for person centred co-
ordinated care for people near the end of life” (National Council for Palliative 
Care, 2015), emphasises the need for brave conversations between 
healthcare professionals and patients. In the acute hospital setting, however, 
discussions around end-of-life care with the PCT are frequently not taking 
place (Gott, Frey, Raphael, O’Callaghan, & Boyd, 2013). Improving the care 
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of those with palliative conditions in an acute hospital has been recognised as 
an area that needs to be addressed internationally (ibid). 
 
It is possible that earlier involvement of the PCT in the care of those with a HM 
could address participants’ desperation for blood, as they are able to provide 
more psychological and spiritual support and afford a more holistic approach 
to goal setting. End of life discussions with members of the PCT, could help 
participants to make difficult but critical decisions about the necessity or benefit 
of BT (Woodwark & Dean, 2016). Indeed, the PCT could help participants 
come to terms with the idea that BT every week are not acceptable, and to 
accept that it may be preferable to spend their limited time at home rather than 
in the hospital, and to view it as a time for saying goodbye and for showing 
forgiveness and gratitude (Geifand, Raspa, & Briller, 2007). 
 
Palliative care is frequently thought to be only for those in a terminal palliative 
phase of disease when the patient is dying, but it is important that nurses and 
doctors recognise that this is not the case. In those with a haematological 
disease, it is useful at any stage throughout the disease trajectory. Alongside 
their medical colleagues, senior haematology nurses are in a prime position to 
refer patients to their palliative care colleagues.  
 
5.9 Research objective 4. Summary of key findings 
Firstly, from the patient experiences reported in this study, it appears that 
participants in the early palliative phase were able to manage their lives and 
their regimes associated with their BT on a day to day basis. They were not 
overwhelmed by constant struggles, rather they “lived their lives day by day” 
(Charmaz, 1997).  
 
Secondly, those in the late or terminal palliative stage reported experiences 
that showed they were overwhelmed with somnolence, adversities and 
desperation, and BT did not help with these aspects, which meant that these 
participants simply “existed day to day” (Charmaz, 1997). Two participants in 
the study, despite their dire situation, retained humour to describe their 
experiences, and all participants hoped that BT would prolong their lives. 
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Thirdly, from an observation of the study findings, it appears that once the 
frequency of BT had been increased to every two or three weeks, this 
coincided with a deterioration in the participant’s disease. Due to the difficulties 
in accurately assessing prognosis, perhaps this frequency of blood transfusion 
support could be employed as an indication that it is the right time to discuss 
end-of-life care and refer patients to the PCT.  
 
5.10 Review of study findings 
The WHO (2014) definition of palliative care (see 5.6.2.1 p. 138) highlights the 
importance of improving patients’ end-of-life care by assessing physical, 
psychological and spiritual problems and implementing measures to help 
relieve suffering.  
 
Given their frail physical condition an aspect that kept appearing in 
participants’ narratives as a hardship that increased their suffering, was their 
need to attend the hospital two or three times a week, every two to three 
weeks. The requirement to arrive early at the hospital exacerbated this 
problem, as participants reported that they had to get up very early to prepare 
for their visit.  
 
The long waits to have their blood tests taken and waiting on the HDU to 
receive their BT also did not appear to enhance participants’ quality of life, as 
they found waiting in clinical areas to be particularly challenging and 
distressing. Indeed, some participants linked the long waiting time they 
experienced with poor-quality healthcare. Most simply accepted the wait while 
others organised their lives to avoid the wait. One study participant suggested 
that waiting on the HDU made him feel less important to the nurses on the unit 
as those patients who were receiving chemotherapy.  
 
Another observation from the participants’ narratives was that it appeared that 
haematologists did not appear to discuss death or the dying process with these 
palliative participants. Rather, it appears that they engaged in a process of 
therapeutic emplotment which involved physicians during clinical encounters 
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“creating for patients an experience of immediacy rather than chronology” 
(Crossley, 2003; Del Vecchio Good, et al., 1994, p. 855; Murray, 2008). That 
is, they focussed on discussing with participants their haemoglobin results and 
the transfusion process rather than prognosis which served to maintain 
patients’ hope of survival. Therapeutic emplotment appeared to sustain 
participants’ faith that BT would prolong their lives, to the extent that they did 
not consider their death until it was imminent. Referral to the PCT, a process 
which the WHO recognise is applicable early in the illness trajectory (World 
Health Organisation, 2018) was not adhered too.  
 
From the experiences described by participants it appears that only two had 
met with a member of the PCT, and this meeting took place only a few weeks 
before their deaths. It appeared that by the time they were referred to the PCT 
it was too late for them to build any form of trusting relationship with the 
Macmillan nurse they met. Thus, most participants did not appear to have any 
contact with members of the palliative healthcare team who are specialised in 
providing emotional, psychological and spiritual support. Participants also 
suggested that because the nurses on the HDU were so busy administering 
chemotherapy, they did not have time to sit and talk to them about aspects of 
their care.  
 
Narratives describing their blood transfusion experiences suggest that the 
participants did not understand the nature of their disease. For instance, one 
suggested that the increased frequency of his BT was because “the blood was 
not doing its job properly” while another participant said that reducing his 
physical activity could maintain his “haemoglobin level at a higher level for 
longer”. This raised concern that communication between healthcare 
professionals and participants was lacking. 
 
Participants described the day they spent on the HDU as a “long day” and “a 
challenging day” because of the time it took to administer three units of blood. 
This led one participant to state it would be better to have two units of blood 
rather than three, because it meant he would only be on the HDU for four or 
five hours rather than six or seven hours. As he became very tired in the 
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afternoon, he thought getting home earlier would be beneficial. Several 
participants described how when they were to have three units in one day the 
nurses would increase the rate of transfusion to ensure that they were 
completed before the scheduled HDU closing time. This practice worried two 
participants who were concerned that they would not be able to tolerate the 
faster rate of infusion.  
 
Three of the participants explained the difficulties they experienced with 
chelating agents, which they described as horrible. One participant said that it 
had been a nuisance for him and that it was a relief when he was informed 
that he could stop administering the Desferrioxamine because of the sore 
injection sites on his abdomen and the difficulties he experienced securing the 
needle in place for ten hours, four times a week. Three participants described 
the nausea and vomiting that they experienced with the oral formulation.  
 
Participants described the overwhelming hardships that they experienced in 
their everyday lives as their disease progressed to the late to terminal palliative 
phase. From the experiences reported, it appears that BT did not help to 
relieve their anaemia-related somnolence or fatigue which meant they could 
not perform normal daily activities like washing or dressing themselves. 
Describing his torpor led one participant to say, “I don’t do nothing I just exist”. 
The narratives of participants in the late or terminal phase suggest that they 
became totally dependent on their families, friends and healthcare 
professionals to help them with every aspect of their everyday lives. They 
became powerless in their everyday lives with no choice over aspects of their 
blood transfusion care, such as choosing the day or time they came for their 
BT. Despite their dire circumstances, however, all the study participants 
remained desperate to receive BT and adjusted their lives to accommodate its 
administration. 
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5.11 Reflection on the link between Dewey, the study process and the 
study findings 
Dewey’s pragmatic philosophical approach, his pragmatic theory of 
experience and his conception of inquiry were employed within this study. The 
following section reflects on the way these aspects are linked to the study 
process and findings. 
 
Eminent philosophers such as Peirce, James and Dewey, promoted different 
versions of pragmatism, however, it is the work of Dewey that served as the 
underlying philosophical foundation for this narrative inquiry study. Dewey 
argued that pragmatism was not orientated towards abstract concerns like 
other research paradigms, such as post-positivist and constructivist traditions, 
but rather its concern lay with consequent phenomenon and possibilities of 
action (Cherryholmes, 1992): 
 
“Pragmatism… does not insist upon antecedent phenomena but upon 
consequent phenomena; not upon the precedents but upon the 
possibilities of action. And this change in point of view is almost 
revolutionary in its consequences…. When we take the point of view of 
pragmatism we see that general ideas have a very different role to play 
than that of reporting and registering past experiences. They are the 
bases for organising future observations and experiences” (Dewey, 
1931, p. 32-33 cited by Cherryholmes, 1992, p. 13). 
 
Dewey’s pragmatic approach allows researchers to transcend the ongoing 
debates between, for example, positivism and constructivism (Kalolo, 2015; 
Morgan, 2014), as Dewey recognised the positive aspects of both post - 
positivist assumptions “that the world exists apart from our understanding of 
it”, and to constructivists assertions “that the world is created by our 
conceptions of it” (Kalolo, 2015; Morgan, 2014, p. 1048).  
 
Dewey wanted the philosophical foundation of knowledge to be grounded in 
the concept of human experience. His version of pragmatism endorsed 
practical problem solving, through a process of inquiry, as the primary means 
to gain practical knowledge. Dewey’s theory recognises that when the 
principles of continuity and interaction are taken together this forms a situation. 
To understand Dewey’s view of knowledge creation one must give credence 
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to his notion of situation which highlights the transaction between people and 
the environment. Dewey recognised two types of situations; habitual or 
determinate, and indeterminate. An indeterminate situation emerges when 
there exists a state of uncertainty or confusion (Miettinen, 2000; Vo, Mounoud, 
& Rose, 2012). In defining the concept of inquiry Dewey’s acknowledged that 
there was transformation of an indeterminate situation into a determinate one:  
 
“inquiry is the controlled or directed transformation of an indeterminate 
situation into one that is so determinate in its constituent distinctions 
and relations as to convert the elements of original situation into a 
unified whole” (Dewey, 1938, p. 108).  
 
In his concept of inquiry, Dewey (1938) recognises that knowledge and action 
are intertwined, and that critical reflection is of central importance in the 
transformation of an indeterminate situation to a determinate one (Vo, et al, 
2012). For Dewey, one of the founders of experiential learning, the underlying 
reason for reflection was the necessity of solving problems faced in habitual 
situations. As such, reflective thinking about situations is a crucial component 
of Dewey’s theory of learning from experience and one that acts as a powerful 
tool within nursing (Benner, Hughes & Sutphen, 2008).  
 
The employment of Dewey’s pragmatic philosophical approach has much to 
offer those undertaking nursing research as it allows the tracing out of practical 
consequences from the research data, which leads to the creation of nursing 
knowledge that advances clinical nursing practice (Benner, Hughes, & 
Sutphen, 2008; Nowell, 2015; Vo, Mounoud, & Rose, 2012). Patricia Benner, 
a venerated and influential nurse researcher, employed Dewey’s pragmatic 
theory as the basic underpinning for her highly influential work to nursing 
practice; ‘From Novice to Expert: Excellence and Power in Clinical Practice’ 
(1984). Benner’s employment of a pragmatic paradigm in the nursing research 
arena introduced the innovative idea that clinical nursing practice itself could 
be used as a knowledge base to inform nursing knowledge and theory. This 
fact was inspirational, as like Benner I wanted to gain practical, nursing 
knowledge by giving priority to people’s everyday experiences by listening to 
patient’s everyday life problems and concerns. Employing Dewey’s pragmatic 
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approach allows nurse researchers the opportunity to use dynamic 
approaches to address the complex and multifaceted research problems often 
encountered in nursing practice (Doyle et al, 2009 cited by Nowell, 2015). 
 
As the bedrock to this study Dewey’s theory of experience and his concept of 
inquiry were invaluable in the creation of knowledge applicable to nursing and 
clinical healthcare practice. Dewey’s concept of continuity, the idea that 
experiences cannot be separated from each other, and interaction, the 
interaction between external conditions in the environment and internal 
feelings and desires, was apparent in the stories of experience told by 
participants in this study. It became obvious that one experience led to 
another, as participants critically evaluated aspects of blood transfusion 
clinical practice and took appropriate action to alleviate or change what they 
perceived was causing them difficulty. Examples of interaction and continuity 
coming together to form a situation was seen for instance in the story told by 
Helen. Helen was dissatisfied with her contact and communication 
(interaction) with a junior physician during a clinic review as she believed the 
doctor did not consider how she was feeling physically when authorising her 
BT. The feeling of discontent she experienced during this clinic review led her 
to make the decision to be reviewed only by a consultant haematologist at 
subsequent clinic visits (continuity). Another example related to Kenneth’s 
decision to attend the Pathology department early in the morning to avoid the 
long queues that occurred later in the day. Experiential learning in this context 
required critical reflection to make sense of and learn from experiences. This 
experiential knowledge was acknowledged as being “personal, practical, 
shaped by, and expressed in practice” (Clandinin, 2013, p 9). 
 
Dewey’s systematic problem-solving approach to inquiry (Figure 2, p. 153) 
appealed to me as a nurse because it may be likened to the cyclical problem-
solving nursing process, a process that ensures quality in nursing care. It 
resonates in two ways: a). a situation within everyday life is recognised as 
being a problem or ‘a puzzlement’, and steps are taken in a systematic manner 
to address the problem, and the situation is resolved through taking the 
appropriate action to resolve the dilemma; b). both seek to create new 
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knowledge or truths to improve the individual’s outcome. The obvious, but 
important difference lies in the fact that during inquiry research is carried out 
meticulously, employs rigorous methods of analysis and provides sufficient 
information for readers to assess claims of validity. Primarily, however, it was 
Dewey’s emphasis on actions and practical outcomes that drew me to his 
philosophical way of thinking. Pragmatism allows the outcomes from my 
qualitative nursing research to be practically useful in clinical practice. As, 
patients’ everyday life experiences are of overriding concern to nurses, 
aspects of Dewey’s pragmatic approach that were particularly ascribed to 
included; the ability to help solve real world problems through inquiry, the 
recognition of the affinity between research and everyday life, and the crucial 
importance that knowledge created was of practical significance. Employment 
of Dewey’s concept of experience allowed a deep understanding of the 
transactional relationship between the study participants and the study 
environment (Vo, Mounoud, & Rose, 2012), and allowed participants’ 
experience “to be honoured as an important source of knowledge and 
understanding” (Clandinin, 2013, p. 17).  
 
Miettinen, (2000, pp. 66-67) outlines Dewey’s phases of reflective learning 
during the inquiry process. In the following section it is adapted to demonstrate 
how reflection and action were employed throughout this piece of research. 
 
Step 1. The indeterminate situation: the habit does not work 
Dewey’s concept of scientific inquiry begins with the researcher locating the 
problem or puzzle that has arisen during everyday life situations that is of 
primary relevance to practitioners. Generally, habitual actions are undertaken 
without reflection, however, when a situation arises that causes consternation 
“reflective thought brings about hesitation and delay that is essential to 
thinking” (Miettinen, 2000, p. 66). Reflective thought initiates a study of the 
conditions that are causing the problematic situation (ibid).  
 
In this current study, reflection on an incident in clinical practice that caused 
concern led to an in-depth search of the literature associated with the 
perceived problem. Dewey’s pragmatic approach allowed a dynamic interplay 
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between theory and practice, where the notion of multiple truths was 
embraced, in the understanding that there is no knowledge that is certain and 
/ or universal. Thus, a diversity of viewpoints about the phenomenon of blood 
transfusion experience is supported. Adopting Dewey’s pragmatism allowed 
precedence to people’s everyday life experiences. The underlying philosophy 
of pragmatism allows the researcher to start their inquiry with a personal 
feeling of puzzlement around an aspect of everyday life in clinical nursing 
practice. This was consistent with my belief that clinical nursing practice itself 
could and ought to inform nursing knowledge and theory (Benner, 1984). 
Furthermore, “Dewey argued that concentrating on a problem that does not 
grow out of an actual situation is merely an intellectual exercise, not science” 
(Dewey, 1938, p. 16, cited by Vo, et al. 2012, p. 16). 
 
Step 2. Intellectualisation: defining the problem 
Miettinen, (2000) highlights that the next stage in Dewey’s reflective cycle 
involves intellectualisation and definition of the problem. Dewey stresses the 
relevance of accurately defining the problem: 
 
Without a problem, there is a blind groping in the dark. The way in which 
the problem is conceived decides what specific suggestions are 
entertained and which are dismissed; what data are selected, and 
which rejected; it is the criterion for relevancy and irrelevancy of 
hypotheses and conceptual structures (Miettinen, 2000, p. 66). 
 
In this study intellectualisation of the problem was met by the formulation of 
the research question and research objectives that addressed Dewey’s two 
criteria of experience, continuity and interaction, and which had been adapted 
by Connelly and Clandinin (2006) into dimensions of sociality, temporality and 
place. 
 
Step 3. Studying the conditions of the situation 
Following Dewey, Miettinin suggests that analysis and diagnosis of the 
conditions then takes place.  
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In this step of the research process the conditions associated with participant’s 
experience of BT were studied through the stories participants told which gave 
rise to the meaning BT had in their lives, and the hardships they encountered. 
Step 4. Reasoning 
In Dewey’s model of reflective thought and action, reasoning is a vital 
component in finding solutions to the dilemma. Miettinin, (2000, p. 66-67) 
suggests that  
“reasoning is composed of the elaboration of the meaning of ideas in 
relation to each other…. In reasoning, thought experiment can be done. 
These thought experiments are important because they allow the return 
to the beginning again”.  
 
In this study thought experiments were undertaken by personal immersion into 
participants’ stories during the narrative analytical approach. Through this 
approach, which involved; narrative coding, broadening, burrowing and 
restorying, the process of reasoning was undertaken which finalised in an 
individual narrative account for each participant. Each narrative account was 
thought of as a patchwork quilt which incorporated many narrative themes 
stitched together. This allowed elaboration of meaning of ideas in relation to 
each other which brought together a holistic picture of what everyday blood 
transfusion life was like, as perceived by the participants in this study and 
which had been the purpose of the study. The insight gained, through the 
thought experiments, allowed for clarification of the hardships endured by 
participants and provided ideas by which to resolve these problems.  
 
Step 5. Testing the hypothesis by action 
The practical outcomes of the research inquiry are of crucial importance for 
Dewey. According to Miettinen, (2000, p. 67) the outcome of Dewey’s 
reflective thought and action during inquiry finalises in either the resolution of 
the problem, or in the formulation of meaning (an idea or concept), that can be 
used as a resource in future problem situations. Dewey (1938) recognised that 
it was impossible to acquire a definitive solution to any inquiry, as with the 
resolution of the situational problem new conditions are instituted, which in turn 
leads to new problems, and thus the cycle starts again. Clandinin refers to this 
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situation in inquiry as ending “in the midst, of ongoing experiences” (Clandinin, 
2013, p.43 - 44).  
 
In this study, following Dewey, the primacy of practice knowledge in elucidating 
practical solutions was viewed as being of essential importance and indeed 
had been one of the principle reasons for undertaking this research. It was 
recognised that implementing practical solutions to resolve issues raised by 
participants could potentially lead to new dilemmas in clinical practice. Abiding 
by Dewey’s cyclical manner of reflective inquiry, however, led to 
recommendations for clinical nursing and healthcare practice (presented in 
Chapter six), which it is believed may serve to improve the blood transfusion 
experience of future patients. 
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Figure 2 Dewey’s model of reflective thought and action linked to study process and findings (Adapted from Miettinen, 
2000, p. 65) 
1.Disturbance and 
uncertainty: Habit 
does not work 
Idea, 
concept 
Solution of the problem  
and control of the action 
4. Critical reflection 
of findings and 
bringing together a 
holistic picture of 
everyday blood 
transfusion life 
3. Exploration of sociality,  
temporality and place 
3. Studying the conditions of the 
situation and formation of a working 
hypothesis 
2. Formulation of 
research question 
and objectives 
2.Intellectualization 
and definition of the 
problem 
1. An incident in 
clinical practice 
caused concern 
4. Reasoning 
5. Recommendations 
for clinical practice 
to improve patients’ 
blood transfusion 
experience 
5. Testing the 
hypothesis by action 
Key:  
Black text Dewey’s model (Miettinen, 2000, p. 65). 
Red text study process and findings. 
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Chapter 6: Conclusions 
6.1 Introduction  
This chapter commences with the study’s key conclusions. This is followed by; 
a) recommendations for clinical haematology blood transfusion practice based 
on the study findings; b) recommendations for advanced nursing practice, with 
reference to the new ‘Advanced Clinical Practice’ descriptors (Health 
Education England, 2017) and c) recommendations to future research 
direction. The chapter concludes with a discussion of the study’s strengths and 
limitations. 
 
6.2 Key conclusions 
Improving patients’ experience of care is a key aim of the NHS (National 
Quality Board, 2015). Improving care services for vulnerable patients in a 
palliative stage of their disease is of major importance (ibid). The findings of 
this nurse-led narrative inquiry study serve to address this ambition. Listening 
to the stories participants told, allowed their experiences associated with blood 
transfusions to be explored in great depth to uncover nuances in healthcare 
and service delivery. The findings of this study provide a path to improve on 
future patients’ experiences of clinical blood transfusion care based on the 
matters that were important to those who participated in this study. 
Furthermore, the uniqueness of studying the end of life journey for this 
population of patients informs healthcare professionals what it is like for 
patients to receive blood transfusions at the end-of-life. As such, 
methodologically, this narrative inquiry study offers an important and unique 
contribution to the literature and demonstrates the way in which the interpretive 
methodology of NI allows everyday life experiences to be captured through 
stories told about healthcare practice.  
Narrative Inquiry has not been used to gain knowledge of patients’ experience 
of blood transfusions before. The approach allowed me to develop a close, 
trusting relationship with participants, which in turn enabled me to attach clear 
meaning to the challenges they experienced which were interwoven into a 
meaningful story that illustrated their values and their beliefs.  
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6.3 Recommendations for clinical haematology blood transfusion 
practice 
Based on the experiences of participants in this study, and observations made 
in connection with these experiences, it is suggested that blood transfusion 
clinical care for palliative haematology patients could be improved in several 
ways: 
 
6.3.1 Develop a one-stop service on the haematology day unit 
As palliative haematology participants found getting to the hospital arduous, 
the care of future patients could be improved by organising a one-stop service 
on the HDU; blood tests, review by a haematologist and administration of BT 
could be organised to take place on the same day and in the same place. This 
would mean that patients did not have to make the journey to the hospital as 
frequently, which could be beneficial in allowing them to spend more time at 
home and less time in the hospital, reduce travel costs and decrease the 
number of times that they are required to get up early to prepare themselves 
for their hospital visit. 
 
6.3.2 Develop a one stop service in the hospice day unit  
A hospice day unit was established for haematology and oncology patients to 
receive blood transfusions and have their blood tests taken. Patients generally 
have their blood taken on one day and return on another to receive their blood 
transfusion. To improve care for palliative patients who require BT a further 
option would be to develop a one stop service in the hospice day unit. The 
hospice day unit was said to provide an environment which was safer, more 
tranquil, more comfortable and homely. From a participant’s experience, the 
care provided in the hospice was found to be more individualised and 
compassionate as the nurses working there were said to spend more time 
talking with her. Furthermore, the phlebotomy service offered in the hospice 
day unit could prevent the long wait associated with the Pathology 
Department. These long waits could be viewed as uncompassionate care. 
Referral of haematology patients to the hospice day unit is not currently 
commonplace although it has the capacity to deal with the relatively small 
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number of palliative haematology patients that could be referred there without 
compromising its own standard of care. 
 
6.3.3 Health care professionals should communicate realistic 
expectations of blood transfusions 
Participants in this study described their overwhelming belief that BT would 
prolong their lives. In the knowledge that BT have been associated with 
increased mortality when administered to those with advanced cancer, and the 
lack of proven beneficial effect in these patients (Preston, Hurlow, Brine, & 
Bennet, 2012; Woodwark & Dean, 2017), it is suggested that all HCP could 
communicate realistic expectations when explaining the benefits of blood 
transfusions.  
 
6.3.4 The palliative care team could be more involved with the care of 
palliative haematology patients 
From the experiences of those who took part in this study, it appeared that 
there was a lack of involvement of the palliative care team (PCT) in the care 
of these palliative haematology participants. More consideration should be 
given by haematology physicians and nurses to involve the PCT whenever 
patients are believed to be in a palliative phase of their disease. Involvement 
of the PCT would help ensure that these patients receive the best end-of-life 
care. Involvement of the PCT could potentially reduce the desperation for BT 
that participants in this study exhibited whenever they were in the late or 
terminal palliative phase of their disease. Provision of palliative care could 
have provided the psychological, spiritual and emotional support that these 
participants, at the end-of-life stage, were entitled to receive, but which 
appeared difficult to provide in the busy environment of a day unit. Due to the 
difficulty in estimating prognosis, given the experiences of those who took part 
in this study, once patients reach the stage where they need BT every two to 
three weeks, this might provide an indication that is time to involve the PCT.  
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6.3.5 HCP should allow patients to take a more active role in their blood 
transfusion care 
Some participants in this study described a lack of autonomy concerning their 
blood transfusion administration. HCP should improve their communication 
with the more elderly and vulnerable haematology patients to help maintain 
their autonomy and allow them to take a more active role in decision making 
around aspects of their blood transfusion care. 
 
6.3.6 Reorganise clinical service for patients requiring three units of 
blood.  
All the participants said they found the “long and boring day” on the HDU 
challenging when they were authorised to have three units of blood, because 
it took six to seven hours to administer this volume which made them feel very 
tired by the end of the day. It is suggested that consideration is given to 
reorganising this clinical service so that patients who require three units of 
blood are admitted to the inpatient ward to receive them.  
 
6.3.7 Attend to blood transfusion patients with compassionate care 
It is recognised in the literature that because of the commonplace nature of BT 
in cancer patients, receiving BT are frequently considered to be of low concern 
in comparison to those receiving chemotherapy (Bishop, Faithful, & Allan, 
2011). One participant in this study reported feeling “unimportant”, “less of a 
priority to the nurses” when he was kept waiting for his BT. Another said he 
felt “a fraud” when nursed close to patients who were receiving chemotherapy. 
It is suggested, therefore, that nurses locally need to make a resolute effort to 
be aware that these patients are vulnerable palliative patients with a limited 
life expectancy, and as such in need of much individualised compassionate 
care and support.  
 
6.3.8 Nurses should perform additional bedside monitoring in elderly, 
palliative patients and those with a cardiac dysfunction history. They 
should also weigh patients prior to BT. 
Nurses responsible for administering BT at the bedside should, in accordance 
with the academic literature perform additional bedside monitoring in elderly, 
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palliative patients and those with a cardiac dysfunction history (Robinson, et 
al., 2017). They should also weigh patients prior to their BT (NHS Blood and 
Transplant, 2016). These measures may help reduce the risk of transfusion 
associated circulatory overload which is the leading cause of death associated 
with BT (Robinson, et al., 2017).  
 
6.3.9 Attend to the hardships associated with chelating agents by raising 
awareness 
Three participants described significant hardships associated with chelating 
agents. These agents were prescribed to reduce their high ferritin level which 
was a result of the many BT they had received. It is important to raise 
awareness of this amongst other healthcare professionals so that they are 
aware of the challenges that these agents impose, which do not appear to be 
consistent with the provision of compassionate healthcare to patients at the 
end of their lives. 
 
6.4 Recommendations for advanced nursing practice in blood 
transfusion care, with reference to the new ‘Advanced Clinical Practice’ 
descriptors (Health Education England, 2017) 
Recommendations for advanced nursing practice in blood transfusion clinical 
care, with reference to the advanced clinical practice (ACP) descriptors, are 
discussed in this section. 
 
A major impact on clinical practice, the quality of care provided, and the 
patient’s experience has been the impact of the European Working Time 
Directive, and the increasing elderly patient population (2005; Green & Pirie, 
2009). To address the impact on clinical care, associated with the changing 
face of modern healthcare practice, the need for increased multi-professional 
working between nurses, doctors and allied health professionals was 
recognised (RCN Policy Unit, 2006). Multidisciplinary health teams, which 
involved listening to patients, families and carers, were perceived to be “the 
indivisible units of high quality health services” (RCN Policy Unit, 2006, p. 5). 
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Working within a multi-professional team, specialist nurses as key frontline 
caregivers to hospitalised patient-care, were perceived to have a major role in 
helping to address the issues inherent in current healthcare (Draper, Felland, 
Liebhaber, Melichar, 2008; Green and Pirie, 2009). This resulted in an 
expansion in the number of NHS senior nursing positions, positions that bore 
an assortment of job titles, including for example: nurse specialist, nurse 
practitioner, advanced nurse practitioner and nurse consultant. No 
standardised academic qualifications or experience criteria, however, 
associated within the roles had been established. This situation was 
addressed in 2017 by Health Education England (HEE) who published the first 
national advanced practice framework which sets out the key principles of a 
multi-professional framework and stipulates the capabilities expected of 
advanced clinical practitioners. A definition of multi-professional advanced 
clinical practice was developed by HEE, in unison with professional bodies, 
academics and patient representatives:  
 
Advanced clinical practice is delivered by experienced, registered 
health and care practitioners. It is a level of practice characterised by a 
degree of autonomy and complex decision making. This is underpinned 
by a master’s level award or equivalent that encompasses the four 
pillars of clinical practice, leadership and management, education and 
research, with demonstration of core capabilities and area specific 
clinical competence. 
Advanced clinical practice embodies the ability to manage clinical care 
in partnership with individuals, families and carers. It includes the 
analysis and synthesis of complex problems across a range of settings, 
enabling innovative solutions to enhance people’s experience and 
improve outcomes (HEE, 2017). 
 
HEE (2017), recognises that advanced clinical practitioners must be educated 
to masters or doctoral level and have expertise within four areas of healthcare; 
clinical practice, leadership and management, education and research. This 
allows a genuinely multi-professional team approach, whereby, regardless of 
the professional background of the practitioner, the patient receives the same 
care if treated by a nurse, allied health professional or physician (HEE, 2017). 
Furthermore, understanding of the advanced clinical practice curriculum by 
healthcare organisations allows them to identify and plan their workforce. This 
is in the knowledge that practitioners working at an advanced level of practice 
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have developed their skills and knowledge to the standard outlined in this 
framework and can transform services to improve patient experience and 
outcomes (HEE, 2017).  
 
Employed as a haematology nurse practitioner I have developed the skills and 
knowledge underpinning the four pillars of practice to the standard outlined in 
the multi-professional framework. In line with these capabilities 
recommendations for advanced nursing practice in relation to blood 
transfusion care and service delivery are proposed in the following section: 
 
Clinical care 
“Nurses and midwives work more closely with patients requiring BT than other 
health professionals” (Green & Pirie, 2009, p. ii). As key frontline caregivers 
this places nurses in a prime position to focus on the needs of the patient and 
improve on the quality of clinical blood transfusion care and service delivery. 
However, it is recommended that nurses working within their professional code 
of conduct and scope of practice (NMC, 2015) as advanced clinical 
practitioners, who are empowered to lead their teams (RCN Policy Unit, 2006), 
lead on innovative models of blood transfusion care to improve patient 
experience and quality of care.  
 
One of the concerns raised in this study related to a lack of clinical continuity 
and another involved a lack of patient-centred care. The haematology 
advanced clinical practice role entrusts a commitment to; improve on issues 
associated with clinical continuity; to help provide more patient-focussed care; 
and to enhance multi-professional team working (HEE, 2017). By 
implementing the recommendations for clinical practice that arose from this 
study, and outlined in section 6.3, these senior haematology nurses can 
address the lack of continuity of care between haematologists and the PCT 
and the lack of patient-focussed care. To act on the outcome of learning from 
this study, however, requires a significant cultural leadership change within the 
organisation.  
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Leadership and management 
Rather than a top-down leadership approach, it has been recognised that 
patients and the frontline multidisciplinary healthcare team are best positioned 
to develop solutions to improve patients’ experience of healthcare services 
(Care Quality Commission, 2018). Nurses, working in the frontline as 
advanced clinical practitioners have developed good leadership and 
management skills. They also have the vision to lead new practice service 
improvements in response to feedback from patients, families, carers and 
other members of the multi-professional team. Excellent leadership and 
management skills are vital to implementing the recommendations of this 
study, as it requires members of the haematology team and the PCT to come 
together to facilitate better team working to shape the best end-of-life care for 
patients requiring BT. This requires the haematology advanced clinical 
practitioner to “pro-actively initiate and develop effective relationships, 
fostering clarity of roles within the teams to encourage productive working” 
(HEE, 2017, p. 9). To do this necessitates a determination to facilitate ways to 
provide consultancy across professional and service boundaries to promote 
joint working and collaboration between the two disparate teams, who must 
unite to agree upon joint standards of care and shared values (RCN Policy 
Unit, 2006). Joint working, which is recommended, is dependent on the 
advanced haematology nurse clinical practitioner being able to facilitate 
between the teams an understanding and respect of the expertise and 
contribution each team can offer. 
 
Education  
Working within the multi-professional four pillar framework it is suggested that 
advanced clinical practice haematology nurses use the conclusions and 
recommendations for clinical blood transfusion practice that emerged from this 
study to educate their colleagues and other members of the multi-professional 
team. In doing so they apply their clinical expertise across professional and 
service boundaries to enhance the quality of BT care, reduce unwarranted 
variation in care and promote the sharing and adoption of blood transfusion 
clinical practice based on research findings.  
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Research 
It is recommended that nurses working at this level of advanced practice 
engage in research activities at masters or doctoral level. This facilitates 
constructive networking with university scholars and other researchers to 
develop evidence-based recommendations that can be applied into their own 
clinical practice and disseminated to others to improve the quality and safety 
of care (HEE, 2017).  
 
6.5 Recommendations for future research 
Based on the findings from this study several recommendations for future 
research are offered. One of the study findings was that participants receiving 
blood transfusions in a day unit appeared to lose feelings of self-worth, as they 
felt “ignored”, “unimportant”, and “a fraud”. Further qualitative research could 
explore the experience of blood transfusions from the perspective of nurses. 
Gaining this understanding may shed further light on this experience and allow 
changes to nursing practice to be made, to reduce some of the negative 
feelings held by the participants.  
 
Another natural extension to the study findings would be to seek the stories of 
haematology consultants and palliative care consultants to explore why 
referral to the new hospice day unit are not occurring. Reasons for lack of 
referral to the PCT have been highlighted in the literature, but little qualitative 
research has been undertaken to gain a deep insight into healthcare 
professionals’ perspectives on this matter. Gaining this knowledge, by 
listening to their stories could help bring about change in physician referral 
practice which may lead to better end of life care for those receiving blood 
transfusions.  
A further extension could be to explore the concept of home blood transfusions 
and investigate why this practice is not taking place within the NHS, especially 
for those patients with a palliative diagnosis. From the few studies that have 
been undertaken to explore BT in the home, it appears that patients perceive 
it to be beneficial both physically and psychologically, and it is said to be cost-
effective. 
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6.6 Strengths of the study 
One of the strengths of this study lies in the methodological and conceptual 
foundations of the narrative inquiry design which is based on Dewey’s (1938) 
pragmatic theory of experience. This theoretical foundation differentiates it 
from other qualitative research approaches as the central phenomenon of 
interest is ‘experience’, which in narrative inquiry is explored through the 
metaphorical dimensions of sociality, place and temporality. Employing this 
framework allowed a focus on the social, personal and changing nature of 
participants’ experiences by exploring; “inwardly to the participant’s personal 
feelings, emotions and hopes; outwardly towards existential conditions, that 
is, the physical environment where the study took place; and temporally, that 
is, past, present and future” (Clandinin, 2013, p. 58). Addressing experience 
in this manner allowed a rigorous exploration of study participants’ experience 
and provided a deep insight into this aspect of clinical practice. Furthermore, 
the methodology is closely aligned with the research aim and objectives and 
there was a close fit between the research undertaken and clinical practice 
(Swanson et al., 1997 cited by Yardley, 2000). 
 
Second. A further conceptual and methodological difference between the 
approach taken in this study and previous research lay in the novel 
stratification of participants’ disease phase into: early, late and terminal 
palliative phases. Grouping participants in this manner allowed for an insight 
into how the participants’ blood transfusion experience changed throughout 
the palliative trajectory, something that has not been illuminated in academic 
literature before.  
 
Third. The issue of gaining the trust of participants, whom I had not met before, 
was overcome by “prolonged engagement”, which meant that I interviewed 
most participants three times. This also allowed for sufficient data to be 
collected to gain an in-depth understanding of the phenomena of interest 
(Lincoln & Guba,1985, cited by Polit, Beck, & Hungler, 2001, p. 313). The 
longitudinal approach over a twelve-month period allowed me to capture each 
individual participant’s meaning of their experience at subsequent interviews. 
This allowed for any differences in perceptions between participants to 
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become clear, for example, some found blood transfusions beneficial, while 
others did not. Some participants wanted to be able to socialise with other 
patients, while another did not. Moreover, discussion and agreement with my 
academic supervisors, who reviewed three of the transcripts and narrative 
accounts, confirmed the overarching storylines (themes) and plotlines 
(subthemes) (Cresswell, 2009). Discussions with my clinical and academic 
supervisors allowed alternative explanations to be explored and discussed 
which helped to validate confidence in the findings (Patton, 2002).  
 
Fourth. As this study originated from a practical stance, that is, to understand 
from the patients’ perspective if the administration of BT were adding to their 
suffering, I believe, following Yardley (2000), that the criterion of “coherence” 
was met. Yardley, in describing the work of another researcher (Hartwell, 
1998), outlines that coherence was met despite,  
 
‘There is virtually no explicit consideration of theory, and the literature 
reviewed relates mainly to the prevalence of recidivism, and hence the 
scope of the problem. But although the treatment of interviewees’ 
statements appears theoretically unsophisticated, taking descriptions of 
their lives more or less at face value’ (ibid, p. 227).  
 
Even so, Yardley (2000) suggested that the study met the criterion of 
coherence because “it is consistent with the practical approach adopted, and 
with the implicitly phenomenological aim of elucidating the perspectives of the 
interviewees” (p. 227). 
 
6.7 Limitations  
Yardley (2017, p. 295-296) suggests that during qualitative analysis the 
researcher must, crucially, be able to show: sensitivity to the data; commitment 
and rigour; transparency; and importance of findings.  
 
6.7.1 Sensitivity to the data 
Yardley (2017, p. 295) promotes the idea that the researcher should not 
impose their own thoughts onto the data by ‘imposing pre-conceived 
categories from the data but carefully considering the meanings generated by 
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the participants’. As a nurse with much experience in caring for haematology 
patients, it was challenging not to be influenced by my own perceptions when 
analysing and interpreting the participants’ stories. There was an ongoing 
conflict between my role as an academic researcher and my instinct to act as 
an advocate for patients, which derived from my commitment to my 
professional role. The subject of my “positionality” or “insider/outsider” position 
and the inevitable imbalance in power relations that this causes has been 
discussed in section 3.9.3 (p. 45) and below.  
 
During interviewing, it was impossible to maintain the position of a detached 
observer and remain “neutral” (Yardley, 2000, p. 221) as the study and 
participant’s illnesses progressed. For example, some participants were in 
such dreadful physical condition by our third interview that I could not help 
myself but let the nurse take over. I wanted to look at the ulcer on an abdomen 
or the dreadful swelling of a participant’s legs and I wanted to take a participant 
to the toilet. Touched by their condition and my need to care for them was 
overwhelming and I became extremely soft and gentle in my approach. This 
invoked the relative, hierarchal, power identity of me as the ‘expert’ and the 
participants as patients despite efforts to downplay my position as described 
in 3.9.3. My concern over my insider position, in this case was handled through 
several strategies: using thick description (Lincoln & Guba, 1985; Polit & Beck, 
2010, p. 1453-1454), which provides information about the study participants, 
the research settings and the research processes, in addition to descriptor and 
demographic information; analysing the narratives in relation to a clear 
analytical framework (Chapter 3); and by maintaining a reflexive and critical 
stance through ongoing discussions with my supervisory team. Moreover, my 
insider position equipped me with insightful sensitivity and an awareness that 
helped me to relate to participants’ narratives and experiences. 
 
6.7.2 Commitment and Rigour 
Recruitment of study participants continued until I believed that no new 
emerging themes from participant stories, that linked with the study aim, were 
forthcoming. It is possible to suggest that data collection would have benefited 
from including more stories concerning the hospice day setting, as this data 
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was acquired from only one participant, which was also the case in the 
community day unit hospital setting. This would have offered the potential for 
“replication” of themes in participants’ stories (Polit & Beck, 2010). However, 
conducting interviews in these settings was not possible due to lack of 
physician referral to these areas. 
 
Reissman (2002) recognises that “evolving theories, disciplinary preferences 
and research questions lead to a number of possible interpretations, 
dependent on the focus of the researcher”, that is, there is a, “possibility of 
multiple truths” (Freeman, 2003, cited by Squire, 2013, p. 57). Polkinghorne 
(2007) also recognises that narrative researchers engaging in interpretation 
will make different claims about their understanding of a text depending on the 
position they take (p. 483-484). This limitation may be addressed potentially 
by “participant validation” of the interim and finalised research texts. Ongoing 
validation of aspects captured in the interim texts was shared with participants 
at subsequent interviews, to check that I had captured the essential features 
of what the experience meant to them (Polkinghorne, 2007), however, it was 
impossible to share the final research texts as sadly, participants had died by 
the time these were produced.  
 
Another limitation of this study was that I chose to focus solely on the content 
of participants’ stories. I did not employ another analytical method to 
triangulate and perhaps strengthen the findings. For instance, Riessman 
(2008, p. 80) suggests that incorporating a structural analysis to a thematic 
narrative analysis “allows topics and voices to be included in qualitative 
analysis that might be missed otherwise”. Although Reissman, (2008, p. 77) 
also recognises, that a detailed structural analysis (as she demonstrates on 
pages 87-88), can complicate the project by making the interview excerpts 
unreadable for those new to narratology.  
 
Structural analysis has not been demonstrated in my thesis analysis, however 
this approach was utilised while reading through the transcripts, where I 
examined for six elements: an abstract; orientation; complicating action; 
evaluation; resolution and coda (Labov, 1972; Labov & Waletzky, 1967). 
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Indeed, I analysed each poem in this manner and sent copies to my 
supervisors, although, I did not feel that in this study undertaking this additional 
analytical approach added to my thematic findings. At the same time the 
process did help me to explore my thematic findings in more detail, and 
identification of the evaluative component in particular helped me to determine 
what an event meant to a participant.  
 
Participants were initially informed about the study through a haematologist. It 
is difficult to know if this influenced the stories they told, or indeed whether it 
was why they chose to participate. However, I do not believe that it had an 
impact on such decisions. Participants were keen to tell me about the 
hardships they endured because they believed that what they told me would 
go towards improving the blood transfusion service for future patients.  
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Chapter 7: Reflection of my Professional Doctorate Path 
7.1 Introduction 
This chapter is a critical reflection of my Professional Doctorate in Nursing 
pathway. It details how I made the decision to complete this programme and 
highlights my learning and development journey. It describes how undertaking 
this programme has increased my professional standing in my employing Trust 
and allowed me to implement changes to clinical practice within the Trust and 
in my own professional area.  
 
7.2 Why I chose the Professional Doctorate in nursing programme 
Employed as a Band 8a Haematology Nurse Practitioner, I held a senior 
position within the nursing hierarchy, which according to the National Core 
Competency Framework for Cancer Nursing equates to “Knowledge and Skills 
Framework" (KSF) Level 3/4. However, I had not reached my goal of becoming 
a Consultant Nurse KSF Level 4/5. To achieve this within my workplace 
required me to attain a doctoral level education, as post qualification learning 
is linked with the KSF framework.  
 
As a working mother with three children and grandchildren undertaking a full 
time PhD was not an option. Turning to the literature I found an article by 
Costley (2013) which highlighted the knowledge contributions of the 
Professional Doctorate (PD):  
 
‘PDs are usually independent and original contributions to a 
professional practice; practitioner research is often a central activity. 
PhD students can develop and apply research in the same way, 
although this is not a key characteristic of the PhD as it is with the PD’ 
(ibid, p. 1). 
 
As the aim of PDs is to give primacy to practical knowledge and to develop an 
original contribution to practice through practitioner-research (Costley, 2013), 
I was drawn to this prospect. The approach was one I was familiar with as I 
had taken a practitioner-research stance during my part-time MA in Healthcare 
Leadership and Practice. Despite completion of my degree, my confidence to 
study at doctoral level was lacking. As the PD programme offers taught 
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elements, it was believed that this preparatory knowledge would provide the 
necessary research skills and confidence to prepare for and complete the final 
thesis component. 
 
7.3 The Professional Doctorate programme: 
After successful application to undertake the PD programme at the University 
of Portsmouth, I was both delighted and scared. The first module, 
“Professional Review and Development”, allowed development of a personal 
portfolio, a necessary requirement for nurses but one that I had not previously 
achieved.  
 
The second module, “Advanced Research Techniques Unit” introduced me to 
qualitative data analysis computer software packages (MAXQDA and NVivo) 
and the “Hierarchy Framework Analysis” described by Richie and Lewis 
(2006). The statistical part of this module I found incredibly challenging. I learnt 
advanced statistical methods and concepts which left me feeling a more 
competent and confident research student, one armed with much knowledge 
about the theory and practice of qualitative and quantitative research 
methodologies applicable to healthcare.  
 
During the third module, “Publication and Dissemination” the learning involved 
covered issues of plagiarism, journal impact factors, the political influence of 
journal editors and editing. This essential knowledge prepared me for 
dissemination of my research findings to the wider community through journal 
publications. Due to time commitments involved with study, work and family, I 
have not been able to publish during the programme. However, I do plan to 
publish in a high impact journal such as the Journal of Advanced Nursing, or 
the British Journal of Nursing, and present my findings at the ‘British 
Committee for Standards in Haematology’ Conference following completion of 
the course.  
 
The outcome of the final taught module was successful completion of a 
research proposal and submission through an NHS research ethical 
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committee. This module introduced me to the ethical and research governance 
frameworks (DH, 2005) within the NHS and my own working environment. 
Over the eighteen months I expanded my academic horizons which helped my 
professional development and clinical practice. It was tremendously hard 
work, requiring excellent time management skills and determination to enable 
me to complete on time and fit with my other obligations and responsibilities. 
However, it fully prepared me for Part 2 of the thesis programme during which 
I developed academically, professionally and personally.  
 
During Part 2 of the PD I became more autonomous in the planning and 
management of my own learning. I gained the confidence to provide 
authoritative solutions when presented with practical problems within my 
professional arena and became more able to make significant and original 
contributions to professional practice. With my increased knowledge and 
confidence, my relationship with colleagues changed. I gained their attention 
and respect in providing professional and intellectual leadership, inspiration 
and motivation, and became mentor to two students undertaking their degrees 
in haematology nursing. I was also involved in regular teaching both to 
individuals and to groups about haematological cancer issues.   
 
7.4 Reflection on changes to clinical practice  
The standing I attained from undertaking the Professional Doctorate has 
allowed me the autonomy to lead changes for patient benefit in numerous 
areas of clinical practice:  
 
• I instigated and operated my own nurse-led Myeloproliferative Disease 
clinic once a week.  
• I set up and operated my own nurse-led Peripherally Inserted Central 
Catheter (PICC) service which I audited. The audit findings were 
presented at a Trust conference which the Chief Executive and Director 
of Nursing attended. The service was established after winning the 
‘Researcher of the Year’ award for my MA findings, which presented 
me with a £1000 prize. I spent the money training to insert PICC lines 
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to establish this single-handed service, where I placed over 1000 PICCs 
in; haematology and oncology patients, coronary care unit patients and 
intensive care unit patients. 
• I set up and operated my own weekly bone marrow biopsy service 
performing almost all the biopsies required by haematology patients. 
• I co-authored the Trust Central Venous Line Policy and personally 
wrote two Patient Group Directives.  
 
7.5 Challenges during the PD programme 
During the final stage of my PD, there have been several challenging personal 
issues to address which delayed completion of my thesis. My interruption from 
studies ended on 18th April 2016 and I returned to my study. I have been given 
assurance by my haematology clinical supervisor that the findings from my 
thesis and implications for clinical practice are relevant and applicable to the 
clinical area. My supervisor has also confirmed that shortly before submission 
some changes have been made. 
 
A further issue, which was overwhelmingly disappointing, was that the Trust 
decided not to appoint any more nurse consultants, this decision being made 
after I and five other nurses had completed a 64-hour workshop to complete a 
consultant practitioner development training programme. Although 
disappointing, I was bolstered by the fact that I had been chosen from a 
substantial number of applicants, because of the intellectual standing and 
respect I had gained within the Trust from undertaking the PD programme and 
the learning experiences this had provided.  
 
Another stumbling block was the change to my original PD proposal which was 
to explore the effect of cranberries in reducing infection in haematology 
patients. After spending many months of writing the proposal for an “NHS 
National Institute for Health Research, Research for Patient Benefit” grant, 
collaborating with the Research and Development unit at my employing Trust 
to secure “Trust sponsorship”, collaborating with the lead trust pharmacist, the 
statistician from the University of Portsmouth and with my academic 
supervisor, we were unsuccessful in securing the grant and the project had to 
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be abandoned. It was, however, an important learning experience, which 
involved interacting and networking with multidisciplinary teams across 
different sites, which is a necessary facet of the research process.  
 
I had anticipated that the NHS ethical review process would be harrowing. To 
complete the Research Ethics Committee Submission form, I had researched 
in depth, through published literature and by discussing with the palliative / 
end of life consultant at my employing Trust how to manage any issues that 
arose at the ethics meeting. My PD learning provided the knowledge and 
confidence I required at the review meeting which was successful first time.  
 
In the act of narrating participants’ stories, I was able to make sense of their 
experiences, but keeping to the word count has proved incredibly difficult. I 
tend to be a verbose writer and examining experience through three 
dimensions resulted in copious data, but with my PD learning and the help of 
my supervisors, I have learnt to master this weakness and write more 
succinctly. 
 
Undertaking this Professional Doctorate qualification has been arduous but 
incredibly rewarding and has fulfilled my lifetime ambition. In broadening my 
academic horizons, my self-esteem has grown, I am a changed person, 
broader in knowledge and able to challenge those I once believed superior or 
with higher intellect. But it is work in progress, I have spent a lifetime learning, 
it is my comforter and I cannot imagine life without study. It gives coherence 
and meaning to my life and allows me to make a positive difference to peoples’ 
lives, therefore my learning and sharing of knowledge must continue. 
 
7.6 A sincere “thank you” note to all the participants in this study 
This thesis ends with my overwhelming gratitude and a sincere “thank you” to 
all the poorly participants in this research study who gave their time 
altruistically to highlight matters associated with BT that were important to 
them, solely for the benefit of future patients. Thus, in gratitude and dedication 
to the stoic participants who took part in this study, this thesis ends with the 
words of Dame Cicely Saunders (1919-2005), words which provide a key 
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message for all healthcare professionals in their daily clinical practice and 
relationship with patients:  
 
You matter  
because you are you 
and you matter 
to the end of your life 
  
We will do all we can 
not only to help you die peacefully 
   but also 
to live until you die  
(Dame Cicely Saunders, 1918-2005). 
  
175 
References 
Adams, K.W., Tolich, D. (2011). Blood transfusion: the patient’s experience. 
American Journal of Nursing. Sept; 111(9): 24-30.  
 
Agarwal, A.K., Murinson, B.B. (2012). New Dimensions in Patient-Physician 
Interaction: Values, Autonomy, and Medical-Information in the Patient-Centred 
Clinical Encounter. Rambam Maimonides Medical Journal Jul; 3(3): e0017. 
Published online 2012 Jul 31, doi: 10.5041/RMMJ.10085 
 
Agnihotri, N., Agnihotri, A. (2014). Transfusion associated circulatory 
overload. Indian J Critical Care Medicine. Jun; 18(6): 396-398.  
 
Alam, A., Lin, Y., Lima, A., Hansen, M., Callum, JL. (2013). The prevention of 
transfusion-associated circulatory overload. Transfusion Medical Review. Apr; 
27(2): 105-12 Elsevier 
 
Andrews, M., Squire, C., Tamboukou. (2013). Doing Narrative Research. 
SAGE publications, Second Edition.  
 
Atkinson, R. (1998). The Life Story Interview. SAGE. 
 
Bamberg, M. (2012). Narrative Analysis. In. H. Cooper (editor in chief), APA 
handbook of research methods in psychology. (3 volumes):77-94. 
Washington, DC: APA Press.  
 
Barthes, R. (1977). ‘Introduction to the Structural Analysis of Narratives’, 
Music, Image, Text. Ed. and trans. Stephen Heath (New York, 1977): 79-117. 
 
Blumberg, N., Heal, J.M., Gettings, K.F., Phipps, R.P., Masel. D., Refaai, M.A., 
Kirkley, S.A., Fialkow, L.B. (2010). An association between decreased 
cardiopulmonary complications (transfusion-related acute lung injury and 
transfusion-associated circulatory overload) and implications of universal 
leukoreduction of blood transfusions. Transfusion. Dec: 50(12): 2738-2744.  
 
Bell, J. S. (2002). Narrative Inquiry: More than just telling Stories. TESOL 
Quarterly. Vol. 36, No. 2, Summer.  
 
Benner, P. (1984). From Novice to Expert: Excellence and Power in Clinical 
Nursing Practice. Pearson Education (US).  
 
Benner, P., Hughes, R.G., Sutphen. (2008). Clinical Reasoning, Decision 
making, and Action: Thinking Critically and Clinically. In Hughes, R.G. (Ed.), 
Patient Safety and Quality: An Evidence-Based Handbook for Nurses: 1-23. 
Rockville (MD): Agency for Healthcare Research and Quality (US): April. 
Google Scholar https://www.ncbi.nim.nih.gov/books/NBK2643/ 
 
Bishop, L., Faithfull, S., Allan, H. (2011). An exploration of the influences on 
clinical decision making and the culture of blood transfusion practice in cancer-
related anaemia using an ethnographic methodology. Support Cancer Care. 
Vol. 19, No. 2: 203-210.  
176 
Bleustein, C., Rothschild, D.B., Valen, A., Valaitis, E., Schweitzer, L., Jones, 
R. (2014). Wait Times, Patient satisfaction Scores, and the Perception of Care. 
The American Journal of Managed Care. May;20(5): 393-400. 
 
BMJ. (2000). Risk of infection from blood transfusion in UK is negligible. 
British Medical Journal Feb 12; 320(7232): 0. PMCID: PMC1117520 
PMID:10669474 
Bolton, G., Delderfield, R. (2018) (Fifth Edition). Reflective Practice: Writing 
and Professional Development. Sage Publications Ltd. ISBN: 9781526411709 
 
Bolton-Maggs, P.H.B., Cohen, H. (2013). Serious Hazards of Transfusion 
(SHOT) haemovigilance and progress is improving transfusion safety. British 
Journal of Haematology. Vol. 163, Issue 3. September 14.   
Doi: 10.1111/bjh.12547 
 
Bosboom, J.J., Klanderman, R.B., Zijp, M., Hollmann, M.W., Veelo, D.P., 
Binnekade, J.M., Geerts, B.F., Vlaar, APJ. (2018). Incidence, risk factors, and 
outcome of transfusion-associated circulatory overload in a mixed intensive 
care unit population: a nested case-control study. Transfusion. Feb. 58(2): 
498-506. 
 
Boyce, A., McHugh, M., Lyon, P. (2003). Proactive palliative choices for 
Haematology Day Unit patients. International Journal Palliative Nursing. Vol. 
9: 544-550.  
 
Breier-Mackie, S. (2001). Patient Autonomy and medical paternity: can nurses 
help doctors to listen to patients? Nursing Ethics. Nov; 8(6): 510-521. 
 
Brereton, L., Gardiner, C., Gott, M., Ingleton., Barnes., Carroll, C. (2012). The 
hospital environment for end of life care of older adults and their families: an 
integrative review. Journal of Advanced Nursing. May; 68(5): 981-93.  
Doi: 10.1111/j.1365-2648.2011.05900.x  
 
British Committee for Standards in Haematology. (BSH) (2012). Guideline on 
the Administration of Blood Components. British Committee for Standards in 
Haematology.   
 
Brody, H., Campbell, M.L., Faber-Langendoen, K., Ogle, K.S. (1997). 
Withdrawing Intensive Life-Sustaining Treatment – Recommendations for 
Compassionate Clinical Management. The New England Journal of Medicine. 
Feb. 27: 336: 652-657.  
 
Brown, J. and Addington-Hall, J. (2008)] How people with motor neurone 
disease talk about living with their illness: a narrative study. Journal of 
Advanced Nursing 62(2), 200-208  
 
Brown, E. and Bennett, M. (2007) Survey of Blood Transfusion for Palliative 
Care Patients in Yorkshire: Implications for Clinical Care. Journal of Palliative 
Medicine. Vo.10, No. 4: 919- 922  
177 
Brown, E., Hurlow, A., Rahman, A., Closs, S.J., Bennett, M.I (2010) 
Assessment of Fatigue after Blood Transfusion in Palliative Care Patients: A 
Feasibility Study. Journal of Palliative Medicine Vol. 13 No. 11: 1327- 1330 
 
Bruner, J, (1986). Actual minds, possible worlds. Cambridge, MA: Harvard 
University Press.  
 
Bruner, J. (1990). Acts of meaning. Cambridge, MA: Harvard University Press. 
Bury, M. (1982). Chronic illness as biographical disruption. Sociology of Health 
and Illness. Volume 4, Issue 2: 167-182 
 
Bury, M. (2001). Illness narratives: fact or fiction? Sociology of Health and 
Illness. Volume 23, No. 3: 263-285. 
 
Butler-Kisber, L. (2002). Artful portrayals in qualitative inquiry: The road to 
found poetry and beyond. Alberta journal of Educational Research, 48(3). 
Retrieved from http://www.ajer.ca/Google Scholar 
 
Butler-Kisber, L. (2005). Inquiry through poetry: The genesis of self-study. In 
C. Mitchell, S. Weber, & K. O’Reilly-Scanlon (Eds.), Just who do we think we 
are? Methodologies for autobiography and self-study in teaching (pp. 95110). 
New York, NY: Routledge Falmer. 
 
Byrne, G. (2017). Narrative inquiry and the problem of representation: ‘Giving 
voice’, making meaning. International Journal of Research & Method in 
Education, 40(1), 36–52. http://dx.doi.org/10.1080/1743727X.2015.1034097 
 
Caine, V., Estefan, A. (2011). The Experience of Waiting: Inquiry into the Long-
term Relational responsibilities in Narrative Inquiry. Qualitative Inquiry. 17(10), 
965-971. 
 
Campos, M.P.O., Hassan, B.J., Riechelmann, R., DelGiglio, A. (2011). 
Cancer-related fatigue: a practical review. Annals of Oncology. 22,1273-1279. 
 
Care Quality Commission (2018). Quality improvement in hospital trusts: 
Sharing learning from trusts on a journey of QI. 
https://www.cqc.org.uk/sites/default/files/20180911_QI_hospitals_FINAL.pdf 
 
Carson, J.L., Kleinman, S. (2018). Indications and haemoglobin thresholds for 
red blood cell transfusion in the adult. Uptodate. 
https://www.uptodate.com/contents/Indications-and-hemoglobin-thresholds-
for-red-blood-cell-transfusion-in-the-adult  
 
Chan, E.A., Jones, A., Wong, K. (2013). The relationships between 
communication, care and time are intertwined: a narrative inquiry exploring the 
impact of time on registered nurses’ work. Journal of Advanced Nursing 69(9): 
2020-2029. 
 
Charmaz, K. (1997). Good Days, Bad Days: The Self in Chronic Illness and 
Time. New Brunswick, NJ: Rutgers University Press.  
178 
Cheng, B.H.W., Sham, M.M.K., Chan, K.Y., Li, C.W., Au, H.Y. (2015). 
Intensive Palliative Care for Patients with Hematological Cancer Dying in 
Hospice: Analysis of the Level of Medical Care in the Final Week of Life. 
American Journal of Hospice and Palliative Medicine. Vol. 32(2): 221-225. 
 
Cherryholmes, C.H. (1992). Source: Notes on Pragmatism and Scientific 
Realism. Educational Researcher, Vol. 21, No. 6, (Aug. – Sep): 13-17 
Published by: American Educational Research Association Stable  
http://www.jstor.org/stable/1176502 DOI: 10.2307/1176502 
Chin-Yee, N., Taylor, J., Rourke, K., Faig, D., Davis, A., Fergusson, D., 
Saidenberg, E. (2018). Red blood cell transfusion in adult palliative care: a 
systematic review. Transfusion. Volume 58(1), 233-241.  
doi: 10.1111/trf.14413. Epub 2017 Dec 1 
 
Clandinin, D.J. (2006). Narrative Inquiry: A Methodology for Studying Lived 
Experience. Research Studies in Music Education, 27(1): 44-54. SAGE 
journals. 
 
Clandinin, D.J. (2013) Engaging in Narrative Inquiry. Left Coast Press, Inc.  
 
Clandinin, D.J., and Connelly, F.M. (2000). Narrative inquiry: Experience and 
Story in Qualitative Research. San Francisco: Jossey-Bass. 
 
Clandinin, D.J., and Rosiek, J. (2007). Handbook of Narrative Inquiry Mapping 
a Methodology. Sage Publications Inc.  
 
Connelly, F.M., and Clandinin, D.J. (1990). Stories of experience and narrative 
inquiry. Educational Researcher, 19(5), 2-14.  
 
Connelly, F.M., and Clandinin, D.J. (2006). Narrative Inquiry. In J. Green, G. 
Camilli, and P. Elmore (Eds), Handbook of complementary methods in 
education research (3rd ed.) (p. 477-87). Mahwah, NJ: Lawrence Erlbaum. 
 
Corbett, C.L., Johnstone, M., Trauer, J.M., Spruyt, O. (2013). Palliative care 
and hematological malignancies: increased referrals at a comprehensive 
cancer centre. Journal Palliative Medicine. May; 16(5), 537-41. 
 
Costley, C. (2013). Evaluation of the current status and knowledge 
contributions of Professional Doctorates. Quality in Higher Education. 19(1): 
7-27. Middlesex University Research Repository.  
https://core.ac.uk/download/pdf/17302784.pdf  
 
Craig, J.I.O., Milligan, P., Cairns, J., McClelland, D.B.L., Parker, A.C. (1999) 
Nurse practitioner support for transfusion in patients with haematological 
disorders in hospital and at home.  Transfusion Medicine. 9, 31-36 
 
Cresswell, J.W. (2009). Research design: Qualitative and mixed methods 
approaches. London: Sage. 
 
179 
Cresswell, J.W. (2013). Qualitative Inquiry & Research Design Choosing 
among Five Approaches (3rd ed.). Thousand Oaks, CA SAGE. 
 
Crichton, N. (2001). Visual Analogue Scale Journal of Clinical Nursing 10(5): 
697-706 http://www.blackwellpublishing.com/specialarticles/jcn_10_706.pdf 
 
Crossley, M.L. (2000). Narrative Psychology, Trauma and the Study of 
Self/Identity Theory and Psychology. Volume 10(4), 527-546. Sage 
Publications.  
 
Crossley, M.L. (2002). Introducing Narrative Psychology. In: Narrative, 
Memory and Life Transitions. University of Huddersfield, Huddersfield, 1-13. 
http://eprints.hud.ac.uk/5127/  
 
Crossley, M.L. (2003). ‘Let me explain’: narrative emplotment and one 
patient’s experience of oral cancer. Social Science and Medicine. 56, 439-448.  
Curt, G.A (2000). The impact of fatigue on patients with cancer: overview of 
FATIGUE 1 and 2. Oncologist. 5 Suppl 2, 9–12.  
 
Dalgaard, K.M., Thorsell, G., Delmar, C. (2010)] Identifying transitions in 
terminal illness trajectories: a critical factor in hospital-based palliative care 
International Journal of Palliative Nursing. Vol. 16, No.2: 87-92 
 
Del Vecchio Good, M. J., Munakata, T., Kobayashi, Y., Mattingly, C., Good, 
B.J. (1994) Oncology and narrative time, Social Science and Medicine. 38, 
855-862. 
 
Denzin, N., & Lincoln, Y. (Eds.). (2011). Handbook of qualitative research (4th 
ed.). Thousand Oaks, CA: Sage 
 
Department of Health. (2005). Research Governance Framework for Health 
and Social Care. Second Edition.  
https://assets.publishing.service.gov.uk/government/uploads/system/uploads
/attachment_data/file/139565/dh_4122427.pdf 
 
Department of Health (2012). Compassion in Practice. Nursing, Midwifery and 
Care Staff, Our Vision and Strategy. London: Gateway reference 18479.  
https://www.england.nhs.uk/wp-content/uploads/2012/.../compassion-in 
practice.pdf 
 
Dewey, J. (1938) Experience and Education. New York: Collier Books.  
 
Draper, D.A., Felland, L.E., Liebhaber, A., Melichar. (2008). The role of nurses 
in hospital improvement. Res Brief. Mar;(3): 1-8. Pubmed NCBI 
https://www.ncbi.nlm.nih.gov/pubmed/18496934 
 
Duggleby, W. (2000). Enduring Suffering: A grounded theory analysis of the 
pain experience of elderly hospice patients with cancer. Oncology Nursing 
Forum, Vol, 27: 825-830.  
 
180 
Duke, S. (2007). A narrative case study evaluation of the role of nurse 
consultant in palliative care. University of Southampton, School of Education, 
Doctoral Thesis. 
 
Duke, S., Appleton, J. (2000). The use of reflection in a palliative care 
programme: a quantitative study of the development of reflective skills over an 
academic year. Journal of Advanced Nursing, 32(6): 1557-1568. PMID: 
11136426 
 
Dunn, A., Carter, J., Carter, H. (2003). Anemia at the End of Life: Prevalence, 
Significance, and Causes in Patients Receiving Palliative Care. Journal of Pain 
and Symptom Management. Volume 26. No. 6. December.  
 
Ekman, K., Swedberg, C., Taft, A., Lindseth, A., Norberg, E., Brink, E, et al 
(2011). Person-centered care – Ready for prime time. European Journal of 
Cardiovascular Nursing. 10(4): 248-251.  
 
El-Jawahri, A, Traeger, L., Kuzmuk, K., Eusebio, J., Vandusen, H, et al (2015). 
Prognostic Understanding, Quality of Life, and Mood in Patients Undergoing 
Hematopoietic Stem Cell Transplantation. Bone Marrow Transplant. Aug; 
50(8):1119-1124.  
 
Ely, M. (2007). In-forming re-presentations. In D. J. Clandinin (Ed.), Handbook 
of narrative inquiry: Mapping a methodology (pp. 567–597). Thousand Oaks: 
Sage Publications. 
 
Engert, Andreas. (2000). Recombinant Human Erythropoietin as an 
Alternative to Blood Transfusions in Cancer-Related Anaemia. Disease 
Management and Health Outcomes. 8(5):259-272. DOI:10.2165/00115677-
200008050-00002 
 
Evans, W.G., Cutson, T.M., Steinhauser, K.E., Tulsky, J.A. (2006). Is there no 
place like home? Caregivers recall reasons for and experience upon transfer 
from home hospice to inpatient facilities. J. Palliative Medicine. Feb; 9(1): 100-
110.  
 
Fenaux, P., Haase, D., Sanz, G.F., Santini, V., Buske, C. (2014).  
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, 
treatment and follow-up. Annals of Oncology. Volume 25, Issue supplement 3, 
1september, p. iii57-iii69, https://doi.org/10.1093/annonc/mds180  
 
Ferrell, B. (2006) Understanding the Moral Distress of Nurses Witnessing  
Medically Futile Care Oncology Nursing Forum; Sept. Vol. 33, No. 5: 922-930 
 
Fitzgerald, M., Hodgkinson, B., Thorpe, D. (1999). Blood transfusion from the 
recipient’s perspective. Journal of Clinical Nursing. Wiley. 
https://onlinelibrary.wiley.com/doi/epdf/10.1046/j.1365-2702.1999.00291.x 
 
Frank, A. (1995). The wounded storyteller: Body, illness and ethics. Chicago, 
IL: University of Chicago Press. 
181 
Frankl, V.E. 1984 (1984). Man’s search for meaning: an introduction to 
logotherapy. 3 Feb. 240 pages. Ryder. 
 
Frazer, H. (2004). Doing Narrative Research. Analysing Personal Stories Line 
by Line. SAGE journals. Vol 3, Issue 2. June 1.  
 
Gao, C., Li, L., Chen, B., Song, H., Cheng, J., Zhang, X., & Sun, Y (2014). 
Clinical outcomes of transfusion-associated iron overload in patients with 
refractory chronic anaemia. Patient Preference and adherence. Volume 8: 
13-517. DOI https://doi.org/10.2147/PPA.S56238 
 
Gattermann, N. (2008). Overview of guidelines on iron chelation therapy in 
patients with myelodysplastic syndromes and transfusional iron overload. 
International Journal of Hematology. Jul; 88(1): 24-29.  
 
Gee, J.P. (1986). Units in production of narrative discourse. Discourse 
Processes. 9: 391-422.  
Gee, J.P. (1991). A linguistic approach to narrative. Journal of Narrative and 
Life History. 1(1):15-39. 
 
Geifand, D.E., Raspa, R., Briller, S.H., Schim, S.M. (2007). End - of - Life 
Stories Crossing Disciplinary Boundaries. Springer pub.   
 
General Medical Council. (2010). Treatment and care towards the end of life: 
good practice in decision making. www.gmc-uk.org/guidance.  
 
Gleeson, C. and Spencer, D (1995) Blood Transfusion and its benefits in 
palliative care. Palliative Medicine 9: 307-313 
 
Goksu, S.S., Gundez, S., Unal, D., Uysal, M., Arslan, D., Tatli, A.M., Bozcuk, 
J., Ozdogan, M., Coskun, H.S. (2014). Use of Blood Transfusion at the End of 
Life: Does it Have Any Effects on Survival of Cancer Patients? Asian Pac J 
Cancer Prev, 15(10): 4251-4254. 
 
Good, B.J., and Del Vecchio Good, M. J. (1994). In the subjunctive mode: 
Epilepsy narratives in Turkey. Social Science and Medicine. 38(6): 835-842. 
 
Gott, M., Frey, R., Raphael, D., O’Callaghan, A., Boyd, J. (2013). Palliative 
care need and management in the acute hospital setting: a census of one New 
Zealand Hospital. BMC Palliative Care. 12: 15 March 28.  
 
Gray, R., Grant-Casey, J., Estcourt, L., Neoh, K., Bennet, M., Malia, C., 
Boland, J. (2016). National Comparative Audit of Red Blood Cell Transfusion 
in Hospices. NHS Blood and Transplant. 
 
Green, J., Pirie, L. (2009). A Framework to Support Nurses and Midwives 
Making the Clinical Decision and Providing the Written Instruction for Blood 
Component Transfusion  
http://hospital.blood.co.uk/media/29173/btframework-final010909.pdf 
 
182 
Groopman, J (2006) The Anatomy of Hope. How you can find strength in the 
face of illness Pocket Books 
 
Guetterman, T.C. (2015). Descriptions of sampling Practices Within Five 
approaches to Qualitative Research in Education and the Health Sciences. 
FORUM: Qualitative Social Research. Volume 16, Number 2. May  
ISSN 1438-5627. Available at: 
http://www.qualitativeresearch.net/index.php/fqs/article/view/2290 
 
Gullick, J., Shimadry, B. (2008) Using patient stories to improve quality of care 
Nursing Times 104: 10: 33-34 
Haematological Malignancy Research Network (2018). HMRN QuickStats. 
https://www.hmrn.org/statistics/quick  
 
Haydon, G., van de Riet, P. (2014). A narrative inquiry: How do nurses 
respond to patients’ use of humour? Contemporary Nurse. 46(2): 197-205.  
 
Haydon, G., Browne, G., van de Riet, P. (2018). Narrative inquiry as a 
research methodology exploring person centred care in nursing. Science 
Direct. Volume 25, Issue 1, February:125-129.   
https://doi.org/10.1016/j.colegn.2017.03.001 
 
Hayward, H., Hiersche, A., Watson, L. (2012). Blood, glorious blood: are 
attitudes to blood transfusions for palliative purposes always positive? BMJ 
Supportive & Palliative Care Pain and Symptom management: Volume 2, 
Issue Suppl. 1. Poster No: 96  
http://dx.doi.org/10.1136/bmjspcare-2012-000196.136 
 
Health Education England (2017). Multi-professional framework for advanced 
clinical practice in England (https://www.hee.nhs.uk) 
https://www.hee.nhs.uk/printpdf/our-work/advanced-clinical-practice/multi-
professional-framework 
 
Hendrickson, J.E., Roubinian, N.H., Chowdhury, D., Brambilla, D., Murphy, 
E.L., Wu, Y., Ness, P.M., Gehrie, E.A., Snyder, R., Hauser, G., Gottschall, J.L., 
Kleinman, S., Kakaiya, R., Strauus, R.G (2016). Incidence of transfusion 
reactions: a multicentre study utilizing systematic active surveillance and 
expert adjudication. Transfusion. Oct; 56(10): 2587-2596.  
doi:10.1111/trf.13730 
 
Henneman, E.A., Andrzejewski, C.Jr., Gawlinski, A., McAfee, K., Panaccione, 
T., Dziel, K. (2017). Transfusion-Associated Circulatory Overload: Evidence-
Based Strategies to Prevent, Identify, and Manage a Serious Adverse Event. 
Crit Care Nurse. Oct. 37(5): 58-65. doi: 10.4037/ccn2017770 
 
Herth, K. (1990) Fostering hope in terminally ill people. Journal of Advanced 
Nursing 15:1250-59. 
 
Hinka, H., Kosunen, E., Metsanoja, R., Puustelli, A., Kellokumpu-lehtinen, P. 
(2002). Decision making in terminal care: a survey of Finnish doctors’ 
183 
treatment decisions in end-of -life scenarios involving a terminal cancer and a 
terminal dementia patient. Palliative medicine. May; 16(3):195-204. 
 
Hoffbrand, A.V., Pettit, J.E. (1993). Essential Haematology. Third Edition, 
Black Well Science. 
 
Holloway, I. (1997). Basic Concepts for Qualitative Research. Oxford: 
Blackwell Science. 
 
Hopkinson, J.B., Hallett, C.E. (2001). Patients’ perceptions of hospice day 
care: a phenomenological study. International Journal of Nursing studies. Vol. 
38, Issue, 1: 117-125.  
 
Howell, D.A., Shellens, R., Roman, E., Garry, A.C., Patmore, R., Howard, M.R. 
(2011) Haematological malignancy: are patients appropriately referred for 
specialist palliative and hospice care? A systematic review and meta-analysis 
of published data. Palliative Medicine Sep; 25(6):630-41. Epub 2011 Jan 12. 
SAGE journals  
 
Howell, D.A., Wang, H.I., Smith, A.G., Howard, M.R., Patmore, R.D., Roman, 
E. (2013). Place of death in haematological malignancy: variations by disease 
subtype and time from diagnosis to death. BMC Palliative Care. 12, 42 
Published online 2013 Nov 19.  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175093/ Doi:10.1186/1472-
684x-12-42  
 
Hsu, M.Y., McCormack, B. (2011). Using narrative inquiry with older people to 
inform practice and service developments. Journal of Clinical Nursing. Mar; 
21(5-6): 841-849. 
 
Hughes-Jones, N.C., Wicramasinghe, S.N., Hatton, C.S.R. (2008). Lecture 
Notes on Haematology. Wiley Blackwell Science. 
 
Jabbour, E., Kantarjian, H.M., Koller, C. and Taher, A. (2008) Red blood cell 
transfusions and iron overload in the treatment of patients with 
myelodysplastic syndromes. Cancer, 112: 1089-1095. Doi:10, 
1002/cncr.23280 
 
Joint United Kingdom Blood Transfusion and Tissue Transplantation Services 
Professional Advisory Committee (JPAC). (2013). Regulations and 
Implementation. https://www.transfusionguidelines.org/regulations 
 
Kalolo, J.F (2015). The Drive towards Application of Pragmatic Perspective in 
Educational Research: Opportunities and Challenges Journal of Studies in 
Education Macrothink Institute ISSN 2162 – 6952, Vol. 5, No. 1: 150-171 
http://dx.doi.org/10.5296/jse.v5il.7145 
 
Killick, S. (2017). Iron chelation therapy in low risk myelodysplastic syndrome 
British Journal of Haematology, 177: 375-387. Doi: 10.1111/bjh.14602  
 
184 
Killick, S.B., Carter, C., Culligan, D., Dalley, C., DasGupta, E., Drummond, M., 
Enright, H., et al. (2013) Guidelines for the diagnosis and management of adult 
myelodysplatic syndromes British Journal of Haematology. Volume 164, Issue 
4. Committee for Standards in Haematology.  
 
Kvale, S, (1996). Interviews: An Introduction to Qualitative Research 
Interviewing. Sage Publications. 
 
Kvale, S., Brinkmann, S. (2009). Interviews Learning the Craft of Qualitative 
Research Interviewing Second Edition. Sage Publications. 
 
Labov, W. (1972). The transformation of experience in narrative syntax. In. W. 
Labov (Ed.), Language in the inner-city: Studies in the Black English 
vernacular (p. 354-396). Philadelphia: University of Pennsylvania Press  
 
Labov, W., & Waletzky, J. (1967). Narrative analysis: Oral versions of personal 
experience. In J. helm(Ed.), Essays on the verbal and visual arts (pp.12-44). 
Seattle: American Ethnological Society/University of Washington Press. 
 
LeBlanc, T.W., El-Jawahri, A., (2015). When and why should patients with 
hematologic malignancies see a palliative care specialist? American Society 
of Hematology Education Book, Dec 5, Vol. 2015, No. 1: 471-478  
 
Leibovitz, A., Baumoehl, Y., Walach, N., Kaplun, V., Sigler, E., Balan, S., 
Habot, B (2004) Medical Staff Attitudes: Views and Positions Regarding Blood 
Transfusion to Terminally Ill Cancer Patients American Journal of Clinical 
Oncology: Vol.27, Issue 5, 542-546  
 
Lemley, C.K. & Mitchell, R.W. (2012). Narrative inquiry: Stories lived, stories 
told. Qualitative research: An introduction to methods and designs, 215-242. 
 
Lincoln, Y.S., Guba, E.G. (1985). Naturalistic Inquiry. SAGE Publications.  
 
Lindsay, G. M., Schwind, J.K. (2016). Narrative Inquiry Experience Matters. 
Canadian Journal of Nursing Research. SAGE journals.  
 
Mast, A.E., Field, J.J. (2012). Iron chelation therapy in patients with 
transfusion-dependent myelodysplastic syndrome. Transfusion. Oct; 52(10), 
2078-2080.  
 
Mattingly, C. (1994). The concept of therapeutic ‘emplotment’. Social Science 
Medicine Mar; 38(6): 811–822.  
 
McCabe, C. (2004). Nurse-patient communication: an exploration of patients’ 
experiences Journal of Clinical Nursing. Jan; 13(1): 41-49.  
 
McCaughan, D., Roman, E., Smith, G. A., Johnson, M., Patmore, R., Howard, 
M., Howell, D.A. (2017). Determinants of hospital death in haematological 
Cancers: findings from a qualitative study. BMJ Supportive and Palliative Care. 
Published Online 2017: 1-9. Doi:10,1136/bmjspcare-2016-001289.  
185 
McCaughan, D., Roman, E., Smith, A.G., Garry, A.C., Johnson, M.J., Patmore, 
R.D., Howard, M.R., Howell, D.A. (2018). Palliative care specialists’ 
perceptions concerning referral of haematology patients to their services: 
findings from a qualitative study. BMC Palliative Care 17(1):33. Retrieved from 
BMC Palliative Care https://doi.org/10.1186/s12904-018-0289-1 pdf 
 
McCracken, G. D. (1988). The Long Interview. Newbury Park, CA: Sage 
Publications. 
 
McGrath, P. (2001) Caregivers’ insights on the Dying Trajectory in Hematology 
Oncology. Cancer Nursing. Vol.24,5:413-421 
 
McGrath, P. (2002). End-of- Life Care for Hematological Malignancies: the 
‘Technological Imperative’ and Palliative Care. Journal of Palliative Care; 
Spring; 18, 1; ProQuest Medical Library: 39-47.  
 
McGrath, P. (2002). Qualitative findings on the experience of end-of-life care 
for hematological malignancies. American Journal of Hospice and Palliative 
Care. Vol. 19, Number 2, March/April: 103- 111. 
 
McGrath, P. (2004) Affirming the Connection: Comparative findings on 
Communication Issues from Hospice Patients and Hematology Survivors. 
Death Studies. 28: 829-848. 
 
McGrath, P. (2014). Haematology and palliative medicine: moving forward. 
Annals of Palliative Medicine. Volume 3, number 1:16-17. doi: 
10.3978/j.issn.2224-5820.2013.12.01 
http://apm.amegroups.com/issue/view/160/   
 
McGrath, P. and Holewa, H. (2007) Special considerations for haematology 
patients in relation to end-of-life care: Australian findings.  European Journal 
of Cancer Care, 164-171. Google Scholar 
 
McLellan, E., MacQueen, K., Neidig (2003). Beyond the Qualitative Interview: 
Data Preparation and Transcription. Field Methods. Volume 15, Number 1, 
February, p. 63-84. Sage Publication. 
 
Mercadante, S., Ferrera, P., Villari, P., Fabrizio, D., Giarratano, A., Riina, S. 
(2009) Effects of Red Cell Transfusion on Anemia-Related Symptoms in 
Patients with Cancer Journal of Palliative Medicine Vol.12, Number 1: 60-63. 
 
Melin-Johansson, C., Odling, G., Axelsson, B., Danielson, E. (2008) The 
meaning of quality of life: Narrations by patients with incurable cancer in 
palliative home care. Palliative and Supportive Care 6, 231-238. 
 
Miettinen, R. (2000) The concept of experiential learning and John Dewey's 
theory of reflective thought and action. International Journal of Lifelong 
Education, 19:1, 54-72, DOI: 10.1080/026013700293458 
 
186 
Mishler, E.G. (1986). Research Interviewing: Context and narrative. 
Cambridge, MA: Harvard University Press.   
 
Monti, M., Castellani, L., Berlusconi, A., Cunietti, E. (1996). Use of Red 
Blood Cell Transfusions in Terminally Ill Cancer Patients Admitted to A 
Palliative Care Unit. Journal of Pain and Symptom Management. 12: 18-22 
 
Morgan, D.L. (2014). Pragmatism as a Paradigm for Social Research. 
Qualitative Inquiry. Vol. 20(8), 1045-1053. SAGE.  
DOI: 10.1177/1077800413513733  
 
Munch, T.N., Zhang, T., Willey, J., Palmer, J.L., Bruera, E. (2005). The 
association between anemia and fatigue in patients with advanced cancer 
receiving palliative care. Journal of Palliative Medicine. Dec; 8(6), 1144-1149.  
 
Murray, M. (2008). Narratives, health and illness. Keele: Keele University 
Press. 
 
Murray, S.A., Kendall, M., Carduff, E., Worth, A., Harris, F.M., Lloyd, A., 
Cavers, D., Grant, L., Sheikh, A. (2009). Use of serial qualitative interviews to 
understand patients’ evolving experiences and needs. BMJ. Sept 28, 339 
 
National Cancer Intelligence Network (NCIN) (2011) Where do patients with 
blood cancers die? www.ncin.org.uk/databriefings  
 
National Council for Palliative Care, (2015) ‘Every moment counts: a narrative 
for person centred co-ordinated care for people near the end of life’ 
https://www.nationalvoices.org.uk/sites/default/files/public/publications/every
_moment_counts.pdf 
 
National Health Service (2012). A framework for NHS patient experience. 
Department of Health and Social Care. 21 Feb. 2012. http://www.gov.The NHS 
Patient Experience Framework. Publications policy and guidance. 
http://www.gov.uk/government/news/a-framework-for-nhs-patient-experience 
 
National Health Service (2014). NHS Actions for End of Life Care: 2014-16. 
NHS England.  
 
National Palliative and End of Life Care Partnership. (2015). Ambitions for 
Palliative and End of Life Care: A national framework for local action 2015 – 
2020. www.endoflifecareambitions.org.uk 
 
National Institute for Clinical Excellence. (NICE) (2003) Guidance on Cancer 
Services: Improving Outcomes in Haematological Cancer. The Manual. 
National Health Service, London, UK. http://www.nice.org.uk  
 
National Institute for Health and Care Excellence. (2015). Blood Transfusion 
guidelines (NG 24). November 2015. 
 
187 
National Quality Board (2015). Improving experiences of care: Our shared 
understanding and ambition.  
 
NHS Blood and Transplant, (2016). 2016 National Comparative Audit of Red 
Blood Cell Transfusion in Hospices. National Health Service. 
 
Niebuhr, H.R. (1963). The Responsible Self An essay in Christian Moral 
Philosophy Westminster John Knox Press. Louisville, Kentucky. ISBN 0-664-
22152-1 
 
Nursing Midwifery Council (2015) The Code: Standards of Conduct, 
Performance and Ethics for Nurses and Midwives (NMC) www.nmc-
uk.org/Nurses-andmidwives/Thecode/The-code-in-full/ 
 
Norfolk, D. (2013). Handbook of Transfusion Medicine. United Kingdom Blood 
Services. 5th edition. TSO: available form www.tsoshop.co.uk  
 
Nowell, L. (2015). Pragmatism and integrated knowledge translation: exploring 
the compatabilities and tensions Nursing Open by John Wiley and sons Ltd. 
doi:10.1002/nop2.30  
 
Okri, B. (1997). A way of being free. London: Phoenix House. 
 
Orme, J., Still, D., Day, R., Evans, J., Perkins P. (2013). The experiences of 
patients undergoing blood transfusion in a day hospice. International Journal 
of Palliative Nursing. Vol, 19. Issue 4: 171- 176. April.  
 
Pandey, S, Vyas, G.N. (2012). Adverse effects of plasma transfusion. 
Transfusion. 52 (Suppl 1), p. 65S–79. 
 
Patterson, W. (2000). Reading Trauma: Exploring the relationship between 
narrative and coping. Nottingham Trent University. PhD thesis.  
 
Patterson, W. (2013). Narratives of events: Labovian narrative analysis and its 
limitations. In: M. Andrews., C, Squire., and M. Tamboukou (eds.). Doing 
Narrative Research. Second Edition. Sage publications Ltd. 
 
Patton, M. (2002). Qualitative research and evaluation method, third edition, 
Thousand Oaks, CA: Sage Publications.  
 
Personal Narratives Group (1989). Truths. In Personal Narratives Group (Ed.), 
Interpreting women’s lives: Feminist theory and personal narratives (p. 261-
264). Bloomington: Indiana University Press.  
Polkinghorne, D.E. (2007). Validity Issues in Narrative Research. Sage 
journals. Volume 13, issue 4: 471-486. 10.1177/1077800406297670. 
 
Polit, D., Beck., C.T. (2010). Generalization in quantitative and qualitative 
research: Myths and strategies International Journal of Nursing Studies Vol. 
47(11): 1451-1458 doi: 10.1016/j.ijnurstu.2010.06.004 
 
188 
Polit, D., Beck, C.T., Hungler, B.P (2001) Essentials of Nursing Research: 
Methods, Appraisal and Utilization. 5th Edition, Lippincott, Philadelphia  
 
Popovsky, M.A., Robillard, P., Schipperus, M., Stainsby, D., Tissot, Wiersum, 
J. (2006). Working Party on Hemovigilance. Proposed standard definitions for 
surveillance of non-infectious adverse transfusion reactions. Available from: 
http://www.ihn-org.com/wp-content/uploads/2011/06/ISBT-definitions-for-
non-infectious-transfusion-reactions.pdf.  
 
Preston, N.J., Hurlow, A.; Brine, J., Bennett, M.I. (2012). Blood transfusions 
for anaemia in patients with advanced cancer. Cochrane database of 
Systematic Reviews, Issue 2. Art. No.: CD009007. DOI: 10. 1002/14651858. 
CD009007.pub2 
 
RCN Policy Unit. (2006). Acute and Multidisciplinary Working. The Royal 
College of Nursing of the United Kingdom and the Royal College of Physicians 
(London). Policy Statement 16/2006  
https://www.rcn.org.uk/about-us/policy-briefings/pol-1606 
 
Reilly, R.C., Lee, V., Laux, K., Robitaille, A. (2018). Using found poetry to 
illuminate the existential and posttraumatic growth of women with breast 
cancer engaging in art therapy. Qualitative Research in Psychology. Jan. 
Volume 15, Issue 2-3: 196-217. 
 
Richardson, L (1994). Writing: a method of inquiry. In N. Denzin & Y. Lincoln 
(Eds.), Handbook of Qualitative Research. London: Sage Publications. 
 
Ricouer, P. (1991). Life in Quest of narrative, in (ed) Wood, D. Paul Ricoeur: 
narrative and interpretation (pp. 20-33), Routledge, London.  
 
Riessman, C. K. (1993). Narrative Analysis: Qualitative Research Methods 
Series 30. A Sage Publications. 
 
Riessman, C.K. (2002). Analysis of Personal Narratives. In J. Gubrium and 
Holstein (eds), Handbook of Interview Research Thousand Oaks: SAGE. 
 
Riessman, C.K. (2005). Exporting ethics: a narrative about narrative research 
in South India. Health: An Interdisciplinary Journal for the Social Study of 
Health, Illness and Medicine. Volume 9(4): 473 – 490. SAGE Publications.  
 
Riessman, C. K. (2008). Narrative Methods for the Human Sciences. 
Thousand Oaks, CA: SAGE Publications. 
 
Ritchie, J., Lewis, J. (2006) Qualitative Research Practice. A Guide for Social 
Science Students and Researchers. Sage Publications. 
 
Robson, C. (1). Designing Case Studies In: Robson, C. (ed) Real World 
Research. Blackwell: London 148. 
 
189 
Robinson, J., Gott, m., Gardiner, C., Ingleton, C. (2015). The impact of the 
environment on patient experiences of hospital admissions in palliative care. 
BMJ Supportive and Palliative Care. White Rose Consortium University of 
Leeds, Sheffield and York.  
 
Robinson, S., Harris, A., Atkinson, S., Atterbury, C., Bolton-Maggs, P., Elliot, 
C., Hawkins, T, Hazra, E., Howell, C., New, H., Shackleton, T., Shreeve, K., 
Taylor, C. (2017). The administration of blood components: a British Society 
for Haematology Guideline. Transfusion Medicine. Feb; 28(1): 2-21. British 
Blood Transfusion Society. doi: 10.1111/time.12481 
 
Roubinian, N.H., Hendrickson, J.E., Triulzi, D.J., Gottschall, J.L., 
Michalkiewicz, M., Chowdhury, D, et al. (2018). Contemporary Risk factors 
and Outcomes of Transfusion-Associated Circulatory Overload. Crit Care 
Med. April; 46(4): 577-585.  
 
Rowlands, J., Noble, S. (2008). How does the environment impact on the 
quality of life of advanced cancer patients? A qualitative study with implications 
for ward design. Palliative Med. Sept.; 22(6): 768-774 
 
Ruspini, E. (2002). An Introduction to Longitudinal Research. Routledge.  
 
Sandlowski, M. (1991). Telling stories: Narrative approached in qualitative 
research. IMAGE: Journal of Nursing Scholarship, 23, p. 161-166. 
 
Sant, M., Allemani, C., Tereanu, C., De Angelis, R., Capocaccia, R., Visser, 
O., Marcos-Gragera, R., Maynadie´, M., Simonetti, A., Lutz, J-M., Berrino, F., 
and the HAEMACARE Working Group (2010). Incidence of hematologic 
malignancies in Europe by morphologic subtype: results of the HAEMACARE 
project. Blood 116: 3724-3734. Doi: 10.1182/blood-2010-05282632  
 
Schick Makaroff, K.L., Sheilds, L., Molzahn, A. (2013). Stories of chronic 
kidney disease: listening for the unsayable Journal of Advanced Nursing 
Volume 69, Issue 12: 2644-2653, Dec. https://doi.org/10.1111/jan.12149 
  
Schrijvers, D., de Samblanx, F., Roila, F. (2010). Erythropoiesis-stimulating 
agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice 
Guidelines for use. Annals of Oncology. Volume 21, Issue suppl- 5, 1 May: 
244-247. 
 
Schwartz, B. (1975). Queuing and Waiting: Studies in the Social Organisation 
of Access and Delay. Chicago: University of Chicago Press. In: Good Days 
Bas Days. The Self in Chronic Illness and Time. (Eds.) K. Charmaz (1997). 
 
Seidman, I.E. (1991). Interviewing as qualitative research: A guide for 
researchers in education and the social sciences. New York, NY, US: teachers 
College Press.  
 
190 
Shaw, J. (2017). Thinking with stories. A Renewed Call for Narrative Inquiry 
as a Social Work Epistemology and Methodology. Canadian Social Work 
Review. Volume 34, Issue 2: 207-227,  
 
Sheldon, F., Sargeant, A. (2009). Ethical and practice issues in qualitative 
research. In: Research Methods in Palliative Care (Eds.) J.M. Addington-Hall., 
Eduardo Bruera., Irene J Higginson., Sheila Payne. (chapter 10, p. 163-179) 
Oxford university Press.  
 
Sjollema, S.D., Hordyk, S., Walsh, C.A., Hanley, J., Ives, N. (2012). Found 
poetry – Finding home: A qualitative study of homeless immigrant women. 
Journal of Poetry Therapy. Dec, Volume 25, Number 4:205-217. 
 
Smith, B. (2016). Narrative analysis. In E. Lyons and A. Coyle (Eds.) Analysing 
qualitative data in psychology (2nd ed) (p. 202-221). London: sage.  
 
Smith, L.B., Cooling, L., Davenport, R. (2013). How do I allocate blood 
products at the end of life? An ethical analysis with suggested guidelines. 
Transfusion (4): April 696-700. http://hdl.handle.net/2027.42/97526  
ISSN: 0041-1132, 1537-2995 DOIs: 10.1111/j.1537-2995.2012.03658.x 
 
Smith, A., Howell, D., Patmore, R., Jack, A., & Roman, E. (2011). Incidence of 
haematological malignancy by sub-type: a report from the Haematological 
Malignancy Research Network Br J Cancer. Nov. 22 105(11): 1684-1692. Doi: 
10.1038/bjc.2011.450 
 
Speck, P. (2009). How to gain research ethics approval. In J.A. Addington-
Hall, E. Bruera, I.J. Higginson, S. Payne (Eds). Research Methods in Palliative 
Care: 275-282. 
 
Squire, C. (2013). From experience-centred to socioculturally-orientated 
approaches to narrative. Doing Narrative Research. P. 47-71. (eds.) M. 
Andrews, C. Squire, M. Tamboukou. (second edition).   
 
Strauss, A., Corbin, J.M. (1990). Basics of qualitative research: Grounded 
theory procedures and technique. Thousand Oaks, CA, US: Sage 
publications, Inc.  
 
Street, J., Khan, W., Tong, A., Shanbhag, V. (2017). Improving waiting times 
in the orthopaedic outpatient clinic. BMJ Open Qual. 2017: 6:  
e000067.doi:10.1136/bmjoq-2017-000067   
 
Swerdlow, S.H., Campo, E., Harris, N.L, et al. (2008). WHO Classification of 
Tumours of haematopoietic and Lymphoid Tissues. Lyon, France: IARC 
Press. 
 
Szende, A., Schaefer, C., Goss, T.F., Heptinstall, K., Knight, R., Lubbert, M., 
Deschler, B., et al. (2009) Valuation of transfusion-free living in MDS: results 
of health utility interviews with patients Health Quality of Life Outcomes 
Volume 7:81 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2746210/ 
191 
Tanneberger, S., Melilli, G., Strocchi, E., Frenquelli, C., Pannuti, Q. F. (2004). 
Use of red blood cell transfusion in palliative care services: is it still up to date 
or is cancer-related anaemia controlled better with erythropoietic agents? 
Annals of Oncology, Volume 15, Issue 5, 1 May: 839-840 
https://doi.org/10.1093/annonc/mdh178  
 
Thomas, S., Glynne-Jones, R., Chait, I. (1997). Is it worth the wait? A survey 
of patients’ satisfaction with an oncology outpatient clinic. Eur J Cancer Care. 
(England). Mar; 6(1): 50-58. 
 
Tierney, S., Seers, K., Tutton, E., Reeve, J. (2017). Enabling the flow of 
compassionate care: a grounded theory study. BMC Health Services 
Research. 17:174: DOI 10.1186/s12913-017-2120-8.  
 
Trimm, D.R., Sanford, J.T. (2010). The Process of Family Waiting During 
Surgery. Journal of Family Nursing 16(4):435-461.  
doi: 10.1177/1074840710385691 
 
Tropea, S. (2011). ‘Therapeutic emplotment’: A new paradigm to explore the 
interaction between nurses and patients with a long-term illness. Journal of 
Advanced Nursing.68(4): 939-947. 
 
Vo, L.C., Mounoud, E., Rose, J. (2012). Dealing with the opposition of rigor 
and relevance from Dewey’s pragmatist perspective M@n@gement Vol. 15. 
No. 4: 367-390  
 
vonPlessen, C., Aslaksen, A. (2005). Improving the quality of palliative care 
for ambulatory patients with lung cancer. BMJ. June 4; 330(7503): 1309-1313.  
 
Wang, X, S. (2008). Pathophysiology of Cancer-Related Fatigue. Clinical 
Journal Oncology Nurs. October’ 12(5 Suppl): 11-20. 
 
Wang, C.C., Geale, S.K. (2015). The power of story: Narrative inquiry as a 
methodology in nursing research. International Journal of Nursing Sciences. 
Vol. 2. Issue 2. June. p. 195-198. Elsevier.  
 
Wang, C.C., Andre, K., and Greenwood, K.M. (2015). Chinese students 
studying at Australian universities with specific reference to nursing students: 
A narrative literature review. Nurse Education Today 35(4): 195-208. doi: 
10.1016/j.nedt.2014.12.005 http://ro.ecu.edu.au/ecuworkspost2013/167/ 
 
Watchel, T.J., Mor, V. (1985) The use of transfusion in terminal cancer 
patients: hospice versus conventional care setting. Transfusion. 25: 113-115 
Watson and Royle. (1987) Watson’s Medical-Surgical Nursing and Related 
Physiology Third Edition, p. 250 Bailliere Tindall. 
 
Williams, G. (1984). The genesis of chronic illness: narrative reconstruction, 
Sociology of Health and Illness, 6, 175-200. 
 
192 
Williams, C., Gardiner, C. (2015). Preference for a single or shared room in a 
UK inpatient hospice: patient, family and staff perspectives. BMJ Supportive 
and Palliative Care. 5(2), p. 169-174. https://doi.org/10.1136/bmjspcare-2013-
000514   
 
Wilson, J., Yao, G.L., Raftery, J., Bohlius, J., Brunskill, S., Sandercock, J., 
Bayliss, S., Moss, P., Stanworth, S., Hyde, C. (2007). A systematic review and 
economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in 
anaemia associated with cancer, especially that attributable to cancer 
treatment. Health Technol Assess, April; 11(13), p. 1-202, iii-iv.   
 
World Health Organization (2014) Global Atlas of Palliative Care at the End of 
Life World palliative care alliance World Health Organization  
http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf  
 
Woods, S., Beaver, K., and Luker, K. [2000] Users’ views on palliative care 
services: ethical implications. Nur Ethics. Jul; 7(4): 314-26. DOI: 
10.1177/096973300000700405 
 
Woodwark, C., Dean, A. (2017). Do blood transfusions make a difference 
when you are dying? Progress in Palliative Care: vol. 25, No. 3, p. 126-131.  
 
Yardley, L. (2000). Dilemmas in qualitative health research. Psychology and 
Health. Vol. 15: 215-228. March.  
DOI: 10.1080/08870440008400302  
https://doi.org/10.1080/08870440008400302  
 
Yardley, L (2017). Demonstrating the validity of qualitative research. The 
Journal of Positive Psychology. Vol. 12, No. 3: 295-296 http://dx 
doi.org/10.1080/17439760.2016.1262624. Routledge Taylor Francis Group. 
 
Zeidan, A.M., Pullarkat, V.A., Komrokji. (2017). Overcoming Barriers to 
treating iron overload in patients with lower-risk myelodysplastic syndrome. 
Critical Reviews in Oncology/Hematology. Elsevier. 
 
193 
Appendices 
Appendix 1 Examples of haematological malignancies, presenting features, routes and settings treatments administered 
Haematological Diseases Common Presenting 
Clinical features 
Routes and settings treatments administered 
Acute leukaemia (myeloid or 
lymphoblastic 
Patients commonly very 
unwell with symptoms of 
fatigue and serious 
infection, anaemia 
bruising/bleeding  
Aggressive induction intravenous chemotherapy, followed by 
cycles of consolidation chemotherapy and bone marrow 
transplant if eligible. Patients with acute lymphoblastic 
leukaemia may in addition receive intrathecal chemotherapy. 
Months of in-patient hospitalization necessary. 
Elderly patients not suitable for intensive treatment may 
receive oral or subcutaneous chemotherapy with blood 
transfusion support. 
Chronic myeloid leukaemia Fatigue, weight loss, night 
sweats, anaemia 
splenomegaly. 
Generally oral chemotherapy as an out-patient. Occasionally 
bone marrow transplant and blood transfusions. 
Chronic lymphoblastic leukaemia May be asymptomatic, or 
present with night sweats / 
symptoms of anaemia.  
May require no treatment / oral or intravenous chemotherapy, 
generally, as a day case patient. 
Blood transfusions may be necessary 
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Lymphomas (Hodgkins or Non-
hodgkins) 
Many patients present 
with palpable lump. 
weakness, fatigue, fever, 
anaemia, night sweats, 
weight loss, enlarged 
spleen /liver 
Low grade may require no treatment initially following a ‘watch 
and wait’ regime for instance in follicular lymphoma.  
High grade lymphomas generally require intravenous cycles of 
chemotherapy / radiotherapy administered in an outpatient 
hospital setting. Or may need BMT. 
Blood transfusions may be necessary 
Myeloma End organ damage, 
frequently presenting with 
bone fractures, kidney 
problems, anaemia. 
Numerous chemotherapy treatments available – oral or IV as 
an inpatient or day case patient. 
Blood transfusion supportive therapy. 
Myelodysplastic syndromes Patients are generally 
anaemic with related 
symptoms  
Most patients require a blood transfusion. Chemotherapy 
administration, however, is largely dependent on factors, for 
instance, age, previous chemotherapy, number of blast cells in 
the blood or bone marrow. Some patients may receive AML 
treatment regime 
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Appendix 2 Letter of invitation to participant 
 
Blood Transfusions in Palliative Haematology: Patient Stories  
 
Dear Mr / Mrs 
 
My name is Laraine Lloyd. I am a registered nurse specialised in the care of 
Haematology patients. I am currently undertaking a research study as part of 
a professional doctorate in nursing at the University of Portsmouth.  
 
The purpose of the study is to try and understand the experiences of patient’s 
(like yourself) of attending the hospital or hospice for regular blood 
transfusions after being diagnosed with a palliative stage haematological 
illness. Little research has been conducted on out patients like you who need 
regular blood transfusions. I would like to hear your experiences as it is hoped 
that by asking patients themselves about their experiences it may help the 
nurses and doctors to understand patient’s needs so that we may find more 
ways to support them.  
 
I am hoping to interview 15-20 patients during a twelve-month period between 
April 2012 and April 2013. If you are willing to take part, you will be invited to 
share your stories about your experiences of having blood transfusions. 
Taking part in the study would involve you being interviewed by me on three 
occasions. The interviews will take place on the same day and in the same 
setting as you are having your blood transfusion, unless you would prefer for 
me to come out to your home to conduct the interview. Family or friends are 
invited to be with you during the interview, if you prefer.  
 
The interview will be audio recorded and will last between 20 minutes to 1 
hour, depending on what you would like to share at interview. You can stop 
the interview at any time.  
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I have attached a copy of the information sheet, which gives more details on 
what taking part in the study involves. Take your time reading this information 
and please feel free to show it to your family, friends or GP. If you would like 
to find out more about taking part in this research study or would like to discuss 
the study further, any of the following people would be more than happy to 
discuss it with you: 
Laraine Lloyd Haematology Nurse Practitioner 01256 313925 or 01256 
433202 Bleep 1143 
(Names have now been removed for confidentiality). 
 
Thank you for reading this letter. 
Laraine Lloyd 
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Appendix 3 Participant information sheet 
 
Study title 
Blood Transfusions in Palliative Haematology: Patient Stories Version 1 
Invitation paragraph 
You are being invited to take part in a research study about your experiences 
of having a blood transfusion. Before you decide whether to take part, it is 
important for you to understand why this research is being done and what it 
will involve. Please take as much time as you wish to read the following 
information carefully and discuss it with your family, friends, GP or any of the 
contacts at the end of this information sheet, if you wish. Please do not hesitate 
to ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
The purpose of this study is to try and understand what it is like for patients 
to attend the hospital or hospice regularly to have a blood transfusion after 
being diagnosed with an illness that affects your bone marrow 
(haematological illness) 
Why have I been chosen? 
You are being asked to take part in this study because you have a 
haematological illness and you have blood transfusions regularly. 
 
Do I have to take part? 
You do not have to take part in this study. It is completely up to you whether 
or not to take part. If you do decide to take part, you will be given this 
information sheet to keep and be asked to sign a consent form during your 
next appointment for your blood transfusion. If you decide to take part, you are 
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still free to withdraw at any time and without giving a reason. This will not affect 
your legal rights or the standard of care you receive now or in the future.  
 
What will happen to me if I take part? 
• The researcher will ask for your permission to write to your GP to let 
them know that you are taking part in this study. 
• The researcher will ask your permission to take information from your 
medical notes. Information such as, your date of birth, your diagnosis, 
your marital status, the date when you had your first blood transfusion 
and the dates of all the blood transfusions you have had since 
• On the day of your blood transfusion you will be asked to fill out a short 
health questionnaire. The questionnaire has 5 short questions which 
will ask you to rate your health on that day. It is expected to take just a 
few minutes to complete. Please do not worry the researcher will show 
you the questionnaire and go over it with you and explain what is 
needed. 
•  You will be interviewed about your experiences of having blood 
transfusions. The interview will take place where you are having your 
blood transfusion (either the haematology day unit or the hospice day 
unit), or if you prefer the researcher can come to your home to interview. 
Family or friends are invited to be present during the interview if you 
would like them to be. 
• Following your first interview you will be interviewed on the day of your 
next two blood transfusions. You will be interviewed a maximum of 
three times in total  
• It is anticipated that interviews will last about 20minutes to an hour 
depending on what information you want to share. When you want to 
stop the interview, it will be stopped immediately.  
• The Researcher will check with you during the interview to make sure 
you are comfortable and would like to continue. If you want to stop for 
any reason and continue the interview at another time it is ok to do this. 
• The interviews will be tape recorded and later written up by the 
researcher. If you do not want to be taped the researcher may take 
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notes throughout the interview to make sure that what you have told her 
is noted down and not forgotten. 
• You will be offered a copy of what has been written up (a transcript) so 
that you can change, cross out or add anything on this transcript. You 
do not have to read the transcript if you do not want to 
If you decide to take part in this study, you will not be required to make any 
additional visits to the hospital or have any additional blood tests. 
 
How long will I be in the study? 
Once you have consented to take part in the study you will be interviewed at 
your next blood transfusion appointment. Following this first interview you will 
be interviewed two more times. It is hoped that these interviews will happen 
consecutively (that is one after the other at each blood transfusion 
appointment). Usually blood transfusions are given 2 - 3 weeks apart. This 
means that you may be in the study between 6 – 9 weeks in total.  
The study will be conducted over a 12-month period and it is hoped to recruit 
between 15 - 20 people in total. 
What are the possible disadvantages and risks of taking part? 
Discussing your experiences may make you feel sad or emotional and may 
be distressing. 
A counsellor, who is specialised in caring for patients with your type of 
illness, is employed at the Trust to provide support and advice. She is 
available to help you if you would like to see her. 
What are the possible benefits of taking part? 
You may not receive any direct benefit from taking part in this study, 
however, we are hoping that talking about your experiences and ‘sharing 
your stories’ may help you and other patients in the future.  
It is hoped that the information you provide will enable our blood transfusion 
care to be improved based on what you tell us.  
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What if something goes wrong? 
If you wish to complain or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms will be available to you. Any 
of the people listed at the end of this information sheet will be happy to advise 
you on how to do this, if needed.  
 
Will my taking part in this study be kept confidential? 
• Your GP will be informed that you are taking part in this study 
• Only the researcher and the medical team taking care of you will have 
access to any study information 
• The researcher will need your permission to use personal details taken 
from your medical notes, including for instance; your date of birth, your 
diagnosis and your marital status. Confidentiality of your medical 
records will be maintained throughout the study 
• All information which is collected about you during the course of this 
study will be kept strictly confidential. Information about you will not 
have your name on it, so that you cannot be recognised from it. 
• All study data will be kept in a locked cupboard that can only be 
accessed by the researcher 
• Any study information on the researcher’s computer will be password 
protected 
• When the final report of the study is made, and the results are published 
you will not be individually identified.   
 
What will happen when the research study stops? 
When the research study stops you will be offered a summary of the 
information gained during the study. This information may help decide how 
best to treat patients, like you, in the future. 
 
What will happen to the results of the research study? 
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• A report of the study will be written up. The researcher will seek to 
publish an article in a suitable nursing journal. The results may also be 
presented at a suitable conference 
• You will be offered a copy of this report if you would like to receive a 
copy. The researcher will discuss this with you during your blood 
transfusion  
 
Who is organising and funding the research? 
Sponsorship for the study has been gained from (name of the employing 
hospital) Hospitals NHS Foundation Trust. There has been no application for 
funding 
 
Who has reviewed the study? 
• The study’s research steering group from The NHS Trust. This group 
includes two members from the ‘Patient Voice Forum’ and ‘Cancer 
Partnership Group’ (who are a panel of general public volunteers).  
• A letter explaining the study has been sent to your medical consultant, the 
director of nursing and the modern matron for cancer services 
• The University of Portsmouth Ethics Committee 
• The Hospitals Research and Development Clinical Governance Committee 
(Address removed for confidentiality) 
The Local Research Ethics Committee has approved this study. Approval 
does not mean that you are recommended to take part. You are entirely 
free to make that decision yourself 
 
What will happen if I have questions when I am in the study? 
If you decide to take part in the study please feel free to ask questions 
concerning the study, or seek help or advice, at any time from any of the 
following people; 
Names removed for confidentiality 
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How you can get more information before you decide whether to take part or 
not? 
If you have any questions concerning this study or require additional 
information, please do not hesitate to contact any of the people listed above 
who will be more than willing to offer advice or support. 
Consumers for Ethics in Research (CERES) publish a leaflet entitled’ Medical 
Research and You’. This leaflet gives more information about medical 
research and looks at some questions you may want to ask. A copy may be 
obtained from CERES, PO Box 1365, London, N16 0BW. Your CNS (names) 
will be pleased to obtain a copy for you. 
You will be given a copy of this information sheet and a signed consent form 
to keep. 
Thank you for taking the time to read this information sheet. 
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Appendix 4 Participant Consent Form 
 
Blood Transfusions in Palliative Haematology: Patient Stories Version 1 
please write your initials in each box 
 
I have read and understood the information sheet (version 1, dated 11  
January 2012) for the above study and have had the opportunity to 
ask questions. 
 
I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, and without my 
medical care or legal rights being affected. 
 
I understand that the interviews will be tape recorded but that I can 
stop the interview at any time without having to give an explanation. 
 
I understand that my medical notes may be looked at by the 
researcher and that all information will remain strictly confidential. 
 
I agree that all information collected about me as part of the study can 
be stored and analysed by the research team in this study. 
 
I understand that what I say may be quoted anonymously when the 
results of this research study are reported. 
 
I agree to take part in the above study. 
 
Name of participant   Signature    Date 
 
Name of practitioner  Signature    Date 
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Appendix 5 Case Report Form 
 
 
CASE REPORT FORM 
 
Blood Transfusions in Palliative Haematology: Patient Stories.  
Version 1. 11/01/2012 
 
 
CLINICAL STUDY SITE: (Name of Hospital) 
 
 
Chief Investigator: Laraine Lloyd 
 
 
 
 
SITE BLOOD TO BE ADMINISTERED: (Please circle as appropriate) 
 
Haematology Day Unit  
 
Hospice 
 
Community Hospital 
 
 
 
I am confident that the information supplied in this case record form is 
complete and accurate data. I confirm that the study was conducted in 
accordance with the proposal and any proposal amendments and that 
written informed consent was obtained prior to the study. 
 
Investigator’s signature: 
 
Date of Signature: 
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SCREENING VISIT 
Date: 
Inclusion Criteria: [Please circle as appropriate} 
1. Has the participant willingly given written Informed Consent? YES     NO 
 
2. Is the participant aged between 18 and 90?                           YES    NO 
 
 
3. Does participant have a palliative phase haematological malignancy or 
illness?                                                                                  YES    NO 
 
 
4. Has participant ceased to receive curative chemotherapy?      YES    NO 
 
 
5. Is participant receiving blood transfusions within HDU or Hospice or 
community hospital?                                                               YES    NO 
 
If any criteria are circled NO then the participant is not eligible for the 
study 
Exclusion Criteria: 
1. Participant is unable to provide Informed consent                 YES    NO 
 
 
2. Participant is cognitively impaired                                          YES    NO 
 
 
3. Participant is unable to speak or understand English sufficiently to 
take part in this study                                                             YES    NO 
 
4. Participant is aged below 18 or over 90                                 YES    NO 
If any criteria are circled YES then the participant is NOT eligible for the 
study 
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SCREENING VISIT 
INFORMED CONSENT 
 
Please note: written informed consent must be given before any study 
specific procedures take place for the purpose of participation in this study. 
 
Has the participant freely given written informed consent? (Please circle as 
appropriate) YES     NO 
 
 
DEMOGRAPHIC DATA: (please circle as appropriate) 
 
Age (years): 
 
Gender: FEMALE     MALE 
 
Marital Status: Married (M)   Widowed (W)   Single (S)   Divorced (D) 
 
 
PREVIOUS BLOOD TRANSFUSION (BT) HISTORY: (please circle) 
 
Has the participant previously had a blood transfusion?      YES    NO 
 
How many previous BT has participant had? 
 
Date of first ever BT? 
 
 
HAEMATOLOGICAL DIAGNOSIS: (please circle as appropriate) 
 
Does the participant have a haematological malignancy YES NO 
If yes, please circle disease category below:  
 
AML      ALL      CML      CLL      NHL      HD      MYELOMA      MDS 
 
 
  
 207 
SCREENING VISIT 
MEDICATIONS TAKEN: (please circle as appropriate) 
 
Is Participant currently taking any medicine?                              YES   NO 
 
If YES Please record all medications below: 
1. 
 
2. 
 
3. 
 
4. 
 
5. 
 
 
PHASE OF HAEMATOLOGICAL DISEASE / ILLNESS  
(Opinion regarding phase of disease to be assessed only by participants’ 
medical team and phase documented in medical notes) 
PHASE DEFINITION (please circle as appropriate) 
Early 
Palliative 
Phase 
The patient is incurably ill 
The condition typically lasts twelve months                 YES 
Late Palliative 
Phase  
The participant is incurably ill 
The condition typically lasts for months                      YES 
Terminal 
Palliative 
Phase 
Disease 
The patient is terminally ill and dying 
The condition leads to death within days/weeks/less than 
six months                                                                    YES 
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SCREENING VISIT 
HAEMOGLOBIN LEVEL PRE-TRANSFUSION (TODAY) 
Date today 
Haemoglobin level (g/dL) 
 
End of visit checklist: to be completed by investigator (Please circle as 
appropriate) 
 
1. Does the participant satisfy inclusion and exclusion criteria    YES  NO 
 
2. Have all screening procedures been completed                      YES  NO 
 
3. Has concomitant medication page been completed                YES  NO 
 
4. Is the Participant willing to proceed                                         YES  NO 
 
Investigator 
Is the Participant to continue                                                          YES  NO 
 
Signature                                                                      Date 
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FIRST BLOOD TRANSFUSION SINCE RECRUITMENT 
Date 
PHASE OF HAEMATOLOGICAL DISEASE / ILLNESS (Opinion 
regarding phase of disease to be assessed only by participant’s medical 
team and phase documented in medical notes.) 
PHASE DEFINITION (please circle as appropriate) 
Early 
Palliative 
Phase 
The patient is incurably ill 
The condition typically lasts twelve months. 
Late Palliative 
Phase  
The participant is incurably ill 
The condition typically lasts for months                      YES 
Terminal 
Palliative 
Phase  
The patient is terminally ill and dying 
The condition leads to death within days/weeks/less than 
six months                                                                  YES 
 
HAEMOGLOBIN LEVEL PRE-TRANSFUSION (TODAY) 
Date today 
 
Haemoglobin level (g/dL) 
 
HAS PARTICIPANT COMPLETED EUROQoL HEALTH 
QUESTIONNAIRE (Please circle as appropriate) 
 
YES     NO  
If NO Investigator to complete WHO Performance Status below: 
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FIRST BLOOD TRANSFUSION SINCE RECRUITMENT 
WHO PERFORMANCE STATUS 
Status Description 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature, e.g. Light 
housework, office work 
2 Ambulatory and capable of self-care but unable to carry out work 
activities. Up and about for more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair for 
more than 50% of waking hours 
4 Completely disabled. Cannot carry out any self-care. Totally 
confined to bed or chair 
  
 211 
SECOND BLOOD TRANSFUSION SINCE RECRUITMENT 
Date 
PHASE OF HAEMATOLOGICAL DISEASE / ILLNESS (Opinion 
regarding phase of disease to be assessed only by participant’s medical 
team and phase documented in medical notes.) 
PHASE DEFINITION (please circle as appropriate) 
Early 
Palliative 
Phase 
The patient is incurably ill 
The condition typically lasts twelve months. 
Late Palliative 
Phase  
The participant is incurably ill 
The condition typically lasts for months                      YES 
Terminal 
Palliative 
Phase  
The patient is terminally ill and dying 
The condition leads to death within days/weeks/less than 
six months                                                                   YES 
 
HAEMOGLOBIN LEVEL PRE-TRANSFUSION [TODAY] 
Date today 
 
Haemoglobin level (g/dL) 
 
 
HAS PARTICIPANT COMPLETED EUROQoL HEALTH QUESTIONNAIRE 
(Please circle as appropriate) 
 
YES     NO  
If NO Investigator to complete WHO Performance Status below: 
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SECOND BLOOD TRANSFUSION SINCE RECRUITMENT 
WHO PERFORMANCE STATUS 
Status Description 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature, e.g. Light 
housework, office work 
2 Ambulatory and capable of self-care but unable to carry out work 
activities. Up and about for more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair for 
more than 50% of waking hours 
4 Completely disabled. Cannot carry out any self-care. Totally 
confined to bed or chair 
  
 213 
THIRD BLOOD TRANSFUSION SINCE RECRUITMENT 
Date 
PHASE OF HAEMATOLOGICAL DISEASE / ILLNESS (Opinion 
regarding phase of disease to be assessed only by participant’s medical 
team and phase documented in medical notes.) 
PHASE DEFINITION (please circle as appropriate) 
Early 
Palliative 
Phase 
The patient is incurably ill 
The condition typically lasts twelve months. 
Late Palliative 
Phase 
Disease 
The participant is incurably ill 
The condition typically lasts for months                      YES 
Terminal 
Palliative 
Phase 
Disease 
The patient is terminally ill and dying 
The condition leads to death within days/weeks/less than 
six months                                                                   YES 
 
HAEMOGLOBIN LEVEL PRE-TRANSFUSION [TODAY] 
Date today 
 
Haemoglobin level (g/dL) 
 
HAS PARTICIPANT COMPLETED EUROQoL HEALTH QUESTIONNAIRE 
(Please circle as appropriate) 
 
YES NO 
  
If NO Investigator to complete WHO Performance Status below: 
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THIRD BLOOD TRANSFUSION SINCE RECRUITMENT 
WHO PERFORMANCE STATUS 
Status Description 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature, e.g. Light 
housework, office work 
2 Ambulatory and capable of self-care but unable to carry out work 
activities. Up and about for more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair for 
more than 50% of waking hours 
4 Completely disabled. Cannot carry out any self-care. Totally 
confined to bed or chair 
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OFF STUDY FORM 
 
DATE OFF STUDY: 
 
 
Reason Off Study (Please circle only the primary reason. Reasons other 
than completed study require explanation next to the response) 
 
Completed Study  
 
Lost to follow up 
 
Non-compliant participant 
 
Concomitant medication 
 
Medical contra-indication(s) 
 
Withdraw consent 
 
Death 
 
Other 
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Appendix 6 Initial conversation prior to first, second and third interview 
and prompts employed in study 
 
Prior to the start of our first interview  
Hello (patient’s name) Thank you very much for agreeing to take part in 
our study and for agreeing to talk to me today. I really appreciate it. I would 
like you to tell me in your own words and in your own way about your 
experiences around blood transfusions. I want you to know that it’s fine to 
stop whenever you want. Please just tell me when you want to stop. 
Perhaps we could talk initially about ‘how did it all begin’, when did you 
start having blood transfusions, and ‘then what happened’?  
 
Prior to the start of our second interview  
Hello, thank you for agreeing to see me again today and talk through your 
experiences of blood transfusions. The last time we talked about your 
experiences of blood transfusion we talked about how they made you feel 
and any benefits that you got from them, we talked about your knowledge 
of blood transfusions and the importance of them to you. We also 
discussed any worries or concerns that you may have about BT. Perhaps 
we can just go over some of that again to make sure I understood what 
you meant. Then, perhaps today we could also talk about what it’s like for 
you coming up here to the unit for your blood transfusion, but let’s just start 
off by you telling me how you have been since your last transfusion.  
 
Prior to the start of our third meeting (interview).  
Hello. Thank you for agreeing to see me again. Please we could go over a 
few things to make sure I understood what you meant when we talked 
about…. 
First, perhaps you could tell me how you have been since we last met.  
Please stop whenever you want. 
Are you ok to continue?  
Do you have any other stories about blood transfusions that we haven’t 
talked about that you could share with me? 
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Examples of prompts employed in this narrative study that related to 
the three - dimensional space 
 
Personal / social (feelings, expectations, challenges, concerns);  
Please could you tell me how you feel about BT 
Please could you tell me how receiving BT affects you 
Please could you tell me any worries or concerns that you may have about 
BT  
The effect of your last BT how was it?  
How do you think you would be today, if you had not had your last blood 
transfusion? 
Could you imagine any circumstances that would make you not want to 
come in for your BT? 
I would like to move on to what has happened today.  
Please could you tell me in as much detail as possible about your day so 
far, since you got up this morning 
 
Place (feelings about setting, difficulties associated with setting); 
Please could you tell me about your day here on the day unit 
Please could you describe in as much detail as possible your day so far 
since you got to the Unit.  
What happened when you got here? 
Could you tell me what you expect to happen today? 
 
Temporality: how the experience changed over time;  
Please could you tell me how did it all begin, when did you first start having 
blood transfusions?  
In the beginning how often were you having BT. Then what happened 
Please could you tell me if you think your experiences have changed since 
you first started having blood transfusions 
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Appendix 7 EQ-5D-3L Health Questionnaire 
 
REC: 12/SC/0282 
Participant study Name/number: 
Date: 
 
Blood Transfusions in Palliative Haematology: Patient Stories 
Version number 1. 11/01/2012 
 
Health Questionnaire 
 
English version for the UK 
(validated for Ireland) 
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By placing a tick in one box in each group below, please indicate which 
statements best describe your own health state today. 
 
Mobility 
I have no problems in walking about ❑ 
I have some problems in walking about ❑ 
I am confined to bed ❑ 
 
Self-Care 
I have no problems with self-care ❑ 
I have some problems washing or dressing myself ❑ 
I am unable to wash or dress myself ❑ 
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities ❑ 
I have some problems with performing my usual activities ❑ 
I am unable to perform my usual activities ❑ 
 
Pain/Discomfort 
I have no pain or discomfort ❑ 
I have moderate pain or discomfort ❑ 
I have extreme pain or discomfort ❑ 
 
Anxiety/Depression 
I am not anxious or depressed ❑ 
I am moderately anxious or depressed ❑ 
I am extremely anxious or depressed ❑ 
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Appendix 8 Findings from participant’s self-reported EQ-5D-3L health questionnaire or WHO performance status tool 
PARTICIPANT 
NAME & 
INTERVIEW 
NUMBER 
MOBILITY 
SCORE 
SELF-CARE 
SCORE 
USUAL 
ACTIVITIES 
SCORE 
PAIN 
DISCOMFORT 
SCORE 
ANXIETY 
DEPRESSION 
SCORE 
VAS 
HEALTH STATE 
SCORE 
Kenneth.1 Int.1 2 1 2 1 1 55 
Kenneth.1 Int.2 1 1 2 1 1 80 
Kennet. 1 Int.3 1 1 2 1 1 75 
Jim. 2 Int.1 2 2 2 2 2 40 
Jim. 2 Int.2 2 2 3 2 2 40 
Jim. Int.3 3 3 3 2 2 40 
Harold. Int.1 2 1 2 2 1 70 
Harold. Int.2 2 1 2 2 2 75 
Harold. Int.3 Unable to complete self-reported health questionnaire WHO status 4 
Lily. Int.1 2 1 2 2 1 50 
Lily. Int.2 2 1 2 2 2 50 
Lily. Int.3 2 3 2 1 1 12 
Ernest. Int.1 2 2 2 2 1 40 
Ernest. Int.2 2 2 2 3 1 35 
Ernest. Int.3 2 2 2 2 1 55 
Helen. Int.1 2 1 3 2 3 45 
Helen. Int.2 2 2 3 2 2 29 
Bill. Int.1 2 2 3 1 2 50 
Bill. Int.2 2 3 3 1 3 50 
Zavier. Int. 1 1 1 1 1 2 90 
Zavier. Int. 2 2 1 2 2 1 40 
Zavier. Int. 3 2 1 2 2 1 50 
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Appendix 9 Ethics Committee approval letter 
 
Health Research Authority 
NRES Committee South Central - Portsmouth 
Bristol Research Ethics Centre 
Level 3, Block B 
Whitefriars Lewins Mead 
Bristol 8S1 2NT 
Telephone: 0117 3421334 
Facsimile: 0117 342 044 
 
 
22 May 2012 
 
Mrs Laraine Lloyd 
Haematology Nurse Practitioner 
(Name and address of hospital removed)  
 
Dear Mrs Lloyd 
 
Study title: Blood Transfusion Storylines: Qualitative Study of Patients' Experience of 
Receiving Blood Transfusions throughout Late-Terminal Palliative Trajectory of a 
Haematological Malignancy 
 
REC reference: 12/SC/0282 
 
The Research Ethics Committee reviewed the above application at the meeting held on 18 May 
2012. Thank you and your colleague, Dr Simpson, for attending to discuss the study.  
 
The research intends to listen to the voice of the day patient who regular attends hospital for 
blood transfusions despite being terminally ill. The Committee asked you to give the context of 
the participant's prognosis. You reported that you would be interviewing those who are in the 
terminal stage of their disease and at the palliative stage of their treatment, so within the last 12 
months of their life. The participant may have between around six months and a few weeks left 
to live. 
 
The Committee asked you to give your rationale for your sample size. You reported that a recent 
audit has shown that patient numbers have recently greatly increased on your unit. You have 
considered that you may need to extend the study period to two years. 
 
The Committee asked you whether you were concerned that the consultants will not refer any 
patients to you as potential participants. You reported that you know those you are working with 
very well and you have no concerns that they will refer to you if they feel the patient is suitable 
to take part. The clinicians are well experienced at working with palliative patients and do not 
treat them paternalistically. 
 
The Committee asked you to clarify your reasoning for completing three interviews. You 
explained that you wish to capture the experience of those who are close to death but are still 
coming in and out of hospital regularly for transfusions. You reported you are interested in how 
the experience changes for the patient as they move towards their death and their disease 
progresses. You wish to interview the 
same individual at different time points as this makes for more valid and comparable 
results. The burden on the participant has been considered and discussed at the steering group. 
You reported that you appreciate the time taken by the participant and will lead a gentle 
conversation taking regular breaks to check on the participant and whether they wish to stop or 
rest. 
 222 
You asked the Committee for their advice regarding the feedback of results to study participants. 
You explained that you have received divided opinions regarding how best to manage this. There 
is an argument that asking the participant to read their transcript is burdensome, however, the 
counter argument states that by giving the participant their transcript to read they are able to take 
ownership of their contribution and make any changes they wish to. You reported that you had 
considered the best solution to be discussing the results with the participant and offering them the 
opportunity to receive feedback if they wish. The Committee reported that it had had very similar 
deliberations and agreed that you had offered an appropriate solution. The Committee suggested 
it was made clear to participants that even where they do agree to receive feedback, they are still 
free not to read it if they so wish. You agreed this would be conveyed. 
 
You asked the Committee for its opinion regarding patients who die before the results become 
available to feedback and whether their relatives should be informed of the results in their place. 
The Chair reported that the Committee would give the issue some consideration. You reported 
that you had considered methods of dissemination such as including a summary in the leukaemia 
newsletter. You confirmed that if relatives of deceased participants did receive the results, these 
would be themes only; they would not be individual transcripts. Dr Simpson explained that when 
a patient dies; their relatives are offered an appointment to discuss clinical matters and any other 
related information, such as participation in research. 
 
The Committee asked you to clarify whether you are involved in the care of the participants. You 
explained that you will know the majority. You clarified that you are not generally involved in 
giving transfusions but is called upon if there is a problem. You have given some consideration 
to the issue of being a researcher and a nurse and explained that you will be very clear that you 
are a researcher not a nurse, will not wear uniform nor carry a bleep. However, your duty as a 
nurse remains and you would advise if and when necessary. These dual roles will be documented 
in the study write up. 
 
The Committee noted that the application refers to a counsellor from the Trust and questioned 
whether this counselling would be available immediately if required and whether the counsellor 
was aware of the planned project. You explained that there is always a counsellor on hand (i.e. 
there is cross cover) and this is made known to patients at the time of their diagnosis. The 
counsellor will be well informed that the study is underway. 
 
The Committee noted that you have considered your own safety by providing your risk 
assessment and lone working policy for any potential home visits. 
 
The researchers were thanked for attending and left the meeting. The discussion continued as 
follows: 
The Committee commented that it had been useful to meet the student researcher who had 
managed the discussion well and agreed it was confident in her ability to conduct the interviews 
despite the sensitive nature of the discussion. 
 
The Committee discussed how to manage the dissemination of results to relatives of 
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patients who die during the research or before the results become available. It was agreed that 
the most appropriate course of action would be to offer the relatives information about receiving 
the study results at the follow up appointment described by Dr Simpson. 
 
Ethical opinion 
 
The members of the Committee present gave a favourable ethical opinion of the above research 
on the basis described in the application form, protocol and supporting documentation, subject to 
the conditions specified below. 
 
Ethical review of research sites 
 
NHS Sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below). 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
Please label the information sheet 'Participant Information Sheet' rather than 'Patient'. 
 
In the invitation letter, please re-word the sentence 'At the moment, little is known about the 
experiences of patients like you... ' to read 'Little research has been conducted on out patients like 
you...' as it is less alarming to the reader. 
 
Please confirm that you will ensure that quotes are not only anonymous but also unidentifiable, 
i.e. if a participant's quote contains information that could identify them such as details of their 
condition or family composition, you will change or remove these sections. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements.  
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk. 
 
Where a NHS organisation's role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations. 
 
It is responsibility of the sponsor to ensure that all the conditions are complied with before the 
start of the study or its initiation at a particular site (as applicable).  
You should notify the REC in writing once all conditions have been met (except for site 
approvals from host organisations) and provide copies of any revised documentation with 
updated version numbers. Confirmation should also be provided to host organisations 
together with relevant documentation 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
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Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed on the attached 
sheet. 
 
Dr Markham, Dr Saunders and Mr Cassidy work in the same department as Dr Ann Dewey, the 
supervisor on this project. The members have no knowledge of the project and it was agreed they 
should remain in the room and take full part in the discussion. 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document "After ethical review - guidance for researchers" gives detailed guidance 
on reporting requirements for studies with a favourable opinion, including: 
Document . .·Version Date . . 
Covering Letter  26 April 2012 
GP/Consultant Information Sheets  11 January 2012 
Interview Schedules/Topic Guides  11 January 2012 
Investigator CV  10 April 2012 
Letter from Sponsor  23 April 2012 
Letter of invitation to participant 1.0 11 January 2012 
Other: CV for Academic Supervisor  24 April 2012 
Other: CV for Laraine Lloyd  10 April 2012 
Other: Appendix 3 Patient Pathway  11 January 2012 
Other: Appendix 8 GANTT Chart 1.0 11 January 2012 
Other: Appendix 5 CASE REPORT FORM 1.0 11 January 2012 
Other: Appendix 9 Confidentiality Policy CO/226/1O  18 October 201O 
Other: Appendix 10 Information Governance Policy CO/192/11  24 March 2011 
Other: Appendix 11 Lone Worker Policy CO/310/10  17 December 2010 
Other: Appendix 14 Consultant Information Sheet 1.0 11 January 2012 
Other: Appendix 15 thematic Analysis of Data 1.0 11 January 2012 
Other: Appendix 16 WHO Performance Status Tool 1.0 11 January 2012 
Other: CV of Haematology Nurse Specialist  15 June 2010 
Other: CV of Clinical Supervisor  22 February 2010 
Other: Board of Examiners Progression Letter  02 April 2012 
Other: Research Risk Assessment for Trust Sponsorship  12 April 2012 
Participant Consent Form: Appendix 2 Patient Consent Form 1.0 11 January 2012 
Participant Information Sheet: Appendix 1, Patient Information Sheet 1.0 11 January 2012 
Protocol 1.0 11 January 2012 
Questionnaire: Appendix 7, EQ-5D health Questionnaire   
REC application 1.0 01 May 2012 
Referees or other scientific critique report 1.0 11 January 2012 
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Notifying substantial amendments 
Adding new sites and investigators 
Notification of serious breaches of the protocol 
Progress and safety reports 
Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views known 
please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
12/SC/0282 Please quote this number on all correspondence  
 
With the Committee's best wishes for the success of this project Yours sincerely 
 
 
Dr Chris Markham 
Chair 
 
Email: scsha,sehrec@nhs.net 
 
Enclosures: List of names and professions of members who were present at the meeting and 
those who submitted written comments 
"After ethical review - guidance for researchers" - sent via e-mail 
 
Copy to: Mrs C P, name of hospital 
  
12/SC/0282 Please quote this number on all correspondence  
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Appendix 10 Research risk assessment for Trust sponsorship 
Please complete the box below with details of the study: 
  
Chief Investigator:  Laraine Lloyd 
Study title: Blood Transfusions in palliative haematology:  Patient Stories [Version 1. 11/01/2012] 
  
study of medicines:                Yes   
  
    
No  
x 
    
R&D Reference Number: 
Funding Body:   Not Applicable                                
    
Please use the guidance tables (included on the 'Ratings Guide' worksheet) to rate the likelihood and different impacts of each of the risks 
below. Please also document the controls that are in place and how effective they are. 
  
H
a
z
a
rd
 T
y
p
e
 R
e
f 
 
Hazard 
Type 
R
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k
 R
e
f 
Risk 
Scenario 
R
is
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1
-5
) 
Impact 
(1-5) 
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t 
 
R
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k
 E
x
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Controls, i.e. what 
is in place to reduce 
the likelihood of the 
risk occurring or 
limit the adverse 
outcome? 
C
o
n
tr
o
l 
E
ff
e
c
ti
v
e
n
e
s
s
 (
1
-5
) 
A
s
s
u
ra
n
c
e
 R
a
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n
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Comments Guidance 
C
li
n
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a
l 
N
o
n
-c
li
n
ic
a
l 
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1 Participant 
rights 
1.1 Entry onto 
the study 
without fully 
informed 
consent 
LL 1 1 2 2 L All clinical staff 
involved in the study 
are up to date with 
GCP training. The 
following controls 
are in place to 
ensure that entry to 
the study without 
Informed Consent is 
negligible: The 
patient's Consultant 
will act as 
'Gatekeepers' to 
protect the interests 
of their patients. 
They will only refer 
a patient if the 
patient would like to 
learn more about 
the study and 
agrees to their 
name being given to 
the researcher. 
Physicians will only 
refer to the 
researcher if they 
believe that: taking 
part in the study will 
not be detrimental to 
patient and patient 
has capacity to 
consent. L. Lloyd 
will consent 
patients. No 
interviews will be 
undertaken until 
written consent 
obtained & 
documented  
1 F L. Lloyd takes 
'Informed Consent' as 
a normal part of her 
clinical practitioner 
role, for instance, prior 
to doing a bone 
marrow biopsy, insert 
a central line or 
administer 
chemotherapy. All 
potential participants 
will be provided with a 
letter of introduction 
and a Patient 
Information Sheet to 
read. They will be 
given a minimum of 
24hrs to think about 
participating. When 
they return to the 
hospital L. Lloyd will 
ask them if they have 
any concerns and if 
they would like to 
participate. If Yes she 
will obtain 'written 
Informed Consent' 
from those wishing to 
take part. One copy of 
consent will be filed in 
medical notes and one 
copy will be given to 
the patient.  
Consider: Vulnerability of the 
patient/ study group and 
capacity to give consent, 
participant information, and 
training of those taking 
consent 
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1.2 Failure to act 
on patient's 
request to 
withdraw from 
the study 
LL 1 1 2 2 L If a patient requests 
to withdraw from the 
study L. Lloyd will 
immediately 
withdraw that 
participant. Any data 
that has been 
collected on the 
participant will be 
destroyed if the 
participant requests 
this.    
1 F Tape recordings and 
transcripts will be 
destroyed at the 
patient's request if 
they no longer want to 
participate in the study 
Consider: Communication 
and recording systems 
1.3 Failure to 
protect the 
privacy of 
participants 
LL 1 1 2 2 L All data collected on 
participants will be 
anonymised by 
coding with a study 
number. The 
Investigator file will 
be kept in a locked 
cupboard in the 
researcher's office. 
Analysis of coded 
data will be on the 
researcher's home 
computer which is 
password protected. 
Data will be backed 
up on an encrypted 
key. Her home has 
an alarm system 
1 F   Consider: Data protection and 
security systems, 
anonymisation 
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2 Participant 
safety 
2.1 Expected 
adverse 
effects of the 
intervention 
LL 1 1 2 2 L Patient's may 
become emotional 
or sad as they talk 
about their BT 
experiences. If a 
participant becomes 
distressed during 
the interview it will 
be stopped and only 
resumed when the 
participant feels 
comfortable to 
continue which may 
be another day or 
time or not at all. 
The over-riding 
responsibility of the 
researcher during 
this study is to abide 
by the NMC Code of 
Professional 
Conduct and protect 
the interests of the 
patients as a priority 
over gaining data for 
the study. The 
researcher has 
much experience in 
supporting patients 
who become 
distressed, 
alternatively, The 
Trust counsellor the 
haematology team, 
Palliative care team 
or PALS are always 
available to provide 
support and advice. 
  F Much consideration 
was given to the 
ethical issues 
surrounding talking to 
these vulnerable 
patients about their 
experiences 
surrounding having a 
blood transfusion [BT]. 
Detailed 
considerations have 
been documented on 
the IRAS Ethical 
Review Form. 
Consider: The nature of the 
intervention, experience of 
staff, susceptibility of the 
population (disease, genetic, 
age, sex), and if a medicinal 
product - development phase, 
licensing status, indications, 
clinical experience, 
pharmacology, drug handling 
requirements 
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2.2 Unexpected 
adverse 
effects of the 
intervention 
LL 1 1 1 1 L No unexpected 
adverse effects are 
expected from 
participating in this 
study 
  F   
 231 
2.3 Risks of the 
intervention 
outweigh the 
benefits 
LL 1 1 2 2 2 The risks of 
participating in this 
study may outweigh 
the benefits for 
individual patients. 
Addington-Hall et al. 
[2009, p.4], 
highlights that 
because of the life-
limiting condition of 
palliative patients 
there may not be a 
direct benefit from 
taking part in 
research, and the 
cost of participating 
in research will 
always, therefore, 
outweigh the 
benefits. They also 
stress, however, 
that even very sick 
patients may wish to 
participate in 
research because 
of: altruistic reasons 
in the hope that they 
can benefit others, 
to give something 
back to society, to 
make sense of their 
situation, 
enhancement of 
personal value, the 
assertion of 
continuing 
autonomy.  
1 F It has been suggested 
that interviewing 
patients, who have a 
palliative cancer 
diagnosis, about their 
experiences of care 
and treatment can be 
'therapeutic and 
empowering'. Sheldon 
and Sargeant [2009, p. 
175] also make a valid 
point when they 
suggest that it is 
important not to deny 
palliative care 
individuals their right to 
choose to participate 
and the opportunity of 
having their voices and 
experiences heard and 
valued. 
Consider: Systems to monitor 
and review adverse effects, 
maintain awareness and act 
on new knowledge. Ability/ 
reliability of participants to 
report adverse events/ 
outcomes 
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2.4 Assessment 
methods are 
hazardous 
LL       0 0 Not applicable   0 not applicable Consider: Procedures, e.g. 
biopsy, xray. 
3 Completion 
of the 
study 
3.1 Insufficient 
resource to 
support the 
study 
LL 1 1 1 1 L A number of HCP 
are involved in the 
study on a voluntary 
and supervisory 
basis, including; Dr 
Simpson [clinical 
supervisor], Dr 
Alloway, [medical 
advisor], Dr Dewey 
and Dr Kilburn 
[academic 
supervisors] and L 
Lloyd [researcher] 
1 F Data collection will be 
in researcher's own 
time as she only works 
2 days per week to 
allow time for 
academic study 
Consider: Staff resource 
required for the study 
3.2 Insufficient 
staff 
competence 
and 
experience 
LL 1 1 1 1 L HCP have all 
received GCP 
training and have 
much experience in 
undertaking 
research in the 
NHS. Dr A. Dewey 
[academic 
supervisor] is an 
expert in 
undertaking 
qualitative research 
studies. 
1 F   Consider: Skills and training 
required, e.g. Good Clinical 
Practice (GCP). 
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3.3 study and 
post-study 
costs exceed 
estimates 
LL 1 1 1 1 L As the study 
involves a very 
small questionnaire 
[which takes 
minutes to 
complete] and 
interviews the study 
costs are minimal. 
L. Lloyd will assume 
the costs of this 
study 
1 F   Consider: Estimation process, 
potential for additional costs 
3.4 Collaboration 
with other 
organisations 
fail 
LL       0 0 Not applicable   0 Not applicable Consider: Number of 
organisations involved, written 
agreements/ contracts/ 
protocols, resource in the other 
organisations 
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3.5 Insufficient 
study 
population 
available 
LL 1 1 1 1 L An audit 
demonstrated that 
10 palliative 
haematology 
patients during an 8-
month period last 
year received blood 
transfusions, that is 
approx. 15 per year.  
The number of 
palliative patients 
rises year on year. It 
is hoped to recruit 
15-20 patients and 
to interview each 
individual a 
maximum of 3 times 
[that is, 45-60 
interviews]. The 
published literature 
suggests that only 
46% of palliative 
patients provide 
follow up data at 8 
weeks. The 
minimum number of 
interviews for this 
study will be 20 
interviews which will 
allow for saturation 
of data. [that is no 
new stories will be 
forthcoming]. The 
study period will be 
extended, if 
necessary to ensure 
that saturation of 
data has been 
achieved.   
  F   Consider: Profile of 
participants 
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4 Reliability 
of Results 
4.1 Expected 
effects are not 
plausible 
LL 1 1 1 1 L The research 
proposal for this 
study has been 
submitted to the 
University of 
Portsmouth Board 
for peer review. The 
board passed the 
submitted proposal 
with 
recommendations to 
be considered for 
strengthening the 
study. The 
recommendations 
will be incorporated 
into the study 
proposal 
  F   Consider: Validation process 
for research project proposal 
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4.2 study size is 
insufficient to 
be 
representative 
LL 1 1 1 1 L It is anticipated that 
a minimum of 15 
patients will be 
recruited. This 
number will allow for 
saturation of data 
with no new insights 
or new stories 
forthcoming.  
As a qualitative 
approach is to be 
employed a ‘non-
probability’ sampling 
method for selecting 
participants will be 
employed as 
statistical 
representation is not 
the aim. This allows 
the researcher to 
focus in on 
individual patients or 
groups which 
provide the most 
pertinent information 
relating to the 
research problem. 
What is most 
important is that the 
sample has the right 
characteristics to 
enable the 
researcher to collect 
‘rich’ data to allow 
detailed exploration 
and understanding 
of the area under 
study.  
  F Study sizes for 
qualitative research 
are generally small.  
Consider: Optimal study 
sizes, target population 
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4.3 Major violation 
of eligibility 
criteria 
LL 1 1 1 1 L Minimal participant 
criteria will be 
applied to ensure 
that the study is fair 
and open to all 
those who would 
like to take part. 
Inclusions All adult 
patients who:  
• have a 
documented late – 
terminal palliative 
phase 
haematological 
malignancy,  
• are no longer 
receiving curative 
chemotherapy but 
may be receiving 
supportive therapy, 
for example, 
antibiotics, antiviral 
medications, platelet 
infusions  
• are attending the 
haematology day 
care or hospice 
setting at (name of 
hospital) hospital for 
a BT 
• are able to provide 
Informed Consent  
  F Exclusions: Only 
patients who are 
unable to provide 
Informed Consent due 
to cognitive 
impairment, or who are 
unable to speak or 
understand English. 
Patients below the age 
of 18 or over 90 will be 
excluded. Also, those 
who decline to 
participate 
Consider: Importance to the 
study, need for checking and 
possible procedures, unduly 
restrictive/ prescriptive 
eligibility criteria 
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4.4 Fraud 
committed 
LL 1 1 2 2 L No finances are 
involved. Patient 
participation will be 
voluntary. No 
funding has been 
applied for. The 
data collected via 
interviews and the 
findings will be 
validated by Dr 
Simson and Dr 
Dewey academic 
supervisor. 
Participants will be 
given the 
opportunity to 
validate the 
transcripts 
  F   Consider: The potential, 
financial/ non-financial 
incentives, consequences, 
options for checking 
4.5 Failure of 
randomisation/ 
blinding/ 
unblinding 
processes 
LL       0 0 Not applicable   0 not applicable Consider: The robustness of 
the procedure, potential for 
loss of allocation concealment/ 
unblinding 
4.6 Incorrect 
outcome 
assessment 
LL 1 1 1 1 L The research 
findings / discussion 
will be submitted to 
the University of 
Portsmouth as a 
thesis   
  F   Consider: Single / double 
blinding, objectivity of 
measure, standardisation of 
assessment, independent 
review, external verification 
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4.7 Data is 
incomplete/ 
inaccurate 
LL 1 1 2 2 L Interviews will be 
audio-recorded and 
transcribed 
verbatim. 
Participants will be 
offered the 
opportunity to check 
a copy of the 
transcripts to allow 
them to check that 
what they have said 
has been recorded 
accurately. Drs will 
act as 'Gatekeepers' 
on this matter and I 
will be guided by 
their advice. 
Language texts will 
be entered into a 
qualitative data 
management 
computer program 
and analysed 
thematically. Initial 
coding and themes 
will be 
independently 
reviewed by a 
medical consultant 
and by an academic 
supervisor who has 
substantial 
experience in 
analysing qualitative 
data. Differences in 
themes will be 
discussed and 
adjusted where 
appropriate. . 
  F L. Lloyd has 
successfully 
completed an 
assessment module in 
qualitative data 
analysis during 
Professional Doctorate 
at University of 
Portsmouth. Also, she 
has attended a 3 day 
training course in the 
analysis of qualitative 
data at the University 
of Southampton. She 
has undergone training 
in the use of MAXQDA 
computer software for 
analysing qualitative 
data at the University 
of Southampton 
Consider: Data type and 
complexity, collection method, 
data entry method, verification 
methods 
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4.8 Breach of 
research 
governance 
procedures 
LL 1 1 1 1 L All staff will have up 
to date GCP training 
(within 2 years) to 
ensure they are 
aware of current 
guidelines. The 
research will be 
carried out to the 
standards outlined 
in the Research 
Governance 
Framework 
  F   Consider: Complexity, staff 
training and experience, 
reporting requirements 
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5 Post-study 5.1 Poor 
academic 
value 
LL 1 1 1 1 L The research is 
being undertaken in 
fulfilment of a 
Professional 
Doctorate in 
Nursing. The 
findings will be 
published in a peer 
reviewed nursing 
journal that has a 
wide distribution, 
such as; Oncology 
Nursing or Cancer 
Nursing or Journal 
of Advanced 
Nursing. Findings 
may also be 
presented as a 
poster at the annual 
British Society for 
Haematology 
meeting and 
disseminated to 
specific patient 
groups, for example; 
leukaemia care and 
lymphoma support 
for publication in 
their newsletters 
  F   Consider: Publication 
potential 
5.2 Intellectual 
property rights 
lost 
LL       0 0 Not applicable   0 not applicable Consider: Confidentiality of 
the study, expected outcomes 
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  This study is (please tick):     Accepted as being within an acceptable level of 
risk 
    Not accepted   
  
  
Researcher: 
 Signature:……………………………….. 
 Date:…………………………………….. 
Research and Development: 
 Dr J K 
Ramage…………………………. 
  Director of Research and Development 
 
Date:…………………………………….. 
      Governance: 
………………….………... 
       Catharine Carter 
       
Date:………………………………………….. 
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Appendix 11 An example of step four of data analysis.  
 
Step four – an example of narrative coding of field texts to interim 
research texts. (Boldened text were placed into a new document) 
R. Perhaps today we could talk about what it’s like for you coming up here 
to the unit for your blood transfusion. Perhaps we could start from the 
morning. 
 
P. Well I don’t have to worry about getting up in the morning for a start, not 
that I lie in bed very long, or go overboard in sleeping very long. I’m usually 
awake on most average day around about seven, seven thirty because I’ve 
always worked all my life. All my life I’ve worked, and I’ve had to go to a job 
that starts at eight o’clock in the morning, so I have always been used to 
getting up reasonably early in the mornings. So, I might get up around, on a 
transfusion day, no on a normal day I would probably get up around seven 
thirty to eight o’clock and have my breakfast and watch breakfast television, 
etc. On a transfusion day I always get up an hour at least earlier, six 
thirty in the morning. And by the time I have made a cup of tea for me and 
the wife. I don’t generally have any breakfast until, I might not have any 
breakfast at all. I go for a shower because I wouldn’t dream of coming up 
here, like today I’ve had a shower, I wouldn’t dream of coming here with 
what might be a perspiration body, it’s not so much I’m dirty it’s just that I 
might be a bit smelly. Ha, ha. So I don’t like to think that is me that’s 
indicating that to anybody else, so I always have a shower prior to coming 
which gives me 20 minutes in the shower I suppose, and then I go 
downstairs and I will have sometimes have a few flakes, or sometimes 
nothing at all because I tend to have my lunchbox, which is a big joke… 
(patient’s name) has got his lunchbox again. But, I’m not very keen on the 
sandwiches that are supplied, I like a cup of tea which I know I’m going to 
get up here, at least one anyway. I always make a little sandwich box of my 
own whether it be a sandwich or something of that nature. But I tend to bring 
one of those Granola bars which are breakfast bars and so when I get here 
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I can have a little breakfast if I like, have a sandwich at lunch time and some 
fruit and a couple of biscuits with the afternoon tea if I feel that I need them.  
 
So, I know that the hours of work for the girls on the floor are not until 
after half past eight now, and one is requested not to get here before 
that, because we can’t get on to the ward until they’ve opened up, 
which feels a bit unfair sometimes. Because when I first started having 
a transfusion, four years ago, the girls were here at eight o’clock. And 
I used to go straight into the ward and (name of nurse), or (name of 
another nurse), or one of the other nurses that might have been 
available at the time would cannulate me straight away, even though I 
might not get my blood until turned half past eight because the 
haemoglobin department wasn’t working until half past eight, but I was 
ready.  
 
But now the girls don’t get here until half past eight, well the first crew 
doesn’t get here until about half past eight, and the rest of them will be in by 
nine, so I don’t come in here now until at least half past eight. I either 
wait in the waiting room if I can’t get in the ward, and then when I do 
get in the ward, I go in the girls won’t cannulate unless they’ve got 
complete freedom of time until nine o’clock which puts me at least an 
hour behind on a transfusion of three units of blood. And three units 
of blood takes somewhere in the region of seven sometimes eight 
hours depending on how busy or how awkward the pump plays up, 
whatever.  
 
So, I feel that’s a bit of a hindrance in lots of ways because before when 
I used to be able to get in just after eight o’clock and get cannulated, 
and when my blood was ready, which it usually was, and if it wasn’t I 
had to wait some. If it was ready I used to get transfused or start my 
transfusion by nine o’clock which gave me a good stretch of the day 
to get dispersed from the ward by five o’clock. But now that can 
change completely although the girls do very, very well at the moment, If I 
 245 
have two units it’s not a problem I might get away by four. If I have to 
go over to three units, it’s not much difference in time because they 
know they’ve got to try and keep the blood changed quickly to help 
with the time to get you finished in time during the working time of their 
employment.  
 
R. What happens if you don’t get finished during the time? 
 
P. Well in the early days, I had this happen to me they were still 
transfusing at six o’clock when the ward was locked-up, and they used 
to have to take me down to, well walk down to, with my pump, to the 
other end to the main ward. And I used to sit in an armchair down there, 
or in an ordinary wooden chair down there next to the vending 
machines, so that everybody could see me sat in the middle of the 
foyer, if you want to call it a foyer, and there I sat until such times the 
blood transfusion was finished and that could happen anything up to 
seven, seven fifteen or seven thirty. Basically, (names of nurses), 
they’ve got their priorities to do before they can even attend to some 
blood patient sat there. So, consequently if my pump was bleeping for 
some attention, whatever it needed, mine was the last on the list to get 
looked at, because there was some other people with more priority 
than me or us whatever. 
 
R. So how did that make you feel? 
 
P. Well it partially made me feel as if I was in the way and secondly as 
if I wasn’t anybody worth looking at, coz a) I don’t think blood patients 
should be mixed up with cancer patients, I think they should be 
separated, bed wise, ward wise, whatever you want to call it, it should 
be separated from the cancer patients because we are not …. They are 
looking for life saving treatment and although we are still looking for 
lifesaving treatment we are not liable to….., because the treatment has 
started, you are not liable to be going to die or anything so your 
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treatment is going to be okay. But with the cancer patient I feel they 
have got to have their treatment otherwise if its broken and not 
attended to as and when its necessary, then they might be in serious 
trouble with their individual problem. I don’t know whether that’s right or 
wrong I don’t know, but that’s what I feel. (Ernest, first interview, p. 15 – 18) 
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Appendix 12 An example of step five of data analysis 
 
Step five – an example of categorization of narrative scenes in the interim 
research texts. Texts colored red highlight the dimensions of 
experience. 
Researcher (R). Perhaps today we could talk about what it’s like for you 
coming up here to the unit for your blood transfusion. Perhaps we could start 
from the morning. 
 
Participant (P). On a transfusion day I always get up an hour at least 
earlier, six thirty in the morning. I don’t generally have any breakfast). 
(Related to Sociality dimension of experience) 
So, I know that the hours of work for the girls on the floor are not there 
until after half past eight now, and one is requested not to get here 
before that because we can’t get on to the ward until they’ve opened 
up (Experience related to Setting / Place dimension as the 
Haematology Day Unit does not open until 08.30am when the nurses 
come on duty).  
 
which feels a bit unfair sometimes, because when I first started having 
a transfusion, four years ago, the girls were here at eight o’clock. 
But now the girls don’t get here until half past eight so I don’t come in 
here now until at least half past eight (experience related to Sociality, 
that is, the existential conditions in the environment. Experience 
regulated by the nursing staff.  
 
I either wait in the waiting room if I can’t get in the ward (setting) and 
then when I do get in the ward I go in the girls won’t cannulate unless 
they’ve got complete freedom of time until nine o’clock (social 
existential conditions- sociality)  
which puts me at least an hour behind on transfusion of three units of 
blood. And three units of blood takes somewhere in the region of 
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seven sometimes eight hours depending on how busy or how awkward 
the pump plays up, whatever (setting). 
 
So, I feel that I’m a bit of a bit of a hindrance in lots of ways (personal 
feelings - sociality). 
If I have to go over to three units, it’s not much difference in time 
because they know they’ve got to try and keep the blood changed 
quickly to help with the time to get you finished in time during the 
working time of their employment (social existential conditions - 
sociality).  
 
R. What happens if you don’t get finished during the time? 
 
P. Well in the early days, I had this happen to me they were still 
transfusing at six o’clock when the ward was locked-up, and they used 
to have to take me down to, well walk down to, with my pump, to the 
other end to the main ward and I used to sit in an armchair down there 
or in an ordinary wooden chair down there next to the vending 
machines, so that everybody could see me sat in the middle of the 
foyer, if you want to call it a foyer, and there I sat until such times the 
blood transfusion was finished and that could happen anything up to 
seven, seven fifteen or seven thirty. (personal feelings-sociality and 
setting).  
 
Basically, because the nurses (names of nurses), they’ve got their 
priorities to do before they can even attend to some blood patient sat 
there. So consequently, if my pump was bleeping for some attention, 
whatever it needed, mine was the last on the list to get looked at, ha, 
ha, because there was some other people with more priority than me 
or us (personal feelings - sociality). 
 
R. So how did that make you feel? 
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P. Well it partially made me feel as if I was in the way and secondly as 
if I wasn’t anybody worth looking at, (personal feelings - sociality)  
 
coz a) I don’t think blood patients should be mixed up with cancer 
patients, I think they should be separated, bed wise, ward wise, 
whatever you want to call it, it should be separated from the cancer 
patients (setting)  
 
They are looking for life saving treatment and although we are still 
looking for lifesaving treatment we are not liable to, because the 
treatment has started, you are not liable to be going to die or anything 
so your treatment is going to be okay, (temporality) 
 
but with the cancer patient I feel they have got to have their treatment 
otherwise if its broken and not attended to as and when its necessary, 
then they might be in serious trouble with their individual problem 
(sociality).  (Ernest, first interview, p. 15 – 18) 
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Appendix 13 Form UPR 16 Research Ethics Review Checklist 
 
